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Summary 
  
Colorectal cancer is the second and third most leading cancer in Europe and the US, 
respectively. One of the main risk factors of this malignancy of the large bowel has been 
associated to western-style diets rich in high saturated fat and meat and low in fiber. 
During the last years, it has been reported that a regular uptake of fruits and vegetables 
may reduce the incidence of colorectal cancer. One of the most consumed fruits in 
western diet patterns are apples. Several epidemiological and case-control studies have 
indicated that usual consumption of one or more apples a day may reduce the risk for 
colon cancer. But so far, the possible preventive effects of apple juice have not been 
completely investigated. 
Our previous examinations showed that polyphenolic extracts from apple juice are 
biologically active in terms of radical scavenging, influence on drug metabolism as well 
as anti-inflammatory and anti-hormonal potential in vitro. Moreover, we used the 
colorectal chemoprevention Apc Min/+ mouse model to study the chemopreventive effect 
of apple juices. This strain is highly susceptible to spontaneous intestinal adenoma 
formation. The results showed that cloudy apple juice and polyphenolic apple juice 
extract had a significant impact diminishing the tumor development in the small intestine 
of Apc Min/+ mice. However, the possible mechanism remained to be understood. 
In the present study, the possible molecular mechanism was investigated in a second 
animal experiment. Animals were treated with water (as a control), cloudy apple juice 
(CAJ), placebo juice (apple juice without polyphenols), 0.2% B-PAE (procyanidin-rich 
apple extract) and a combination between cloudy apple juice and 0.2% B-PAE. 
Both cloudy apple juice and B-PAE intervention significantly reduced adenoma 
development by 24% and 34%, respectively. These findings indicated polyphenols as the 
main chemopreventive compounds in this model. On the other hand, placebo juice and 
cloudy apple juice plus B-PAE treatments, inhibited intestinal adenomas in a non-
significant manner by 7% and 17%, respectively. Moreover, placebo juice intervention 
enhanced small adenomas in the whole small intestine.   
In the liver, cloudy apple juice- and cloudy apple juice plus B-PAE-treated animals 
resulted in an induction of Phase II enzymes (GST, QR, and TrxR). Further 
investigations identified a high concentration of polyphenol metabolites in the urine of 
animals treated with cloudy apple juice and cloudy apple juice plus B-PAE. This indicated 
that polyphenol metabolites may reach the liver after intestinal absorption. However, due 
to an overnight fasting prior to dissection, the protein content of liver cells of mice in the 
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water and B-PAE intervention groups was disminished. Several enzymatic activies such 
as CYP1A1, QR and TrxR were decreased as a result of this fasting effect. In contrast, 
placebo juice, CAJ and CAJ + B-PAE maintained hepatic protein contents due to the 
carbohydrate uptake from these drinks. 
The possible mechanism of the development of adenomas was investigated using 
protein array technology. Proteomic analysis revealed that fasting effects increased 
phosphorylated ERK and the target iNOS in intestinal adenomas. Similarly, Cyclin D1 
was reduced but only in the middle parts of the small intestine. B-PAE treatments 
reduced fasting associated effects by decreasing p-ERK, iNOS, and Cyclin D1.  
Since only very low concentrations of metabolites of polyphenols were found in urine and 
in analogy to other comparable compounds, a direct passage into the intestine or 
hepato-biliary excretion can be assumed. Therefore these results might be attributed to 
procyanidins acting locally. 
CAJ and B-PAE treatments did not affect inflammation markers such as nitric oxide 
content in urine or PGE2 in serum. In vivo levels of apple polyphenols were not high 
enough to efficiently inhibit these inflammation markers.  
Cyclin D1 was strongly reduced in the distal parts of the small intestine by CAJ and CAJ 
+ B-PAE. As well as in a non-significant manner, beta-catenin was reduced in a similar 
way.   
Overall, apple polyphenols from CAJ and B-PAE reduced adenoma development in the 
Apc Min/+ mouse model. This chemopreventive potential was dependent on the intestinal 
bioavailability. Control animals (12 h fasted) resulted in an increase of Erk 
phosphorylation and of iNOS expression. B-PAE-treated animals suppressed these 
fasting-associated effects compared to water controls as well as in the groups that had 
access to high-calorie apple juice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary  15 
 
Zusammenfassung 
 
Das kolorektale Karzinom ist die zweithäufigste Krebsart in Europa, in den USA die 
dritthäufigste. Als ein Hauptrisikofaktor gilt die westliche Ernährung, die reich an      
gesättigten Fettsäuren und Fleisch sowie arm an Ballaststoffen ist. Im Laufe der Zeit 
zeigte sich, dass ein regelmäßiger Verzehr von Obst und Gemüse die Tumorinzidenz 
senken kann. Eine der am häufigsten konsumierten Früchte in der westlichen Ernährung 
ist der Apfel. Verschiedene epidemiologische Studien sowie Fallkontrollstudien haben 
gezeigt, dass der regelmäßige Verzehr von einem oder mehr Äpfeln täglich das Risiko, 
an kolorektalem Karzinom zu erkranken, senken kann. Ein möglicher präventiver Effekt 
von Apfelsaft wurde bisher jedoch nicht vollständig untersucht. 
Unsere vorangehenden Untersuchungen zeigten in vitro folgende biologischen 
Aktivitäten von Polyphenol-Extrakt aus Apfelsaft: Radikalfänger-Eigenschaften, 
Beeinflussung des Fremdstoffmetabolismus sowie antiinflammatorisches und 
antihormonelles Potential. 
Darüber hinaus untersuchten wir den chemopräventiven Effekt von Apfelsaft am  ApcMin/+ 
Maus Modell für kolorektale Chemoprävention. Dieser Stamm entwickelt spontan in 
hohem Maße intestinale Adenome. Die Ergebnisse zeigten, dass trüber Apfelsaft und 
Apfel - Polyphenol - Extrakt signifikant die Tumorentstehung im Dünndarm der ApcMin/+ 
Maus hemmen. 
Dieser Mechanismus konnte bisher jedoch nicht vollständig geklärt werden. 
In der aktuellen Studie wurde der mögliche molekulare Mechanismus in einem zweiten 
Tierversuch erforscht. Die Tiere erhielten Wasser (Kontrollgruppe), naturtrüben Apfelsaft, 
Placebo-Apfelsaft (Apfelsaft ohne Polyphenole), 0.2% B-PAE (procyanidinreicher 
Apfelsaftextrakt) und eine Mischung aus trübem Apfelsaft und 0.2% B-PAE. Sowohl die 
Gabe von Trübsaft als auch die von B-PAE reduzierten signifikant die Neubildung von 
Adenomen um 24% bzw. 34%. Dieser Befund kennzeichnet die Polyphenole als 
vorrangige chemopräventive Bestandteile dieses Modells. 
Placebo-Saft und die Mischung aus Trübsaft und 0,2% B-PAE hemmten die 
Adenomentwicklung lediglich im nicht signifikanten Bereich (7% bzw. 17%). Die Zufuhr 
von Placebo-Saft erhöhte sogar die Bildung von kleinen Adenomen im gesamten 
Dünndarm. 
In der Leber zeigte sich bei den mit Trübsaft und den mit dem Gemisch aus Trübsaft und 
B-PAE behandelten Tieren eine Induktion von Phase II Enzymen (GST, QR und TrxR). 
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Weitere Untersuchungen zeigten eine hohe Konzentration an Polyphenolmetaboliten im 
Urin der Tiere dieser Gruppen. Dies weist darauf hin, dass Polyphenolmetabolite nach 
Resorption im Darm in die Leber gelangen. 
Durch Fasten über Nacht vor der Sektion  war jedoch der Proteingehalt in der Leber in 
der Kontrollgruppe (Wasser) sowie der B-PAE Gruppe vermindert. Auch die Aktivität 
verschiedener Enzyme wie z.B. CYP1A1, QR and TrxR sank in Folge des Fastens. Im 
Gegensatz dazu blieb in den anderen Gruppen (Placebo–Saft, trüber Apfelsaft und 
trüber Apfelsaft mit B-PAE) auf Grund der Kohlehydratzufuhr durch diese Säfte der 
Proteingehalt in der Leber stabil. 
Der mögliche Mechanismus des Adenomwachstums wurde mit Hilfe von Protein arrays 
untersucht. Proteomische Untersuchungen zeigten, dass Fasten die Phosphorylierung 
von ERK und die Expression des Zielproteins iNOS bei Darmadenomen steigerte. In 
ähnlicher Weise wurde Cyclin D1 reduziert, jedoch nur im mittleren Teil des Dünndarms. 
Die Behandlung mit B-PAE reduzierte fasten-assoziierte Effekte durch Abnahme von p-
ERK, iNOS und Cyclin D1. Da kaum nachweisbare Konzentrationen von Polyphenol–
metaboliten im Urin gefunden wurden, kann auch in Analogie zu vergleichbaren 
Substanzen eine direkte passage in den Dünndarm oder eine hepato-biliäre Exkretion 
angenommen werden. Somit können diese Ergebnisse möglicherweise einer lokalen 
Wirkung von Procyanidinen zugeschrieben werden. Entzündungsparameter wie der 
Stickoxydgehalt im Urin oder PGE2 im Serum wurden durch Trübsaft und B-PAE nicht 
beeinflusst. Die in vivo–Spiegel der Apfelpolyphenole reichten nicht aus, um diese 
effektiv zu hemmen. 
Cyclin D1 wurde durch Trübsaft und Trübsaft gemischt mit B-PAE in distalen Anteilen 
des Dünndarms stark reduziert. Wenn auch nicht signifikant, so wurde β–catenin in 
ähnlicher Weise reduziert. 
Zusammenfassend kann man sagen, dass Apfel-Polyphenole aus trübem Apfelsaft und 
B-PAE das Adenomwachstum im ApcMin/+ Maus Modell hemmten. Das chemopräventive 
Potential war abhängig von der intestinalen Bioverfügbarkeit. Erhalten die Tiere 
aussliesslich wasser (12 Std nüchtern) war die phosphorylierung bzw. expression von 
Erk und iNOS erhöht. Erhalten die Tiere B-PAE, waren diese Fasten-assoziierten Effekte 
reduziert im Vergleich zur Waserkontrolle, wie auch in den Gruppen, die Zugang zu 
hochkalorischen Apfelsaft hatten. 
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1 INTRODUCTION 
1.1 Cancer Chemoprevention 
1.1.1 Cancer Facts  
 
Cancer, derived from the Latin word for crab, is a group of diseases characterised by 
uncontrolled cell growth and the spread of abnormal cells. Cancer is often linked to 
high mortalility. 
According to the World Health Organisation (WHO) in the year 2000, there were 
more than 10 million cases of cancer recorded worldwide. This is predicted to 
increase by 50% to the year 2020, reaching up to 15 million cases. In Europe and the 
United States, cancer is the second most common cause of death in the general 
population, and is the first cause of death in the 45-65 age range 
(www.who.org/cancer). 
Cancer is a multifactorial illness that is caused by internal factors (genetic 
predisposition, hormones, immune conditions and mutations that occur from 
metabolism) and external factors (diet, tobacco, carcinogen exposure, radiation and 
infections) (Minamoto et al., 1999). 
1.1.2 Carcinogenesis  
 
Carcinogenesis is a multistep and multifunctional phenomenon, in generally divided 
into initiation, promotion and progression. Only malignant tumors are able to be 
invasive and to metastasize while benign tumors are self-limited in their growth 
(Fidler, 1999). A schematic representation of multistage carcinogenesis is described 
in Fig.1 (left). 
The process is initiated with the transformation of a normal cell into an initiated cell 
as a result from genetic damage. This step is a rapid and irreversible process 
involving extracellular and intracellular events. Environmental carcinogens, such as 
aflatoxins, polycyclic aromatic hydrocarbons (PAH) and nitrosamines are 
procarcinogens, which must be metabolically activated by Phase I enzymes in order 
to become electrophilic active carcinogens. If these electrophilic carcinogens interact 
with genomic DNA, carcinogen-DNA adducts are formed, which may lead to 
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oncogene activation or tumor suppressor gene inactivation. Metabolic activation is 
performed by Phase I enzymes (CYP450 and flavin-dependent monooxygenases) 
which involve oxidation, hydroxylation and reduction reactions. The CYP1A1 and 
CYP2A1 are examples of this enzyme family. Procarcinogens like PAH and N-
nitrosamines are known to induce both enzymes forming intermediate carcinogens 
and therefore increasing cancer risk (Smith et al., 1998). Reactive oxygen species 
(ROS) are also actively implicated in the metabolic activation of procarcinogens 
(Halliwell et al., 2000; Rushmore and Kong, 2002). In addition, ROS and carcinogens 
can lead to epigenetic alterations like DNA methylation. Such epigenetic changes 
can strongly affect the regulation of gene expression (Cerda and Weitzman, 1997). 
Tumor promotion comprises the selective expansion of initiated cells. Initiated cells 
undergo tumor promotion into preneoplastic cells which is considered to be relatively 
slow and reversible. Clonal progress of initiated cells produces a larger population of 
cells that are at risk of further genetic modifications and malignant conversion. This is 
attributed to growth factors, hormones and inflammation mediators (Greenwald, 
2002). These factors influence cellular signaling, and processes like cell growth 
regulation, proliferation and differentiation may be affected (Kelloff, 2000). In addition, 
ROS formation may result in damage of DNA, proteins or lipids. However, oxidative 
stress is involved during progression as well (Breimer, 1990). 
Progression is the last stage of tumor growth with neovascularisation processes and 
metastatic potential. Tumor progression comprises the extension of the malignant 
phenotype through additional mutations and genome instability. Progression provides 
the impetus for conversion from benign adenomas to infiltrative and finally 
metastasizing neoplasms (Harris, 1991).  
Carcinogenesis prevention appears as a practical approach in order to reduce 
cancer-related mortality (Sporn and Suh, 2002). A schematic representation of the 
strategies for prevention is shown in Fig.1 (right). 
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Fig. 1. Schematic representations of carcinogenesis (left) and mechanism of chemoprevetion (right). 
See text for details. QR, NAD(P)H:quinone oxidoreductase; GST, glutathione-S-transferase; ROS, 
reactive oxygen species; RNS, reactive nitrogen species; COX, cyclooxygenase; iNOS, inducible nitric 
oxide synthase; PGE2, prostaglandin E2; MAPK, mitogen-activated protein kinase; Akt, protein kinase 
B. Adapted from (Gerhauser, 2008) and (Fodde et al., 2001). 
 
1.1.3 Chemoprevention 
 
The aim of chemoprevention is the use of chemicals or dietary components to block, 
inhibit or reverse carcinogenesis (Sporn and Newton, 1979). Chemopreventive 
agents should have little or no toxicity, have a high efficacy, able to be orally 
administrable, have a known mechanistic action and low costs (Ferguson, 1994).  
Depending on different stages along the natural history of disease, prevention can be 
roughly classified into three levels: primary prevention focusing on the prevention of 
onset of disease, secondary prevention aiming at early diagnosis and early treatment 
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if  onset has occurred, and tertiary prevention which is at the last step trying to avoid 
recurrence, further progression, and complications (Zanker, 1999). Tab.1 describes 
each stage. 
 
Tab. 1 Chemoprevention strategies. Adapted from (Zanker, 1999) and (Tsao et al., 2004). 
 
As depicted in Fig. 1 (right), the process of carcinogenesis offers multiple targets for 
chemopreventive strategies. In the initiation stage, anti-mutagens either directly 
inactivate mutagens or block their metabolic activation. 
Efficient inhibition of phase I enzymes to reduce metabolic activation may decrease 
DNA damage and therefore reduce cancer risk (Ioanides et al., 1998). 
Detoxification and therefore excretion will be completed via conjugation reactions 
(Phase II enzymes). Phase II enzymes (Glutathione S-transferases (GST), UDP-
glucuronosyltransferases, sulfotransferases and N-acetyltransferases) involve 
covalent attachment of small polar endogenous molecules to form water-soluble 
compounds (Ioanides et al., 1998). Detoxification through phase II enzymes is 
another preventive mechanism and may lead to decrease DNA damage (Goodman 
et al., 2006). 
Anti-oxidant mechanisms and possibilities to scavenge ROS contribute to an 
interesting prevention strategy which can affect all stages of carcinogenesis. A 
decrease in the oxidative stress status prevents cellular damage (Droge, 2002). 
Besides inactivation of ROS, alteration of tumor promoters plays an important role in 
the delay of carcinogenesis. Inflammation is a response triggered by damage to living 
tissues and is associated with multistage carcinogenesis through genetic and 
 
CHEMOPREVENTION  STRATEGIES 
 
 
POPULATION 
 
EXAMPLES
 
PRIMARY 
 
 
Avoidance of cancer-causing  
behaviour and exposure 
 
Healthy 
 
Smokers 
 
SECONDARY 
 
 
Cessation of exposure to carcinogenic 
agents of risk and screening to detect 
earlier stage malignancies  
 
Individuals with premalignant 
lesions 
 
Oral 
leucoplakia 
patients 
 
TERTIARY 
 
 
Administration of agents intended to 
prevent cancer development and to 
inhibit or delay the occurrence of 
metastases 
 
 
Patients cured of their initial 
cancer or individuals definitively 
treated for their premalignant 
lesions 
 
 
Oral cancer 
patients 
Introduction 
 
 
 
21
epigenetic changes (Hussain and Harris, 2007). Induction of cyclooxygenase-2 (Cox-
2) results in an increase of prostaglandin (PG) synthesis. PGs increase is strongly 
linked with apoptosis resistance and proliferation in epithelial tissues (Helliwell et al., 
2004; Jabbour et al., 2002). Reactive nitrogen species (RNS) include multiple highly 
reactive molecules, which are mostly derived of nitric oxide produced by the inducible 
nitric oxide synthase (iNOS). Furthermore, RNS may also contribute to oxidative 
stress and Cox-2 induction (Klaunig and Kamendulis, 2004). Both Cox-2 and iNOS 
have been involved in the promotion stages mediating intracellular signalling like 
protein kinases and transcription factors like the activator protein-1 (AP-1) (Kundu 
and Surh, 2005). 
A vast variety of cytoplasmic protein kinases are involved in relaying events in the 
cellular signalling. Components of upstream or cytoplasmic signalling networks 
include protein kinases, such as the family of proline-directed serine/threonine 
kinases named mitogen-activated protein kinases (MAPKs). Abnormal or improper 
activation or silencing of the MAPK pathway or its downstream transcription factors 
can result in uncontrolled cell growth, leading to malignant transformation (Surh, 
2003). The Ras/MAP kinase cascade as a well-known example is important in 
tumorigenesis, leading to increase mitogenesis via induction of Cyclin D1 (Lavoie et 
al., 1996). The inhibition of abnormal cell proliferation via modulation of cell cycle 
progression is one of the important strategies for chemoprevention (Alao, 2007).  
In the progression stage, induction of apoptosis and inhibition of angiogenesis are 
important protective mechanisms against neoplastic transformation. 
Multiple dietary and pharmacological agents have been investigated for 
chemopreventive potential (Kelloff, 2000). 
According to their mechanism of action these agents can be classified as blocking or 
suppressing agents. Blocking agents are mostly related to inhibition of initiation 
processes, whereas suppressing compounds are considered to inhibit malignant 
expression of initiated cells (De Flora, 1998). Examples of well investigated 
chemopreventive compounds targeting various stages of carcinogenesis are 
summarized in Tab. 2. These agents have been shown to prevent cancer 
development in experimental models for chemoprevention (in vitro and in vivo). 
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Tab. 2 Carcinogenesis stages and chemoprevention strategy. 
  
CHEMOPREVENTIVE  
STRATEGY EXAMPLE COMPOUND REF. 
 
 
Phase I inhibition 
 
 
Cyp1A2 
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a 
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INITIATION 
     
antioxidant effects Catalase Vitamin C d 
anti-tumor promoting effects MAPK  Curcumin e 
anti-hormonal effects Aromatase Genistein f 
anti-inflammatory activity Cycloxygenases Flavonoids g 
PROMOTION 
inhibition of cell proliferation Cyclin D1 Resveratrol h 
     
induction of apoptosis Caspases Quercetin i 
inhibition of angiogenesis VEGF, MMP ω-3 PUFAs j 
     
PROGRESSION 
 
 
References cited: a (Surh et al., 1995) b (Zhang et al., 1994)  c (Wei et al., 1999) d (van Haaften et al., 
2003) e (Mehta and Moon, 1991) f (Allred et al., 2004) g (Kim et al., 2004) h (Ahmad et al., 2001) i (Wei 
et al., 1994)  j (Szymczak et al., 2008).  
1.2 Colorectal cancer development 
1.2.1 Facts and statistics 
 
Colorectal cancer (CRC) is a disease of the large bowel, including colon, rectum and 
appendix. 
In western societies, CRC is the second most frequent malignancy. More than 
940.000 cases occur annually worldwide and nearly 500.000 patients die from the 
disease each year (www.who.int). Colon and rectum cancers have a lower incidence 
in developing countries (Novak 2003).  
More than 420.000 cases were estimated for Europe in the year 2008. In men, CRC 
was the second most common type cancer in incidence and the third in women. In 
terms of mortality, it was second among men and women with more than 220.000 
deaths (World cancer report 2008, WHO). Mortality has increased 1.8% from 2004 to 
2006 (Boyle and Ferlay, 2005; Ferlay et al., 2007). Significant increase rates have 
been observed in East European countries such as in the Czech Republic and 
Slovakia. Industrial growth and poor CRC screening procedures may be associated 
with this increase (Center et al., 2009). 
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According to the WHO 2008 World cancer report, CRC was the third cancer in 
mortality and incidence in the US during 2008 in both sexes. However, there is a 
tendency for a reduction. This might be attributed to early screening programs like 
colonoscopies, flexible colon sigmoidoscopies and faecal occult blood tests (Umar 
and Greenwald, 2009). 
CRC aetiology has been thoroughly studied during the last decades. Age remains the 
most important risk factor for CRC. Although this disease can occur at any age, 
about 90% of diagnosed cases correspond to patients over 50 years old (American 
Cancer Society, www.cancer.org).  
Only approximately 8% of CRC cases are defined as hereditary cancer syndromes 
(Weitz et al., 2005). The two major syndromes are Familial Adenomatous Polyposis 
(FAP) and Hereditary non polysis colorectal cancer (HNPCC) (Fig. 2). 
 
 
        
 
 
 
 
 
 
                        Fig. 2 CRC risk factors and causes. (Weitz et al., 2005) 
 
FAP is an autosomal-dominant disease characterized by development of multiple 
colonic adenomas at early age due to a mutation in the Apc gene (Groden et al., 
1991). The incidence for FAP is estimated at about 1 in 8000 live newborns  
(Fearnhead et al., 2001). The clinical diagnosis of FAP depends upon the detection 
of hundreds to thousands of adenomatous polyps in the colon and rectum of affected 
patients. The polyps typically appear by the third decade of life but also in 
adolescence. Colonoscopy is suggested as screening procedure for FAP families. 
Untreated, CRC invariably develops by the early forties at the latest. The risk of 
developing CRC is reduced using prophylactic colectomy or proctocolectomy (Beech 
et al., 2001). HNPCC or Lynch syndrome is an autosomal-dominant disorder caused 
by germline mutations of mismatch repair (MMR) genes (Lynch et al., 1992). In 
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addition, HNPCC patients have microsatellite instability (Jass et al., 2002; Liu et al., 
1996). Other minoritary syndromes like Flat adenoma, Cowden, and Peutz-Jeghers 
syndromes belong to the hereditary cancers as well (Lynch and de la Chapelle, 
2003). 
Presence of the mutated genes that cause familial colorectal cancer increases the 
risk of developing the disease. These mutations may be passed from one generation 
to the next or may be a product of a person's environment. This latter class does not 
really fulfil the hereditary CRC criteria (Weitz et al., 2005). 
A low percentage (2%) of CRC holds a direct relation with inflammation, because 
inflammation is directly associated with carcinogenesis (Coussens and Werb, 2002); 
(Itzkowitz and Harpaz, 2004). 
In most of the cases, sporadic CRC is mainly influenced by environmental factors, 
with no familial or hereditary component. Lower penetrance genes combined with a 
Western-style diet contribute to the majority of sporadic CRCs (Heavey et al., 2004). 
1.2.2 Adenoma-carcinoma sequence  
Development of CRC is a multi-step process and occurs through the accumulation of 
several discrete events. Originally described by Vogelstein (Fearon and Vogelstein, 
1990) the adenoma-carcinoma sequence is developed by genetic mutations which 
bring histologic changes (Fig. 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 A revision of the Vogelstein adenoma-carcinoma sequence. Adapted from McDonald et al. 
(2006). See text for details. ACF, aberrant crypt foci 
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An initial mutation in a stem cell within a crypt gives rise to dysplastic progeny, which 
induces the development of a monocryptal adenoma after successive replication 
cycles. More mutations are acquired as this process continues leading to genetic 
instability and ultimately to cancer (McDonald et al., 2006). Several proteins are 
involved in this sequence. 
One of the initial events in the development of CRC is Apc mutation. Approximately 
80% of sporadic colon tumors show mutation in this gene (Powell et al., 1992). The 
great majority of Apc mutations lead to a truncated protein. Lack of functional Apc 
protein leads to accumulation of β-catenin in the cytosol and its nuclear translocation 
(compare chapter 1.3.3). Downstream targets of Apc/-catenin include genes related 
with inflammation, proliferation, angiogenesis and oncogenes.  
Histologically, the first recognisable manifestation of epithelial alterations are 
aberrant crypt foci (ACF).  Apc mutations are still present at the ACF stage and they 
are related with the degree of dysplasia of these early lesions. ACF are putative 
precursors of colon cancer and have been described in mice after carcinogen 
induction (Bird, 1987).  
Likewise, germ-line mutations of DNA MMR genes like MLH1 and MSH2 participate 
in the initial stages as well. Microsatellite instability is attributed to these mutations 
and is found in approximately 15% of CRC (Ionov et al., 1993). 
Another crucial mechanism during early stages is DNA methylation. Epigenetic 
events play an important role in gene regulation and DNA methylation modifies gene 
functions during cancer development (Hamilton, 1992). On one hand, CRC shows a 
decreased level of whole genomic methylation as one of the earliest molecular 
abnormalities (Makos et al., 1992) which can lead to genomic instability and therefore 
facilitating or accelerating tumor progression (Rodriguez et al., 2006). But on the 
other hand, like in the Apc gene, promoter hypermethylation results in a decreased 
expression of the protein (Esteller et al., 2000). 
The second step in the evolution towards intestinal cancer is acquisition of K-Ras 
mutations. This protein belongs to the low molecular weight GTPases and regulates 
cell growth, apoptosis, motility and differentiation. K-Ras activating point mutations 
occur in about 50% of human sporadic CRC cases (Malumbres and Barbacid, 2003). 
K-Ras mutations affect mostly specific codons (12-13,59-61) relevant to the 
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endogenous guanine triphosphatase activity, leading to the constitutive activation of 
the Ras/Raf/MEK/ERK signal transduction pathway (Cox and Der, 2002). 
Further malignant progression towards the carcinoma stage involves loss of 
heterozigosity (LOH) of the chromosome 18q. In this region the tumor suppressor 
DCC and the transduction proteins SMAD4 and SMAD2 are located (Fearon et al., 
1990). SMAD2 and SMAD4 are pivotal proteins of the transforming growth factor-β 
(TGF-β) pathway which are involved in cell proliferation, differentiation, motility, 
adhesion or apoptosis (Massague, 2000). SMAD2 and SMAD4 mutations are usually 
found in CRC and are associated with its malignant progression (Fodde et al., 2001; 
Riggins et al., 1996). DCC (deleted in colon cancer) is a membrane protein involved 
in axon guidance but it is often linked to chromosomal instability and acts as a 
putative tumor supressor (Cho and Fearon, 1995; Mueller et al., 1998). 
In most malignant cases, colorectal tumors are characterized by TP53 alterations. 
This tumor suppressor protein plays an important role in many cellular processes like 
DNA repair, apoptosis, cell cycle mutations, etc. TP53 mutations are closely 
associated with the transition from adenoma to carcinoma and such mutations occur 
in colorectal carcinomas (Baker et al., 1989; Baker et al., 1990).  
1.2.3 Colorectal cancer chemoprevention 
 
Pharmacological agents such as NSAIDs (non steroidal anti inflammatory drugs), 
e.g. aspirin and sulindac, as well as Coxibs (Cox inhibitors) have been intensively 
studied in CRC prevention. Nevertheless, dietary compounds with promising results 
in pre-clinical models have also attracted the interest of cancer prevention scientists. 
In 1993, the CAPP-1 (Concerted Action Polyp Prevention) trial studied the preventive 
effects of aspirin in FAP patients; a significant reduction in the size of the largest 
recorded polyps was reported in patients who stayed in the trial for more than a year. 
Adverse effects were not described (Mathers et al., 2003). A similar trial (CAPP-2) 
was designed for HNPCC patients but no inverse association between aspirin and 
colorectal adenomas was found. Moreover, almost no severe incidences were 
observed (Burn et al., 2008).   
Until now, two cohort and five case-control studies have been carried out with aspirin 
in sporadic CRC. Although aspirin reduced the risk of colon adenoma development, 
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gastrointestinal bleeding and gastric/duodenal ulcer have been described as adverse 
events. This is due to unspecific selectivity of aspirin which inhibits both Cox 
isoenzymes. Cox-1 is constitutive expressed and involved in gastrointestinal 
protection. Cox-2 on the other hand is an inducible protein related to inflammation 
and tumor promotion (Cuzick et al., 2009). Other NSAIDs such sulindac showed 
unspecific Cox inhibition as well. Five small randomised trials have investigated 
sulindac in FAP patients; three described adenoma regression but the other two 
studies failed to find any effect. No specific adverse effects were indicated (Giardiello 
et al., 2002; Herendeen and Lindley, 2003). 
Celecoxib is more specific for Cox-2 inhibition than NSAIDs (Warner et al., 1999). 
Therefore, Celecoxib was tested in 3 clinical trials. In a first randomised double-blind 
comparison of FAP patients, celecoxib caused a decrease in number of polyps and 
burden (Steinbach et al., 2000). Further randomised double-blind comparisons in 
sporadic colorectal adenomas were the APC (Adenoma Prevention with Celecoxib) 
and the PreSAP (Prevention of Sporadic Adenomatous Polyps) trials. Both studies 
showed a reduced adenoma incidence but unexpected cardiovascular side effects 
were reported. Due to these adverse events, Celecoxib trials were suspended and 
the FDA (Food and Drug Administration in US) alerted for its increased risk of 
cardiovascular events (Arber, 2008). 
Future clinical studies should focus on the examination of phytochemicals, which are 
considered generally to be of low hazard and well tolerated. Based on epidemiologic 
studies, dietary agents such as calcium, folate and polyphenols are now considered 
for clinical trials for CRC prevention.   
Calcium supplementation has been studied as a promising CRC agent but 
contradictory results have been observed in both FAP patients and sporadic 
adenomas. Whereas colonic crypt fission was reduced in both FAP and sporadic 
cases, no significant changes were identified in terms of colonic mucosa proliferation 
in two large human studies. However, in two randomized double-blind comparisons, 
calcium supplementation suggested an inverse relation with adenoma recurrence in 
sporadic CRC patients (Sharma et al., 2001). During 2003, a large double blind 
placebo controlled trial in patients with familial CRC cancer revealed a weak relation 
in adenoma recurrence. The authors indicated that no sufficient evidences are found 
to recommend calcium supplementation in CRC prevention (Weingarten et al., 2005). 
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Likewise, epidemiologic and clinical studies indicate that dietary folate intake and 
blood folate levels might be inversely associated with sporadic colorectal cancer risk 
in terms of adenoma recurrence (Kim, 2003). During the last years, folate was 
supplemented in a large prospective cohort. Long term use resulted in a 30% CRC 
risk reduction. But contradictory results were obtained in a double-blind, placebo-
controlled phase III trial which revealed that 1 mg folate per day had no effect to 
reduce the adenoma recurrence (Cole et al., 2007). 
Dietary polyphenolic compounds like curcumin have shown interesting results in a 
pharmacokinetic study. After 7 days treatment, Cox-2 and the M1G DNA adduct (3-
(2-deoxy-b-di-erythro-pentafuranosyl)-pyr[1,2-A]-purin-10(3H)one) were significantly 
reduced. Moreover curcumin was investigated in a small cohort of FAP patients. After 
6 months, patients showed a reduction in polyp number and size. This could also be 
demonstrated in a similar study with quercetin (Cruz-Correa et al., 2006). At the 
moment, other trials are recruiting patients for a phase II study of sporadic CRC with 
curcumin.  
1.2.4 Animal models in colorectal cancer prevention 
 
Animal models offer valuable preliminary data upon which human clinical trials can 
be based. 
During the last years, several colorectal in vivo models have been developed. Among 
them, the carcinogen-injected azoxymethane (AOM) rodent model and the ApcMin/+ 
(Min) mouse model are the most common models in prevention studies for colorectal 
carcinogenesis studies (Femia and Caderni, 2008). 
In the AOM model, dimethylhydrazine is metabolized to AOM and 
methylazoxymethanol (MAM). MAM is metabolised to methyldiazonium which can 
induce neoplastic transformation through DNA/RNA alkylation of colonic epithelial 
cells (Greene et al., 1987). AOM-induced tumors are similar to human tumors in 
terms of histopathological characteristics. However, Apc mutations are rare, and they 
show lack of p53 mutations. Moreover, they hardly develop metastasis (Green and 
Hudson, 2005). 
In contrast, Min mice hold a mutation in the Apc gene resulting in a protein truncated 
in position 850 (Moser et al., 1990). This mouse homolog mutation also appears in 
patients with FAP. In addition, Apc716, Apc1309 and Apc1368 are other Apc mutated 
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mouse models generated depending on the mutation position. Similar to the human 
situation different mutations lead to diverse genotypes. For example, the Apc716 
mouse develops 5-6 times more adenomas than Min mice (Oshima et al., 1995). 
1.3 ApcMin/+ (Min) mouse model 
 
1.3.1 Wnt signaling pathway and targets 
 
The Min mouse model holds an Apc punctual mutation leading to an inactive protein 
form. The Apc protein is involved in the Wnt signaling pathway, where a “Apc protein 
complex” regulates the canonical signal transduction (Fearnhead et al., 2001). The 
Apc mutation was firstly described in 1987 regardless to colon cancer. It is localized 
on the chromosome 5 (band 5q21-22) (Bodmer et al., 1987). The human Apc gene 
has 8535 bp containing 21 exons and shares a 90% homology with the murine form. 
The most important regions of the Apc protein are the 15/20 amino acid region and 
the armadillo region. The first region allows β-catenin binding and the second 
contains multiple sites for phosphorylation (Fodde et al., 2001). A schematic 
representation of the Wnt pathway can be observed in Fig. 4A and B. 
 
 
 
 
 
 
 
 
 
  
 
Fig. 4A. Schematic representation of Wnt signaling pathway. Without Wnt ligands the Apc 
complex remains active. DV1, Disheveled-1; CK1, Casein kinase-1; GSK3β, Glycogen synthase 
kinase 3 beta; TCF/LEF, T-cell factor/Lymphoid enhancer-binding factor 1; Wnt, Wingless Int-1. 
Adapted from KEGGS database. 
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Fig. 4B. Schematic representation of Wnt signaling pathway. Wnt ligand binding inactivates the 
complex. DV1, Disheveled-1; CK1, Casein kinase-1; GSK3β, Glycogen synthase kinase 3 beta; 
TCF/LEF, T-cell factor/Lymphoid enhancer-binding factor 1; Wnt, Wingless Int-1. Adapted from 
KEGGS database. 
 
The canonical Wnt signaling pathway uses the Apc complex for the regulation of β-
catenin target genes (Rubinfeld et al., 1996). In the absence of Wnt ligands β-catenin 
is phosphorylated by GSK-3β kinase and subsequently ubiquitinated. Finally, it is 
degraded by the proteasome (Orford et al., 1997). In this situation, the Apc complex 
is active (Fig. 4 A). 
In presence of Wnt ligands, the Frizzled receptor induces Disheveled (DV1) protein 
phosphorylation, including recruitment and inactivation of GSK-3β kinase. Because 
β-catenin can not be phosphorylated, it is released and binds to DNA-binding 
proteins of the T-cell factor (TCF) family (Behrens et al., 1996) (Fig.4 B). β-Catenin 
and TCF are the main cofactors of TCF-LEF (T-cell factor/ Lymphoid enhancer-
binding factor 1). However, there are other important factors to activate specific 
target genes (Shitashige et al., 2008). Different targets of the Wnt signaling pathway 
have been described. A representative list of TCF-LEF target genes is shown in Fig. 
5. 
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    Fig. 5. Wnt target genes. Adapted from (Dihlmann and von Knebel Doeberitz, 2005) 
 
In the Min mouse model, the Apc truncated protein results from a modification of 
thymine to an adenine nucleotide in codon 850. This short Apc protein is unable to 
maintain the Apc complex active, implying that β-catenin is always unphosphorylated 
and therefore released. Phenotypically, these mice will spontaneously develop 
adenomas in the SI and colon (Moser et al., 1990). 
1.3.2 Comparison between FAP and the Apc Min/+ mouse model 
 
Based on the genetic similarity to FAP and many sporadic CRC, the Min mouse 
model is considered as a useful model for chemoprevention studies. When planning 
chemopreventive intervention studies in the Min mouse model one has to be aware 
of its limitations. 
First studies using the Min mouse model proved that most of the adenomas were 
found in distal parts of the SI (small intestine), whereas in humans, tumors are 
principally found in the colon. This has been the principal critique to this model. 
Recently, a histopathological study comparing tumors from FAP patients and from 
Min mice showed similarities in duodenal microadenomas. Because of these 
similarities the authors conclude that the Min mouse is a good model of FAP, in 
contrast to detractors (Preston et al., 2008). 
Also the occurrence of K-Ras and TP53 mutations differs between FAP and the Min 
mouse model. While K-Ras plays an important role in human CRCs there are no 
common K-Ras mutations in the Min mouse model (Shoemaker et al., 1997). 
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Recently however, it has been reported that Min mice with Ras knockout developed 
increased numbers of intestinal tumors and had a decreased survival (van der 
Weyden et al., 2008). Likewise, TP53 mutations which are common in human colonic 
adeno-carcinomas are not found in Min mice (Fazeli et al., 1997).  
Another controversy is the relation of PPARɣ in the human situation and the Min 
mouse model. Different effects have been observed with PPARɣ agonists. In human 
CRC cell lines such compounds induce growth inhibition linked with G1 cell cycle 
delay (Sarraf et al., 1998), whereas administration of PPARɣ ligands enhance polyp 
numbers in Min mice (Lefebvre et al., 1999). Surprisingly, Apc mutation in 
combination with PPARɣ gene knockout enhanced tumor development (McAlpine et 
al., 2006). This could be attributed to an increase in epithelial proliferation since 
similar results were obtained in Min mice with PPARɣ antagonists. Authors described 
an up regulation of Cyclin D1 and c-Myc genes (Fujisawa et al., 2008). 
Despite the critiques and controversies, the Min mouse model has been a suitable 
model for chemopreventive agents in pre-clinical evaluation.  
1.3.3 Chemoprevention studies in the Min mouse model 
 
Until the end of 2008, 294 different agents have been applied in Min mouse 
experiments including dietary and other chemopreventive compounds. This has been 
described in a systematic database of different Min mice experiments (Corpet and 
Pierre, 2003). The most commonly tested compounds have been Cox-2 inhibitors, 
NSAIDs, and dietary phytochemicals. 
Cox-2 inhibitors can serve as a standard example of intervention studies using Min 
mice. Diet mixed with 500 ppm Celecoxib caused significant reductions in tumor 
multiplicity by 71%. Other pharmacological agents like NSAIDs showed similar 
inhibition efficiencies (Sulindac 160 ppm: 49% and piroxicam 200 ppm: 36%). 
Although aspirin showed a variation in polyp inhibition (24%-50%), this model seems 
to be satisfactory for the evaluation of such chemical agents. 
In the database phytochemicals from dietary agents have been reported with 
different efficiency. Different percentages of adenoma reduction have been reported 
for plant phenolics: 0.1% curcumin (63%), 0.1 (+)-catechin: (71%) and 0.32 % 
Epigallocatechin-gallate (45%). Other agents such as resveratrol are still under 
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discussion due to contradictory results. Two studies have showed 24% and 70% 
tumor inhibition and another did not confirm this preventive effect (Sale et al., 2005; 
Ziegler et al., 2004). In addition, positive effects have been demonstrated for 
chemopreventive constituents of cruciferous vegetables: 0.06% Sulforaphane (50%) 
and 0.05 % PEITC (32%). Dietary fiber seems to be less effective than polyphenols 
in Min mice adenoma prevention: 7% White bran, 10% rye bran, 19% resistant starch 
and 6% fructo-oligosacarides result in less than 12% tumor reduction. Moreover, 2.5 
% inulin enhances tumor formation by 40%. 
Tea is the most consumed beverage in the world aside from water. Green tea 
polyphenols have been extensively studied as cancer chemopreventive agent. A 
0.08% and 0.16% green tea extract inhibited intestinal tumorigenesis in Min mice by 
37% and 47%, respectively (Ju et al., 2005). Further combination experiments with 
80 ppm sulindac and 1.5% white tea provided greater tumor suppression than tea or 
sulindac treatment alone (Combination: 88%; white tea: 50%; sulindac: 50%) (Orner 
et al., 2003).  
1.3.4 β-catenin accumulated crypts as potential new biomarker 
 
 
ACF lesions have been described as putative early preneoplastic lesions and have 
frequently been used for preclinical cancer chemoprevention studies. The number of 
ACF depends on the age of rodents, the doses of carcinogen and intervention time. 
In 5 week old rats treated with AOM (25 mg/ Kg BW), more than 200 ACF per colon 
can be identified. However, in the Min mouse model a lower frequency of ACF 
lesions are found. As an example, only 2-3 ACF per colon are found in 7 weeks old 
Min mice (Mori et al., 2004). These lesions show an increased grade of dyplasia 
compared to AOM ACF lesions; thus they are referred as ACFMin. ACFMin are not 
elevated above the surrounding mucosa and its adequate identification depends on 
the homogeneity of blue methylene staining (Paulsen et al., 2001). Overall, ACFMin 
might not be satisfactory pre-neoplastic biomarkers in the colon. 
Yamada et al. described a different type of lesions in the colon of Min mice which 
were designated as β-catenin accumulated crypts (BCAC). BCAC are regarded as 
independent lesions from ACF because they show excessive nuclear β-catenin 
staining. Moreover, BCAC have a higher grade of histological dysplasia and 
proliferative activity than ACF, thus these lesions are considered premalignant. 
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Approximately 10 BCAC per colon are found in 5 week old Min mice (Hata et al., 
2004; Yamada et al., 2000). This represents an advantage compared to the lower 
number of adenomas in the colon of Min mice. The study of BCAC in the Min mice is 
interesting in order to focus on the question whether chemopreventive substances 
are still active in the colon and whether this situation could be compared to humans.  
1.4 Health benefits of apples   
1.4.1 Epidemiology facts. 
 
Apples are the most important fruit produced in temperate climate regions of the 
world and play an important part in the U.S. diet. They are the second most popular 
fresh fruit consumed by Americans (USDA, US Dept. of Agriculture). The world apple 
production in the marketing year 2003/04 was estimated at 43 million tons (USDA, 
US Dept. of Agriculture). In Germany, apples are the most consumed fruits. During 
2006, each family consumed a mean of 21.5 kg apples (ZMP Zentrale Markt- und 
Preisberichtstelle GmbH; 2007). 
Several studies have described the beneficial effects of apple products, especially 
those related to malignant diseases such as diabetes, cardiovascular diseases, 
obesity and cancer (Boyer and Liu, 2004). 
Apple consumption and CRC risk has also been evaluated in epidemiological 
studies. The first study was performed in 1996. Deneo-Pellegrini observed a dose 
dependent CRC relative risk (RR, the risk of developing a disease) reduction (RR= 
0.4; 95% CI= 0.25-0.66) in a case control study in Uruguay for people consuming 3 
or more apples per week (Deneo-Pellegrini et al., 1996). 
During the last 5 years 3 epidemiological evaluations have been performed in Italy, 
USA and Scotland. In an Italian meta-analysis of case-control studies an inverse 
association between consumption of one or more apples/day and risk for colorectal 
cancer (OR= 0.8; 95 % CI = 0.71-0.90) was shown. Other cancers displayed an OR 
(odds ratio, ratio of the probability of occurrence of an event to the probability of the 
event not occurring) reduction as well (Gallus et al., 2005). In the USA, evaluations 
from a large cohort study (Nurses´ Health Studies) estimated a significant reduction 
in colorectal adenomas for the highest quintile of apple consumption (RR=0.83; 95 % 
CI=0.7-0.98) compared to the lowest quintile (Michels et al., 2006). More recently, in 
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a case control study conducted in Scotland, significant reductions were reported in 
CRC risk in the highest quartiles of flavonols, quercetin, procyanidins and flavan-3-
ols consumption. However, weaker evidence was shown when comparing highest 
versus lowest intakes of apples (OR=0.91; 95% CI=0.65-1.26) (Theodoratou et al., 
2007). 
1.4.2 Apple juice components 
 
 
Which components are responsible for the benefits? Apples constitute an important 
part of the human diet, as they are a source of dietary fibre, monomeric and dimeric 
carbohydrates, minerals and biologically active compounds, such as vitamin C 
(ascorbic acid) and certain phenolic compounds (Souci et al., 2005). 
Apples and apple juice (AJ) are rich sources of phytochemicals and a major 
contributor of flavonoids, antioxidants known for their protective effects. The content 
varies from 0.01 % to 0.1 % of the fresh weight (Heim et al., 2002; Wojdylo et al., 
2008).  
The most important polyphenols in apples are: 
Phenol carbonic acids (1): 
Chlorogenic acid (3-O-caffeoyl-D-quinic), and its isomers. 
Flavonoids: 
- FLAVAN-3-OLS (2):  
Epicatechin, catechin and their polymeric structures.  
-  FLAVONOLS (3): 
 Quercetin and its mono- and diglycosides. 
-  DIHYDROCHALCONES (4): 
 Phloretin xyloglucoside and phloridzin. 
The concentration of these phenolic compounds is strongly dependent on the variety 
of apples, maturity, area of cultivation and year of harvest (Alonso-Salces et al., 
2004; Guyot et al., 2003).   
Although part of the polyphenols may be lost during the AJ processing, procyanidins 
remain as the principal polyphenol class (Guyot et al., 2003). Catechin oligomers, 
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known as oligomeric procyanidins (OPC) are the major compounds in apples and AJ. 
In apples, from 40% to 50% of the total polyphenols are procyanidins (monomers and 
dimers: 116-411 mg/kg and OPC: 388-1622 mg/kg). Moreover, procyanidins are also 
the main active compounds found in AJ and polyphenolic apples extracts. Industry 
commercializes clear AJ and cloudy apple juice (CAJ). While CAJ is a good source of 
procyanidins, clear AJ is very poor (Ozsmiansky, Wolniak et al. 2007). This has been 
also demonstrated analyzing CAJ extracts, which contain between 48-61% of the 
OPC. On the other hand, clear AJ extracts may contain similar total polyphenol 
amounts; although procyanidin content is lower (28-49%). They have the potential to 
exert strong anti-oxidative activity (Vanzani et al., 2005).  
Phenol carbonic acids are the second most abundant polyphenols in apples (45-384 
mg/kg) and in CAJ (74 – 259 mg/l). These compounds are mainly found in the pulp 
and responsible for the characteristic acidic taste in some apple varieties and CAJ. 
Amounts of flavonols (Apples: 116 – 411 mg/kg, CAJ: 46 – 124 mg/l) and 
dihydrochalcones (Apples: 20 – 155 mg/kg, CAJ: 14 – 87 mg/l) are also found in the 
apple peel. Both are involved in protection against the effects of solar radiation 
(Merzlyak et al., 2008). Anthocyanins such as cyanidin-3-galactoside and other 
cyanidin glycosides are also found in red apples but in a low concentration (0-37 mg/ 
kg) (Vrhovsek et al., 2004). Calculated amounts were adapted according to a 
comprehensive review from Gerhauser (Gerhauser, 2008). 
 
1.4.3 Chemopreventive potential of apples and apple compounds  
 
Several in vitro and in vivo studies on apple polyphenols report mechanisms 
consistent with protection against colon cancer carcinogenesis. The 
chemopreventive potential is mainly due to polyphenols and pectin which can affect 
the overall process of carcinogenesis by several mechanisms.  
Apple constituents and their chemopreventive effects have been rewieved recently 
(Gerhauser, 2008). Polyphenols are known to influence carcinogen metabolism. 
Pectins reduce the anti- mutagenic potential at the initiation stage and may induce 
DNA remethylation and histone deacetylases inhibition which may activate tumor 
suppressor genes. 
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Polyphenolic compounds such OPC and quercetin conjugates are involved in anti-
oxidative activities as scavenging O2-, OH- and ROO- radicals. Other known 
mechanisms in the promotion stage of carcinogenesis are anti-inflammatory effects 
such as interference with Cox-2 and NF-κB. Furthermore, signal transduction 
pathways involved in tumor growth are another target of polyphenolic compounds. 
The most representative signalling pathways are MAPK and Wnt.  
In the progression stage both, pectins and polyphenols are reported to block cell 
growth by inhibiting cell cycle-related proteins, they may even induce apoptosis.  
All mentioned mechanisms have been discussed by Gerhäuser (Gerhauser, 2008). 
 
1.4.3.1 In vitro CRC chemopreventive activity 
 
At initiation stage, the modulation of Phase I and II carcinogen metabolism with apple 
polyphenols has been investigated in different in vitro systems. Inhibition of CYP1A1 
activity by AJE has been reported by Pohl et al. In the Caco-2 cell line, a strong 
decrease was observed in Cyp1A at mRNA and protein expression and enzymatic 
activity by AJE treatment (Pohl et al., 2006). In addition, detoxification enzymes like 
GSTs and UGTs were upregulated in LT 97 cell lines treated with polyphenolic apple 
extracts (PAE, 128 µg/ml for 24 h). These cells were obtained from differentiated 
microadenomas which represents colonic preneoplastic lesions (Veeriah et al., 
2006). 
Apple polyphenols have been shown to posses strong antioxidant activity in vitro, 
mainly associated with the phytochemical components rather than with the effect of 
vitamin C (Eberhardt et al., 2000). In one study, when a reconstituted AJE (50-100 
µg/ml) mix was added to HT29 and Caco-2 cells, tert-butylhydroperoxide (TBH)-
induced reactive oxygen species (ROS) levels were decreased after 24 h incubation. 
Modulation of menadione-induced DNA damage was mostly decreased in Caco-2 
cells and less effected in HT-29. Quercetin conjugates, caffeic acid and chlorogenic 
acid were identified to be responsible for the preventive potential (Schaefer et al., 
2006). Other studies using the Comet assay method demonstrated that phenolic 
compounds from apple pomace (leftover material after juice extraction) decreased 
DNA damage in HT29 cells (McCann et al., 2007). 
The anti-inflammatory effects of apple polyphenols have also been investigated. 
Apple extracts inhibited nuclear factor kappaB (NF-κB) in MCF-7 breast cancer cells 
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and human umbilical vein endothelial cells. NF-κB is a transcription factor involved in 
the activation of inflammatory proteins, e.g. Cox-2 and iNOS (Davis et al., 2006; 
Yoon and Liu, 2007). Moreover, epicatechin, phloretin and OPC inhibited Cox-1 
activity from sheep seminal vesicle microsomes in a dose-dependent manner 
(Zessner et al., 2008).  
Fridrich et al. have described cell proliferation inhibition when HT29 cells were 
incubated with a polyphenolic apple extract. Furthermore, protein tyrosine kinase 
activity of the EGFR signalling pathway and PKC activity were effectively inhibited by 
the polyphenolic apple extract (Fridrich et al., 2007b). Similarly, inhibition of cell 
growth was observed by a mix containing 78% polymeric procyanidins in the SW620 
human metastatic colon carcinoma (IC50 = 45 µg/ml) (Gosse et al., 2005). However, 
this can also be attributed to short chain fatty acids (SCFA) which are fermented from 
fiber and some polyphenols. These compounds have been described to inhibit cell 
proliferation via inhibition of histone deacetylases and induction of cell differentiation 
(Davis et al., 2006). 
At the progression stage, colon cancer preventive strategies include mechanisms to 
induce apoptosis. Polyphenolic apple extract induced apoptosis in HT29 cells with 
activation of caspase 3 and DNA fragmentation by 2 mg/ml PAEt (Kern et al., 2007). 
In vitro experiments in B16 mouse melanoma cells and mouse mammary tumor cells 
revealed that apple procyanidins increased mitochondrial membrane permeability 
and cytochrome c release. In addition, activation of caspase-3 and caspase-9 was 
identified (Miura et al., 2008). Also, SCFA are related to apoptosis induction 
(Sengupta et al., 2006).  
 
1.4.3.2 Colon cancer chemopreventive efficacy in vivo 
 
Not many animal experiments using apple juice or apple polyphenols have been 
performed until now and most of them have focused on cancer prevention. 
Nevertheless, experiments related to neural and cardiovascular disorders have also 
been conducted (Aprikian et al., 2002). 
Several studies have focused on colon cancer prevention potential. In one study of 
AOM-induced aberrant crypt foci, rats received 0.01% of a procyanidin mixture (74.8 
% procyanidins) in water. Hyperproliferative crypts and ACFs were 50% reduced in 
comparison with the water control (Gosse et al., 2005).  
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In the rat model for chemically-induced colon carcinogenesis using DMH, Barth et al. 
compared treatments with clear AJ and CAJ. Although both drinks contained similar 
polyphenol amounts, CAJ pectin levels were 3 times higher. CAJ suppressed DMH 
induced genotoxic damage in mucosa cells of the distal colon. Both treatments 
reduced in similar manner the crypt cell proliferation index, but only CAJ reduced 
ACF (Barth et al., 2005). In a second study, conducted to determine which fraction 
was causing these effects, CAJ was fractionated in a total polyphenol fraction and a 
cloud particle fraction consisting of proteins, fatty acids, polyphenols, and cell wall 
polysaccharides. As in the first experiment, CAJ results reduced ACF numbers but 
each fraction failed to reduce genotoxicity in colonocytes and ACF lesions. In 
contrast, crypt cell proliferation index was statistically significant reduced by CAJ, the 
total polyphenol fraction and the cloud particle fraction. Authors argued that the 
chemopreventive potential may be attributed to a combination effect of both fractions 
(Barth et al., 2007). 
Apple pectin has also been investigated for its chemopreventive potential. It is found 
at a range of 1-1.5% in apples. A study in Japan using the AOM-induced rat model 
showed a reduction in the multiplicity of colon tumors where diets were 
supplemented with 20% of either apple or citrus pectin. Only animals fed with apple 
pectin had a diminished tumor number (Ohkami et al., 1995). Results were 
reproducible in a second animal experiment with the same set up. Similar results in 
terms of tumor number and incidence were observed. In addition, animals fed with 
20% apple pectin had significantly reduced PGE2 levels in distal colon mucosa 
(Tazawa et al., 1997). This heteropolysaccharide acts as an anti-mutagen due to its 
ability to scavenge mutagens and to reduce mutagen concentration as a result of the 
increased fecal bulk (Gerhauser, 2008). 
Other apple compounds like carbohydrates have been studied in Min mice. Enriched 
diets with 20% apple pomace were used as a source of resistant carbohydrates. 
After intervention, the treatment increased the mass of the SI. Moreover, the distal SI 
parts and colon showed increased cell proliferation and the crypt fission. 
Significantly, polyp number and polyp burden were augmented in all parts of SI. In 
the colon, polyp diameter and tumor burden was increased as well (Mandir et al., 
2008). Underlying mechanisms are not completely understood so far, but 
degradation of carbohydrates to short chain fatty acids and a subsequent increase in 
cell proliferation has been discussed. 
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Overall, pectin, fiber and polyphenols are the apple compounds mostly responsible 
for effects on the whole process of carcinogenesis. 
1.5 Bioavailability  
 
Biological efficacy in vivo is dependent on the bioavailability of dietary components, 
except for the gastrointestinal tract where local effects may occur. 
Bioavailability is defined operationally and pharmacologically as the proportion of the 
compound administered orally that is absorbed from the GI tract. This represents the 
proportion of the compound that appears in plasma over time. The biological effects 
of polyphenols depend on their bioavailability and their chemical structure. This 
determines their rate and level of intestinal assimilation, and the nature of the 
metabolites circulating in the plasma (Scalbert and Williamson, 2000). The absorption 
of flavonoids in the intestine may be limited by the transport of flavonoids or their 
metabolites back to the intestinal lumen by ABC transporters (Walle et al., 1999). A 
general overview of the bioavailability of polyphenols is showed in Fig. 6. 
Usually, in the intestine many flavonoid aglycones tend to pass through epithelial 
cells where they are further conjugated by methylation, sulfation or glucuronidation 
(Day et al., 2001; Spencer et al., 2004) (Fig. 6, A1-A2). 
In the SI, flavonoid glycosides can be deglycosylated by β-glucosidases including 
lactase phlorizin hydrolase which has specific activity towards flavonoid glycosides. 
The resulting flavonoid aglycon can be absorbed via passive diffusion through the 
enterocytes and also be conjugated (Crespy et al., 2001) (Fig. 6, B). However, the 
sodium-dependent glucose transporter-1 (SGLT-1) might be implicated in the 
absorption of flavonoid glycosides. Flavonoids can be deglycosylated within the cell 
by cytosolic β-glucosidase and further conjugated (Walgren et al., 2000) (Fig. 6, C1-
C2). 
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Fig. 6. Schematic representation of absorption, transport and metabolism of polyphenols.  
Flav. aglyc., Flavonoid aglycones; Fl. glyc, Flavonoid glycosides; OPC, oligomeric proyanidins; PPC, 
polymeric procyanidins; PCA, Phenol carbonic acids; GMF, gut microflora; DHPPA, 3,4- 
dihydroxyphenyl propionic acid; PHL, phloroglucinol; DHPAA, 3,4-dihydroxyphenyl acetic acid; 
SGLT1, sodium-dependent glucose transporter 1; LPH, lactate phloridzin hydrolase; β-GLC, β-
glucosidase; COMT, catecholamine orthomethyl transferase; UGT,  UDP-glucuronyltransferase, SULF 
sulphotransferase; Fl. conj, conjugated flavonoid. Dashed lines indicate passive diffusion. Different 
absorption pathways: (A1-A2) Passive diffusion and conjugation of flavonoid aglycones, (B) Flavonoid 
glycosides can be hydrolyzed by LPH, (C1) transport of some flavonoid glycosides through the 
membrane by SGLT-1 and (C2) hydrolysis via β-GLC to release free flavonoid, (D) Effects of gut 
microflora. Schema adapted (Scalbert and Williamson, 2000). 
 
Most phenol carbonic acids like chlorogenic acid cannot be absorbed in the SI due to 
the lack of esterase activities. But they can be hydrolyzed and metabolized by the gut 
microflora (Couteau et al., 2001). Human intervention studies showed that half of the 
ingested chlorogenic acid is converted to hippuric acid in the colon, most likely by 
microbial metabolism (Olthof et al., 2003) (Fig. 6, D1-D2). 
Procyanidins have also been investigated but most experiments have been 
performed in vitro. Because of their molecular size, procyanidins are likely not as 
easily absorbed in the SI. Experiments on the in vitro absorption through a cell 
monolayer derived from Caco-2 cells indicated that radiolabeled procyanidin 
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monomer, dimer and trimer were absorbed in contrast to procyanidin polymers 
having an average degree of polymerisation of 7 (Deprez et al., 2001). The same 
group reported that procyanidin polymers can be degraded by the colonic microflora 
in vitro into low-molecular-weight aromatic acids. The resulting metabolites might  
well be absorbed in vivo through the colon (Deprez et al., 2000).  
 
1.6 Aims of the project  
 
Colorectal cancer (CRC) is the second most common cancer in the world. It is 
particularly common in western countries and its incidence is strongly associated with 
certain dietary patterns. Prevention strategies are required to reduce CRC risk in the 
population. 
We previously demonstrated that the chemopreventive potential of apple 
polyphenolic extracts by several in vitro assays. Apple procyanidin extracts contained 
the strongest activities of all apple polyphenols.   
The general aim of the present study was to characterize in vivo molecular 
mechanism underlying the chemopreventive effects of cloudy apple juice (CAJ) and 
polyphenolic apple extracts (PAE).   
 
1- In our earlier experiments, CAJ and PAE intervention in Min mice significantly 
reduced adenomas numbers in comparison to water control. However, the 
mechanism remained unclear. In order to determine the possible mechanism 
involved in the transition from normal tissue to adenomas, gene expression patterns 
of Wnt signalling target genes were measured in normal mucosa in animals treated 
with CAJ and PAE in comparison with water control. 
 
2- The previous in vitro experiments have identified procyanidins as strong 
chemopreventive compounds in CRC prevention. In the present work, a second Min 
mice experiment was conducted to identify which compounds might be responsible 
for the preventive effects.  
Five treatments were tested, including CAJ, Placebo (AJ without polyphenols), B-
PAE (procyanidin-rich extract), the combination of CAJ + B-PAE and water. From this 
animal experiment, adenomas were collected to study known signalling pathways 
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related with adenoma progression including: 1) phosphorylated proteins in the MAPK 
signalling pathway, 2) Wnt signalling pathway and target genes, and 3) proliferation 
markers. These experiments were performed using proteomic technology (Reverse 
phase protein arrays). 
 
3- The previous in vitro experiments have suggested that PAEs might play a role in 
drug metabolism and have anti-inflammatory potential. To confirm them in vivo, in the 
present work, livers from the second animal experiment were used to measure 
activities of phase I and phase II enzymes, which are related with the initiation stage 
of carcinogenesis. Also, biomarkers such as PGE2 in plasma and protein and NO in 
urine were measured to determine possible anti-inflammatory potentials. 
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2 MATERIALS AND METHODS 
 
Chemicals 
 
Acrylamide/Bisacrylamide    Roth, Karlsruhe 
Agarose      Sigma, Steinheim 
Ammonium persulfate     Roth, Karlsruhe 
Boric Acid      Sigma, Steinheim 
Bromophenol blue     Serva, Heidelberg 
Bicinchoninic acid      Sigma, Steinheim 
BSA protein standard    Sigma, Steinheim 
BSA       Sigma, Steinheim 
Dyethylenpyrocarbonate    Sigma, Steinheim 
Dithiothreitol      Sigma, Steinheim 
DMSO      Merck, Darsmtadt 
Di-potassium hydrogen phosphate  Merck, Darmstadt  
Ethanol      Sigma, Steinheim 
Ethidiumbromide     Gibco,  BLR. Eggenstein 
Ethylacetate      Sigma, Steinheim 
EDTA      Sigma, Steinheim 
Formaldehyde     Sigma, Steinheim 
Glycerol      Merck, Darmstadt 
Glycine      Roth, Karlsruhe 
Hexane      Sigma, Steinheim 
Methanol      Karl Roth, Karlsruhe 
3-(N-Morpholino)-propanesulphonic acid Sigma, Steinheim 
Perchloric-acetic acid    Calbiochem, San Diego, USA 
Phosphoric acid     Sigma, Steinheim 
Potassium Chloride     Merck, Darsmtadt 
Potassium dihydrogen phosphate  Roth, Karlsruhe 
2-Propanol      Sigma, Steinheim 
Sodium dodecyl sulfate     Sigma, Steinheim 
Sodium azide     Merck, Darmstadt  
Sodium Chloride     Sigma, Deisenhofen 
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TEMED      Roth, Karlsruhe 
Triton X-100               Sigma, Steinheim 
Tris-Base      Roth, Karlsruhe 
Tris-HCl      Roth, Karlsruhe  
Tween-20                Sigma, Steinheim 
Odyssey Blocking Buffer              Li-Cor, Bad Homburg 
RNAse Zap                Ambion, Austin, USA   
Urea      Sigma, Steinheim 
 
 
Instrumentation  
 
 
In vitro assays: 
SpectraMax 340 PC (Molecular Devices, Munich) 
Fluorimeter Cytoflour 4000 (Perseptive Biosystems, Framingham, MA, USA) 
Fluorimeter SpectraMax Gemini XS (Molecular Devices, Munich) 
Saur Oxygen electrode (Saur, Reutlingen) 
 
Liver enzymatic assays: 
Ultraturrax homogenizer (IKA Labortechnik, Staufen) 
Avanti Bioprocessing Centrifuge System (Beckman, Fullerton, USA) 
Beckam Ultracentrifuge (Beckman, Fullerton, USA) 
 
Animal dissection: 
Heparinised capillaries (In vitro Diagnosticum, Berlin) 
Hematocrite centrifuge, M 1101 (Compur, Munich) 
Dissection microscope (Olympus, Planegg) 
20x gauge needle (BD, Heidelberg) 
 
RNA, DNA extraction and Polymerase Chain Reaction: 
Micro-dismembrator (Sartorius, Göttingen, Germany) 
Teflon containers (Sartorius, Göttingen, Germany) 
RNA lysis buffer (Qiagen, Hilden, Germany) 
RNeasy Qiagen kit (Qiagen, Hilden, Germany) 
DNase assay kit (Qiagen, Hilden, Germany) 
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Gel Electrophoresis Chamber (Bio-Rad, München) 
Electrophoresis power supplier Power Pac (Bio-Rad, München) 
Biofuge centrifuge (Heraeus, Hanau, Germany) 
Eppendorf spectrophotometer (Eppendorf, Hamburg, Germany) 
Eppendorf PCR Thermocycler (Eppendorf, Hamburg, Germany) 
Real time PCR, iCycler IQ5 (Bio-Rad, Munich) 
Quartz cuvette (Steinbrenner, Wisenbach, Germany) 
RNAse free water (Qiagen, Hilden, Germany) 
 
Immunohistochemistry: 
Tissue embedding system (Sakura Finnetek Gmbh, Staufen) 
Slide staining machine (Sakura Finnetek Gmbh, Staufen) 
Microtome RM 22 35 (Leica, Bensheim) 
Embedding cassettes (Fischer Scientific, Houston, USA) 
AxioSkop 2 MOT (Carl Zeiss, Göttingen) 
Axiovsion 4.0 (Carl Zeiss, Göttingen) 
 
Infrared-based protein detection arrays with quantitive read out (IPAQ): 
Odyssey fluorescence scanner (LI-COR, Lincoln, USA) 
Qiagen dismembrator (Qiagen, Hilden, Germany) 
3 mm stainless steel balls (Qiagen, Hilden, Germany) 
Rocking shaker (Thermo-Fisher Waltmann, WA, USA) 
Nitrocellulose membranes (Grace Bio-labs, Bend, OR, USA) 
Piezo spotter (Biochip-Arrayer, Whaltman, MA, USA) 
Genepix (Molecular devices, Munich, Germany) 
Protein Mini-gel Wet Transfer System (Bio-Rad, Munich, Germany) 
SDS-PAGE electrophoresis equipment (Bio-Rad, Munich, Germany) 
 
PGE2 ELISA: 
Sucking Pump (Sartorius, Göttingen, Germany) 
Scintillation counter PE2000 (Perkin Elmer, Whaltman, MA, USA) 
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2.1 Description of apple products for intervention  
 
In collaboration with Dr. Will and Ms. Melanie Olk (Forschungsanstalt Geisenheim, 
Dept. of Wine and Drink research) a cloudy apple juice and polyphenolic enriched 
extracts were obtained. Apple (Malus domestica) varieties used for the CAJ06 and 
extracts are summarized in Tab. 3. 
 
                   Tab. 3. Apple varieties used for CAJ06 and B-extracts. 
CAJ 06 AE03-B AE06-B 
Bohnapfel Melrose Bittenfelder 
Maunzen Granny Smith  
Winterrambour Golden Delicious  
Tafelobst Jonagold  
              
 
CAJ06 
For the preparation of CAJ06, 1000 kg of mixed varieties of cider and dessert apples 
(Tab. 3) were mashed with a cutting mill (Seepex). The mash was then squeezed 
with a horizontal press (Bucher HP-L 200). The juice is referred to as A-juice (A-
CAJ). After centrifugation (Westfalia Tellerseparator SAR 3036), A-CAJ was shortly 
heated (85 °C, 30-40 s) and lastly stored in stainless steel tanks. The CAJ was filled 
in 0.75 l bottles and kept at 4 °C. 
A clear apple juice (AS06-clear) was produced from the same harvest. CAJ06 was 
shortly incubated with an enzyme mix (50 mL/t Fructozym P, Erbslöh Geisenheim) 
then finned (10 g/hl Gelatin, 40 ml/hl Kieselsol, and 50 g/hl Bentonit, Erbslöh) and in 
the end separated and cross-flow filtered (Seitz, Mikro). 
 
Placebo Juice 
Placebo juice was obtained from the AS06-clear. Initially, a glass-chromatography 
column (Pilot 750x200 mm, Fa. Kronlab/YMC) was prepared with adsorbent SP70 
resin. The column was firstly washed with distilled water and then AS06-clear was 
added to remove all polyphenolic compounds. The polyphenol-free eluate was filled 
up in 0.75 l bottles and kept at 4 °C. Placebo juice and CAJ have similar 
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characteristics except in polyphenolic content (CAJ: 452 mg/L), ascorbic acid and 
colloids. Such drinks contain always high amounts of potassium (Tab. 4). 
 
                    Tab. 4. Comparison between CAJ06 and Placebo juice.  
 
 
 
 
 
 
 
 
 
            
          
 
 
 
                   
 
                    Data obtained from Dr. Will and Ms. Melanie Olk. 
 
B-PAE06 
For this extract, a lyophilized apple extract was obtained from apple pomace. 1200 
Kg of Bittenfelder apples were processed with a Seepex cutting mill and processed 
as described above. The pomace was mixed 1:2 with demineralized water at 95 °C. 
This mix allows to set an optimal enzyme temperature (54°C). Afterwards, an 
enzymatic digestion was carried out for 2 h (pectinases and cellulases, 300 g/t, 
Erbslöh). After this step, the mixture (referred as B-juice) was decanted. Due to the 
higher amounts of pectin a second pectinase digestion was performed. The 
Polyphenols from 200 l of B-AS06 were retained on 15 l of adsorber resin SP 70 
(Resindion, Italy) and packed into a chromatography column (Pilot 750x200 mm, Fa. 
Kronlab/YMC, Germany). Water-soluble constituents were removed with 50 l distilled 
water. Afterwards, polyphenolic compounds were eluted with 25 ml of 96% ethanol. 
The polyphenolic eluate was concentrated by evaporation using a rotary evaporator, 
 Cloudy AJ 06 Placebo 06 
Glucose g/l 18.9 23.7 
Fructose g/l 69.2 71.4 
Saccharose g/l 21.7 16.9 
Sorbitol g/l 4.7 4.6 
Polyphenols mg/l 452 0 
Ascorbic acid mg/l 47 10.6 
Na   mg/l 8 7 
Mg  mg/l 51 48 
Ca  mg/l 49 49 
K    mg/l 1145 1146 
Colloids mg/l 584 120 
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reconstituted in double-distilled water, and subsequently freeze-dried to 600 g yield 
extract. 
B-PAE03 
The production of this extract was similar to that of the AE06-B. However, 1200 kg 
from a mixture of different dessert apples was used. The polyphenols of 550 l from B-
AS03 were extracted using a 55 l resin adsorbent P-495 (Bucher Alimentech, 
Auckland, New Zeeland) in a Bucher-adsober. Carbohydrates, organic acids and 
minerals were removed with 200 L distilled water. Elution was completed using 50 l 
96% technical ethanol and the alcoholic extract was freeze dried in a polar phase. A 
yield of 260 g was obtained. 
The quantitative determination of apple polyphenolic compounds was performed in 1 
g/l diluted in 10% methanol (in water) using a 1090 HPLC/DAD system (Hewlett-
Packard,Germany) prepared with 25 x 4.6 mm Aqua 5 µm C18 column and with a 
4x3 mm C18 ODS pre-column (Phenomenex, Germany). Elution was performed in 
acetonitrile and 2 % acetic acid. Detection wavelengths were: 280 nm for flavonols 
and dyhydrochalcones, 320 nm for phenol carbonic acids and 360 nm for quercetin 
derivates. A summary of the polyphenol composition is shown in Tab. 5. 
In CAJ, chlorogenic acid was identified as the major low molecular weight (LMW) 
component. Due to difficulties in analyzing oligomeric and polymeric procyanidins 
only LMW polyphenols were determined by CAJ.  
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         Tab. 5. Comparison between B-PAE (mg/g) and CAJ (mg/l).  
          Low molecular weight polyphenol composition.  
              
            (1) Phenol carbonic acids (2) Flavan-3-ols (3) Dyhydrochalcones (4) Flavonols 
              Data obtained from Dr. Will and Ms. Melanie Olk 
 
B-PAE03 was obtained from different apple mixes during 2003 and B-PAE06 was 
acquired from a single apple variety during 2006. Both B-PAE differ in composition 
and distribution. The HPLC analysis revealed less low molecular weight (LMW) 
poylphenol amounts for B-PAE06 in comparison to B-PAE03 (B-PAE03: 310 mg/l 
and B-PAE06: 227 mg/l). The B-PAE03 contained more flavonols and 
dyhydrochalcones but less phenolcarbonic acids. Similar amount of monomeric and 
dimeric procyanidins were found. CAJ06 contained more LMW compounds 
compared with both B-PAEs (CAJ: 452.8 mg/). However, 50% of the present 
polyphenols were phenol carbonic acids. CAJ showed considerable amount of 
Polyphenols  mg/l mg/g mg/g 
Sample-Name Classification CAJ06 B-PAE03 B-PAE06 
     
Cumaroyl glucose 0.1 0.00 0.20 
Chlorogenic acid 177.8 19.20 76.55 
Cryptochlorogenic acid 5.3 3.00 5.02 
Caffeic acid 0.2 4.00 0.69 
3-Cumaroyl-China acid 4.5 3.00 0.70 
5-Cumaroyl-China acid 5.5 5.50 0.16 
4-Cumaroyl-China acid 41.8 3.80 52.13 
Cumaric acid 
(1) 
0.4 4.20 0.57 
Procyanidin B1 8.5 6.20 2.37 
Catechin 6.9 2.70 4.25 
Procyanidin B2 71.2 18.40 17.09 
Epicatechin 36.3 17.70 14.27 
Procyanidin C1 
(2) 
35.8 n.d. 13.55 
Phloretin-2'-xyloglucoside 40.9 31.70 9.63 
Dihydrochalcones 4.5 n.d. 0.68 
Phlorizin 
(3) 
9.0 78.90 24.37 
Quercetin-3-galactoside 1.3 8.10 2.82 
Quercetin-3-glucoside 0.6 12.30 0.62 
Quercetin-3-xyloside 0.3 18.10 1.35 
Quercetin-3-arabinoside 0.4 3.50 0.00 
Quercetin-3-rhamnoside 
(4) 
1.5 25.10 0.92 
       TOTAL  452.8 310.0 227.94 
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monomeric and dimeric procyanidins as well as dyhydrochalcones. Lower 
concentrations of flavonols were identified (Tab. 5). 
Since the polyphenolic B-PAE06 contents were different in comparison to the B-
PAE03, 0.2% was prepared as a mixture of the two different extracts.  
2.2 In vitro chemopreventive characterisation   
(Under the supervision of Ms.Karin Klimo and Dr. Clarissa Gerhäuser) 
 
All extracts were previously characterized in a battery of cell- and enzyme-based in 
vitro marker systems which include modulation of drug metabolism, anti-oxidant, 
radical-scavenging, anti-inflammatory and anti-tumor promoting activities. A short 
description of the assays is described in Tab. 6 (Gerhauser et al., 1997). 
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2.3 Min mouse intervention study 
2.3.1 Intervention 
 
A total of 90 6-7 weeks old male C57BL/6J-ApcMin/+ mice were obtained from the 
Jackson Laboratory (Bar Harbor, ME, USA). The animal protocol (35-9185.81/G-
134/06) was approved by the animal committee at the regional council in Karlsruhe.  
Animals were randomly divided (with comparable initial body weights) in groups of 6. 
All groups were maintained of a controlled temperature and humidity environment 
with a 12-h light/dark cycle. Animals were provided free access to drinks and food but 
a special soy free diet was given to avoid a possible influence of soy compounds. 
After 5 days of adaptation, the intervention started for 10 weeks (Fig. 7 and 8). Five 
different interventions were compared the animal experiment. The animals received 
either tap water as a control, placebo juice, CAJ06, CAJ06 plus 0.2 % B-PAE or 
0.2% B-PAE ad libitum, respectively. Liquid uptake was monitored daily and food 
uptake twice per week; moreover, all animals were weighed twice per week. Animals 
appearing sick were sacrificed immediately. 
Since not all animals could be delivered a once, the intervention study was described 
in to three sub-experiments (SE) running in parallel (Fig. 8). 
 
 
   
 
 
  0                7        8                                                                               17 (weeks) 
 
Fig.  7. ApcMin/+ intervention scheme (A: adaptation time). 
 
 
 
 
 
 
                 
                  10 WEEKS INTERVENTIONA 
 90 ApcMin/+ 
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    0        3     4                 10                 13     14 (wk) 
 
 
Sub-experiment (SE) 1 = three intervention groups à 6 animals: Placebo, CAJ and 
CAJ + B-PAE  
Sub- experiment 2 = nine intervention groups à 6 animals:  2x Water, 2x 0.2% B-
PAE, 2x Placebo, 2x CAJ and 2x CAJ + B-PAE. 
Sub-experiment 3 = three intervention groups à 6 animals: CAJ + B-PAE, Water and 
0.2% B-PAE. 
 
Fig. 8. Description of sub-experiments.  
 
 
2.3.2 Dissection 
 
Solutions and reagents: 
PBS cold 
Phos-STOP phosphatases inhibitors (Roche, Mannheim) 
Complete proteases inhibitors (Roche, Mannheim) 
Heparin (Sigma, Steinheim) 
Indomethacine (Sigma, Steinheim) 
70% Ethanol p.a. 
 
 
 
 
    SE-1 n=18          
      SE-3 n=18           
        SE-2 n=54           
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PBS-buffered Formalin 4 %: 
40 ml Formalin 
4.4 g Na2HPO4 .2H20    
25.9 g Na2HPO4.12H20   
Filling up to 1000 ml Millipore water 
 
Mice were weighed before being euthanized. Animals were anesthetised by CO2 
inhalation and sacrificed by heart punction. Blood was extracted with a heparinised 
20x needle. The hematocrit was determined using a hematocrit centrifuge with 
heparinised capillaries and centrifugation at 10.000 rpm for 10 min. Blood was 
splitted into two tubes, one with 10 Units of heparine for subsequent determination of 
antioxidant capacity (ORAC) and another with 30 µl 100 µM indomethacine for 
subsequent PGE2 elisa assay. Both tubes were centrifuged at 10.000 rpm for 10 min. 
Serum samples were stored at - 80 °C until analysis. 
Initially, the spleen and the liver were taken and directly weighed. Spleens were 
completely fixed in 4% PBS-formalin. Livers were cut in 2 pieces and one part was 
shock-frozen in liquid N2 and the other fixed in PBS-formalin. SI was completely 
removed, washed with ice-cold PBS, GI tract was divided in 3 parts (duodenum, 
jejunum and ileum). Colons were prepared according to the BCAC protocol (Hata et 
al., 2006) (compare to chapter 2.3.7). Each piece was opened longitudinally and 
flattened on paraffin section table and properly washed. Faecal rests and cecum 
were removed. During the tissue dissection remainders of fatty and mesenteric tissue 
were removed and discarded. 
Each treatment was divided in to 3 groups (Groups; G1, G2 and G3; each n=30) and 
different experiments were planned. Fig. 9 illustrates a detailed plan. 
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        Fig. 9. Experiment planning scheme. Each treatment was divided in to 3 groups (G1, G2 and   
        G3). BCAC: b-catenin accumulated crypts. See text for description 
 
 
Histopathologic examination (G1 and G2) 
Spleen and liver sections were formalin-fixed, paraffin-embedded cut into 3 µm slices 
and stained H&E. The histopathological examination was performed by Prof. Karbe 
(Wülfrath). 
Liver enzymatic assays (G1 and G2) 
Livers were removed and divide in 2 parts. One was snap-frozen in liquid N2 and 
stored at -80° C before preparation of cytosolic and microsomal liver fractions.  
Swiss rolls (G1 and G2) 
All SI parts were fixed for 4 h with PBS-buffered formalin. After this time, number, 
location, and size of visible adenomas in the entire intestine were determined under 
the Olympus lighted magnifier. Adenomas were classified as small (<1mm), middle 
(1-3 mm) and large (>3mm). Finally, the tissue was rolled to swiss rolls, overnight 
dehydrated in 70% ethanol and embedded in paraffin (see section 2.8.1). 
Adenoma protein expression (G3) 
After opening the GI tract longitudinally, the mucosa was cleaned with ice cold PBS 
(containing phosphatases and proteases inhibitors tract). Adenomas were directly 
counted after the dissection and excised, snap-frozen in liquid N2 and stored at -80°C 
until further analysis of protein expression and phosphorylation (see chapter 2.9). 
Due to the possible fast protein degradation and phosphatase activity, adenomas 
were only counted in total and not divided according to size.  
 
Groups Spleen Pathology 
Liver 
pathology 
Liver 
enz.assay 
Swiss 
Rolls 
  Adenoma 
Prot. Exp. 
Colon 
BCAC 
G1 
 
     
G2      
 
G3      
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β-catenin accumalted crypts (G2)  
In collaboration with Prof. Mori and Dr. Yamada (Tumor Pathology Dept. Gifu 
University, Japan) murine colons were “en face” embedded for the examination of 
microlesions. Colons were removed and washed with cold PBS to remove faeces 
completely. Four mm diameter glass bars were inserted along the colon, and colons 
were incubated in buffered formalin for 5 min, then opened longitudinally, cleaned 
with PBS and flattened on a Whatman paper using two staples on each end. Fixation 
was performed overnight at room temperature. The next day, adenomas were 
excised and the colon was divided in 3 parts (proximal, middle and distal). Tissues 
were placed in histological sample nets and overnight dehydrated in 70 % ethanol 
(see chapter 2.8.3). 
2.4 Clinical markers in serum 
2.4.1 Serum protein determination 
 
Reagents: 
1 mg/ml BSA standard (Sigma, Steinheim) 
Bio-Rad reagent (Bio-Rad, Munich) 
 
Bio-Rad Protein Assay was used to determinate concentration of serum proteins in a 
96 well plate format. The assay is based on the method of Bradford (Bradford, 1976). 
Bio-Rad reagent was diluted 1:5 in Millipore water and filtered through 0.45 µm filter. 
Serum samples were diluted 1:200 and 1:400. A BSA standard was used as a 
reference. 
 
Composition per well 
190 µl Bio-Rad reagents (diluted) 
10 µl serum sample or standard 
 
Plates were incubated for 5 minutes at room temperature and then measured at 595 
nm.  
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2.4.2 ORAC determination  
 
Reagents: 
Perchloric-acetic acid 
0.5 N NaOH  
2,2-Azobis-(2-amidinopropane) dihydrochloride  (AAPH, Polyscience, USA)  
Trolox (Calbiochem, USA) 
 
ORAC Buffer: 
0.75 mM Na2HPO2  
0.75 mM KH2HPO4  
0.21 µM Fluorescein 
 
In order to precipitate proteins, 20 µl of 0.5 M perchloric-acetic acid was added to 20 
µl of serum, mixed and centrifuged for 10 min at 4°C in an Eppendorf centrifuge. 
Afterwards, supernatants were neutralized with 1.2 µl 0.5 N NaOH and diluted 1:5 in 
ORAC buffer. For the ORAC assay, 20 µl were used for determination. 
The decline of fluorescence was measured at 37 °C for 120 min until completion 
using a Cytofluor 4000 fluorescent microplate reader (excitation wavelength ex 
530/25 nm, emission wavelength Em 585/30 nm). Results were expressed as ORAC 
units, where 1 ORAC unit equals the net protection of fluorescein produced by 1 µM 
Trolox. 
 
Composition per well: 
190 µl ORAC buffer 
10 µl diluted serum 
 
2.4.3 PGE2 determination 
 
Materials: 
Supelco LC-18 Reverse phase extraction (Sigma, Steinheim) 
PGE2 ELISA Kit (R&D, Abingdon, UK) 
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Reagents: 
3H-PGE2 conjugate 0.1 mCi/ml (Perkin Elmer, Whaltman, MA, USA) 
Ultra pure water (Cayman chemicals, Ann Arbor, MI, USA) 
Acetonitrile (ACN) 
15 % Ethanol 
Hexane 
Etylacetate 
RD5-39 Buffer (Elisa kit R&D kit) 
 
This assay determines the PGE2 content in serum. A preliminary extraction using a 
reverse phase extraction protocol (C18 reverse phase columns) is required to avoid 
cross reactions with other serum components.  
Serum was spiked with a radioactive tracer to determine the column extraction 
efficiency. 10 nCi [3H]-PGE2 were added to the serum sample as an internal standard 
(360 µl RD5-39 buffer, 40 µl serum and 20 µl 1:100 3H-PGE2) and mixed well. Then, 
as initial CPM (counts per minute) measure, 20 µl were quantified in the scintillation 
counter. 
Proteins were then precipitated by adding 20 µl 4 N HCl, mixing and cooling down for 
15 minutes on ice and the serum mix was centrifuged at 13.000 rpm for 1 minute. 
Supernatant was afterwards subjected to solid phase extraction using C18 columns 
which had been previously preconditioned (10 ml ethanol) and equilibrated (10 ml 
water). The supernatant was pipetted directly on to the C18 column and slowly eluted 
under constant pressure conditions (1-2 drops per second). Columns were washed 
(water, 15% ethanol and hexane, 5 ml each) and analyte elution was carried out (4 
mL ethylacetate). The eluate was kept at -80 °C until analysis.   
Ethylacetate was evaporated under a nitrogen atmosphere and samples were 
resuspended in 250 µl of RD5-39 buffer. Recovery was calculated measuring 20 µl of 
the reconstituted sample in a scintillation counter and adjusted to the initial volume. 
PGE2 in plasma was quantitated using a PGE2 immunoassay kit. The principle of the 
immunoassay is based on a competitive ELISA technique in which PGE2  present in 
serum competes with a fixed amount of HRP-labelled PGE2 for sites on a mouse 
monoclonal antibody plate. A negative control (NSB wells) and a blank (Bo) were 
pipetted together with the standard and serum. 
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NSB wells 
150 µl R5-39 buffer 
50 µl PGE2 conjugate 
 
 
Bo wells 
100 µl R5-39 buffer 
50 µl primary antibody solution 
50 µl PGE2 conjugate 
Sample or Standard 
100 µl STD or serum 
50 µl R5-39 buffer  
50 µl PGE2 conjugate 
 
The plates were incubated for 2 h at RT on an orbital shaker. Afterwards, each well 
was washed 4 times with 400 µl wash buffer and 200 µl of substrate solution were 
added. The plate was incubated for 30 min at RT, protected from light. Finally, 50 µl 
stop solution was added to each well. The O.D. was determined using the microplate 
reader system at 450 nm. A PGE2 standard curve was created using a four paramater 
logistic curve-fit equation (Table curve software) and the corresponding PGE2 serum 
concentration was then calculated for each sample. 
 
2.5 Quantification of polyphenol metabolites and 
clinical markers in urine 
2.5.1 HPLC-DAD determination 
(collaboration with Jn.Prof. Elke Richling and Ms.Hannah Bergmann) 
 
Materials: 
0.45 µm Filters (Sartorius, Göttingen, Germany) 
Bond Elut C18 Solid phase cartridges (Varian, Germany) 
4.6 x 150 mm Atlantis columns (Waters, USA) 
 
Reagents: 
Phosphoric acid 
Formic acid / Acetonitril (ACN) 
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Urine was filtered with a 0.45 µm filter, 1.8 ml urine was diluted in 200 µl 80% 
phosphoric acid and mixed. Afterwards, the diluted urine was centrifuged for 10 min at 
10.000 rpm and 300 µl supernatant was added onto a C18 solid phase column and 
eluted with methanol. The polyphenol metabolites were measured with a HPLC-DAD 
using a 4.6 x 150 mm Atlantis column in a gradient of 1% formic acid (in water) in 
acetonitril in a flow of 0.8 ml/min. A final volume of 10 µl was injected and the 
polyphenols were detected using the respective absorption maximum. 
 
2.5.2 Creatinine determination 
 
Reagents: 
10 mM Picric acid 
100 mM Na OH 
0.005 % Creatinine standard 
The detection of creatinine was performed in a 96 well plate format. The assay is 
based on the method of Owen et al. (Owen et al., 1954). The 100 mM NaOH solution 
was diluted in 10 mM picric acid in a relation of 1:5. Urine was diluted in a range of 
1:5 and 1:10 and 10 µl were used for determination. 
Composition per well 
200 µl Reagent Na OH / picric acid (1:5) 
10 µl Urine or creatinine standard 
 
The absorbance was recorded at 492 nm with a SpectraMax 340 PC plate reader at 
25 °C, measuring at 0 s and 60 s time points. The final value was calculated 
comparing the increment of absorbance between the creatinine standard and the 
sample. In order to obtain reliable results, the difference between the creatinine 
standard the diluted urine samples should be less than 10%.  
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2.5.3 Protein  quantification 
 
Reagents: 
1 mg/ml BSA standard (Sigma, Steinheim) 
Bicinchoninic acid solution (Sigma, Steinheim) 
Cupper solution (Sigma, Steinheim) 
Trichloroacetic acid (TCA) 
 
The bicinchoninic (BCA) method was used to determinate the protein concentration of 
urine in a 96 well plate format. The assay is based on the method of Smith et al. 
(Smith et al., 1985). Cupper was diluted in BCA in a 1: 50 relation. Urine was 
previously diluted 1:20 and 1:50 in water. 
Proteins were precipitated using 980 µl 10% TCA and 20 µl diluted urine. Afterwards, 
samples were mixed, cooled down for 30 min on ice and centrifuged at 10.000 rpm for 
10 min at 4°C. The protein pellet was resuspended in 480 µl 10 % TCA and 
resuspended again. Samples were centrifuged at 10.000 rpm for 10 min at 4°C and 
the supernatant was discarded. Pellets were mixed in 450 µl BCA-Cupper solution 
(50:1) and 200 µl per well were pippeted in duplicated in a 96 well plate A BSA 
standard from 1µg/µl to 0.0025 µg/µl was used as a reference; as already described 
for the urine samples this standard curve was also precipitated in 10% TCA. Plates 
were incubated for 60 minutes at 37°C and then measured at 562 nm. 
 
2.5.4 Determination of nitrite and nitrate levels  
 
Reagents:  
VCl3 (Sigma, Steinheim) 
1 N HCl (Prolabo, Strasbourg, France) 
N-(1-Naphthyl) ethylenediamine dihydrochloride (NEDD) (Sigma, Steinheim) 
Sulphanilamide (Sigma, Steinheim) 
KNO3 (Sigma, Steinheim) 
NaNO2 (Sigma, Steinheim) 
 
VCl3 solution: 
400 mg VCl3 in 50 ml 1 N HCl 
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Griess reagent: 
 0.1 % NEDD in water  
Sulphanilamide (2% w/v) in 5 % Phosphoric acid (v/v) 
 
Nitrite and nitrate levels of urine were measured following the reduction with VCl3  
(Miranda et al., 2001). Urine samples were diluted 1:2 and 1:4 in water. 
A nitrate standard solution (100 µl) was serially diluted (from 200–1.6 µM) in duplicate 
in a 96-well plate. After loading the plate with diluted urine (100 µl), addition of VCl3 
(100 µl) to each well to reduce nitrate to nitrite was rapidly followed by addition of the 
100 µl Griess reagent. Nitrite was measured in a similar manner except that samples 
and nitrite standards were only exposed to Griess reagents. The Griess reaction 
forms a chromophore from the diazotization of sulfanilamide by acidic nitrite followed 
by coupling with bicyclic amines such as N-1-(naphthyl) ethylenediamine. Diazonium 
products can be measured at 540 nm (Fig.10). 
 
 
 
 
 
 
 
 
Fig. 10.  Formation of diazonium products in acidic conditions (Miranda et al., 2001). 
 
NO2 determination (no incubation) 
100 µl NaNO2 standard (200-1.6 µM) or urine sample 
100 µl Griess reagent 
 
TOTAL Nitrite and nitrate determination (45 min 37 °C) 
100 µl KNO3 standard (200-1.6 µM) or urine sample 
100 µl Griess reagent 
100 µl VCl3 
 
Each reaction was mixed in a 96 well plate and shaken before measure. 
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2.5.5 Carbohydrate determination 
(Under supervision of Ms.Melanie Olk) 
 
Reagents (R-Bio-pharm, Darmstadt): 
BR-2: 100 mM Triethanolamine buffer (pH=7.6), 36.6 mM NADP and 100 mM ATP  
BR-3: 320 U /ml Hexokinase and 160 U/ml glucose-6-phosphate dehydrogenase  
BR-4: 700 U /ml phosphoglucose isomerase  
 
The enzymatic detection of glucose/fructose was performed in a spectrophotometer 
in cuvette format at 25 °C. Urine was diluted 1:10 and 1:20, 100 µl were used for 
determination. All incubation steps were performed at RT and all absorbencies were 
recorded at 340 nm. Water was used as a blank. 
Each diluted urine sample or water (100 µl) was incubated for 3 minutes with 1.9 ml 
Millipore water and 1 ml of reagent BR-2. Afterwards, the Absorbance (Abs1) was 
measured. In the second step, 20 µl of BR-3 were pipetted in each sample, mixed 
and for 15 minutes incubated, and a second absorbance (Abs2) was determined. In 
the last step, 20 µl of BR-4 were added, mixed and 15 minutes incubated, and a third 
absorbance was measured (Abs3).  
Determination of glucose was calculated using the following absorbance differences: 
Δ Abs-gluc = (Abs2-Abs1) sample - (Abs2-Abs1) blank 
Determination of fructose was calculated using the following absorbance differences: 
Δ Abs-fruct = (Abs3-Abs2) sample - (Abs3-Abs2) blank 
 
      V x MW 
C (g/l) =        x Δ Abs (glucose or fructose) 
         ε x V x d x 1000 
V = final volume (3.020 ml for glucose or 3.040 ml for fructose) 
v = sample volume (0.1 ml) 
MW= molecular weight of glucose or fructose (180.16 g/mol) 
d = light path (1cm) 
ε = Extinction coefficient of NADPH (6.3 l × mmol-1 × cm-1) 
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2.6 Liver Enzymatic activities 
 
2.6.1 Preparation of cytosolic and microsomal protein fractions 
 
Reagents: 
Lysis buffer (pH=7): 
60 mM KH2PO4  
60 mM Na2HPO4  
250 mM Sucrose  
0.5% KCl  
Microsome buffer (pH=7.4) 
200 mM KH2PO4  
10 mM MgCl2  
 
 
 
All steps were carried out under cold conditions to avoid protein degradation. Mice 
livers (approximately 1 g) were homogenized in 12 ml of cold lysis buffer in 
ultraturrax homogenizer and then centrifuged at 9000 g for 15 minutes. Lipids were 
discarded using a cotton filter and 10 ml supernatant was ultracentrifuged for 45 
minutes at 35.000 rpm. A clear supernatant was collected for cytosolic proteins and 
aliquoted. Microsome pellets were resuspended in 1.5 ml of microsomes buffer and 
aliquoted. 
Glutatione S-transferase (GST), quinone reductase (QR), thioredoxin reductase 
(TrxR) activities and glutathione (GSH) were determined in cytosolic fractions and 
Cyp1A1/Cyp2B1 in microsomal fractions. Protein determination of both fractions was 
performed using the BCA method. 
 
2.6.2 Quantitative determination of liver protein content 
 
The BCA method was used to determinate the protein concentration of cytosolic and 
microsomal fractions in a 96 well plate format. The same reactives were used as 
described before (see section 2.5.3). Protein lysates were diluted 1:15 and 1:30. A 
BSA standard was used as a reference. 
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Composition per well 
190 µl BCA reagent + Cupper (50:1 diluted) 
10 µl serum sample or standard 
 
Plates were incubated for 60 minutes at 37°C and then measured at 562 nm. 
 
2.6.3 Glutathione S-transferases (GST) 
 
GST activity was determined using cytosolic liver protein supernatants as source of 
GST and CDNB (1-chloro 2,4-dinitrobenzol) as a substrate (Keen et al., 1976).  
 
Reagents: 
GSH stock (Sigma, Steinheim) 
CDNB  (Sigma, Steinheim) in EtOH 
 
GST reaction mix:   
90 mM KH2PO4 / K2HPO4 Buffer pH = 6.5 
0.9 mM CDNB  
2.25 mM GSH  
Per well: 
20 µl diluted cytosol 
180 µl GST reaction mix 
 
The mix was incubated shortly at 37 °C. Liver cytosols were diluted 1:300 in lysis 
buffer (see 2.5.1) and 20 µl (approximately 30-80 µg prot) each were used for 
determination. The absorbance was recorded at 340 nm with a SpectraMax 340 PC 
plate reader at 37 °C, using its kinetic mode at 15 s intervals during a 15 min reaction 
time. The rate of conjugated CDNB formation was calculated using the extinction 
coefficient (ε) 9.6mM−1 cm−1 and a well diameter of 0.6 cm. After calculations, a factor 
of 35 was calculated. Data were normalized to protein concentration. 
             1 
C (mmol/l) =              x Δ Abs (Units/min) 
              ε x d x 1000 
d = light path (0.6 cm, 200 µl end volume per well) 
ε = Extinction coefficient of CDNB (9.6 l × mmol-1 × cm-1) 
c (mmol/ml) = 175 x Δ Abs (Units/min), then for 200 µ/welll the factor is 35. 
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2.6.4 NAD(P)H: Quinone oxidoreductase (QR) 
 
QR activity in liver cytosol was determined by measuring the kinetics of NADPH-de-
pendent menadiol-mediated reduction of 3-(4,5-dimethyl-2-thiazyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) (Gerhauser et al., 1997). 
 
QR reaction mix: 
0.08 % BSA 
0.87 mM MTT 
20 mM Tris/HCl  
0.01% Tween-20 
5 µM FAD+ 
23 µM NADP+  
0.75 mM glucose-6-phosphate  
 
Per well: 
50 µl diluted cytosol 
200 µl reaction mix 
 
 
 
 
 
Shortly before measurement, the reaction mix was incubated at 37 °C and the 
substrate menadione and enzyme glucose-6 phosphate-dehydrogenase were added: 
1.5 U of Glucose-6-phosphate-dehydrogenase 
38 µM Menadione (diluted in ACN) 
 
Liver cytosol was diluted 1:30 in lysis buffer and 50 µl each were used for 
determination. Plates were measured at 595 nm using a SpectraMax 340 PC plate 
reader each 30 s during a 15 min interval and the rate of MTT reduction was 
calculated using the molar extinction coefficient of 11,600 M–1 cm–1 and according to 
the well volume a diameter of 0.75 cm. Values were normalized to protein content.  
After calculations, a factor of 29.4 was calculated  
             1 
C (mmol/l) =              x   Abs (Units/min) 
                ε  x d x 1000 
 
d = light path (0.75 cm, 250 µl end volume per well) 
ε = Extinction coefficient of MTT (11.6 l × mmol-1 × cm-1) 
 
c (mmol/ml) = 117.6  x Δ Abs (Units/min), then for 250µl/ well the factor is 29.4. 
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2.6.5 Thioredoxin reductase (TrxR) 
 
The measurement of TrxR activity was based on the NADPH-dependent reduction of 
5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) (Hill et al., 1997). The activity was 
corrected for non-TrxR-dependent DTNB reduction by addition of auranofin, a TrxR 
inhibitor (Becker et al., 2000).  Liver cytosolic fractions (40-90 µg) were incubated in 
presence of auranofin (5 µM) or buffer. Plates were incubated at 37 °C for 20 
minutes. 
Reagents: 
Auranofin (Sigma, Steinheim) 
DTNB  (Sigma, Steinheim)  
 
Reaction mix  
70 mM KH2PO4 Buffer  
1.5 mM EDTA  
0.004 % BSA  
0.3 mM DTNB  
Per well: 
25 µl diluted cytosol 
225 µl reaction mix 
 
0.2 mM NADPH  
 
The absolute Trx activity was calculated using with difference between absence of 
auranofin (total reductase enzymatic activity) and presence of auranofin (total 
reductase activity in absence of Trx activity). 
A 10 min Kinetics was determined over 15 minutes taking one measure every 30 
seconds at 412 nm. The rate of DTNB reduction was calculated using the molar 
extinction coefficient of 13,600 M–1 cm–1 and normalized to protein content. After 
calculations, a factor of 24.5 was calculated and according to the well volume a 
diameter of 0.75 cm. Data were normalized to protein concentration 
       1 
C (mmol/l) =        x Δ Abs (Units/min) 
         ε  x d x 1000 
 
d = light path (0.6 cm, 250 µl end volume per well) 
ε  = Extinction coefficient of DTNB (13.6 l × mmol-1 × cm-1) 
c (mmol/ml) = 97.6  x Δ Abs (Units/min), then for 250µl/ well the factor is 24.4. 
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2.6.6 Glutathione (GSH) 
 
Total liver glutathione was determined using 5,5′-dithiobis(2-nitrobenzoic acid) DTNB 
(Tietze, 1969). 
Cytosol was deproteinized using 1% SSA One cytosol volume was mixed with 2 
volumes of SSA 1% and centrifuged for 5 minutes at 10.000 rpm. After 
deproteinization, cytosol was diluted 1:10 in water and 40 µl was used for the assay. 
GSH standards (from 800 pmol to 20 pmol) were prepared from 100 µM GSH stock 
solution (diluted in water). 
 
Reagents: 
GSH stock (Sigma, Steinheim) 
DTNB (Sigma, Steinheim)  
 
GSH Stock Buffer (pH= 7.5) 
125 mM Na2HPO4 
6.3 mM NaEDTA 
 
 
 
 
GSH reaction mix: 
16 mM Tris-HCl pH 7,4                                               
0.61 mM Glucose 6 Phosphate  
18.7 µM NADP+  
0.57 mM DTNB  
0.26 U Gluc.6 Phos. Dehydrogenase                          
0.24 U Gluthatione Reductase  
 
A 5 minutes kinetics was determined taking one measure every 30 seconds at 412 
nm using a SpectraMax 340 PC plate reader nm. GSH content was calculated using 
the standard curve (10 µM to 0.25 µM GSH in stock buffer) and to normalized to 
protein concentration. 
 
Per well: 
40 µl diluted cytosol 
170 µl reaction mix 
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2.6.7 Cyp1A1/Cyp2B1  
 
Etoxyresorufin- and Pentoxyresorufin- O-deethylase (EROD and PROD) activities 
was monitored by the continuous spectrofluorimetric procedure of Prough (Prough et 
al., 1978). Fresh microsomes were diluted in 1.5 ml microsomes buffer in order to 
homogenize. Afterwards, they were homogenized through a 20-gauge syringe. 
 
Substrates: 
7-Ethoxyresorufin, EROD (Invitrogen Gmbh, Karlsruhe) 
7- Pentoxyresorufin, PROD (Invitrogen Gmbh, Karlsruhe) 
 
For analysis, microsomes for analysis were diluted 1:16 in microsomes buffer and 
shortly mixed. 
 
Cyp Buffer: 
0.2 M Phosphate Buffer (microsomes 
buffer) 
3.4 mM Glucose-6-phosphate  
1.3 mM NADP + 
 
EROD/PROD reaction mix: 
2 µM 7-Ethoxyresorufin (in Cyp Buffer) 
25 µM 7-Pentoxyresorufin (in Cyp Buffer) 
5 U Gluc-6-phosphate dehydrogenase  
 
Fluorescence intensity was measured using a microplate spectrofluorometer each 30 
s during 10 min (excitation 522 nm and emission 530 nm). The rate of resorufin 
formation (nmol resorufin formed per minute) was determined by comparing the rate 
of increase (slope) in fluorescence to a resorufin standard curve (20 µM-0.2 µM). 
 
nmol resorufin/min = (AFU/min) / slope standard 
 
Data were normalized to protein content (nmol/mg/min) 
 
Per well: 
100 µl Reaction mix substrate 2 µM EROD or 25 µM PROD 
100 µl diluted microsomes 
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2.7 Gene Expression experiments 
2.7.1 Total RNA isolation and quantification 
 
Buffers and solutions: 
RNA Lysis Buffer (RLT Buffer) + 1% -Mercaptoethanol  
a) Tissue disruption 
 
1 cm of colon and normal small intestinal tissue respectively was lysed using a micro-
dismembrator S in a Teflon container. 600 µl of 1% -ME RLT lysis buffer (Qiagen, 
Hilden, Germany) was added to each sample, homogenized for 45 sec at 2500 rpm. 
b) RNA purification 
(Qiagen, Hilden, Germany) 
 
600 µl of 70% ethanol was added to the tissue lysate. 600µl mix was loaded carefully 
onto a Qiagen column and centrifuged for 15 s at 10.000 rpm. The eluate was 
discarded. 
In order to avoid genomic DNA contamination a DNAse digestion was applied. Each 
sample obtained 10 µl of DNAse I and 70 µl DNA digestion buffer (RDD, DNase kit, 
Qiagen). This mix was pipetted directly onto the column membrane and incubated for 
20 min at RT. After that, the column was washed with 350 µl of wash buffer-1 (RW1 
buffer, RNeasy kit) and centrifuged for 15 sec at 10.000 rpm. A second wash followed 
using 700 µl of RW1 buffer and the samples were centrifuged again. The eluates 
were in both cases discarded. The column was washed with 500 µl of RPE Buffer 
(RNeasy kit) and centrifuged for 2 minutes at 10.000 rpm. The eluate was again 
discarded. This last step was repeated once and then the column should be dry. 
Finally, the RNA elution was completed with RNAse free water (RNeasy kit). A first 
elution with 40 µl was followed by another 25 µl. Each elution was centrifuged for 1 
min at 10.000 rpm. The RNA eluates were combined, then aliquoted and kept at   
- 80°C. 
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c) RNA quantification and determination of RNA integrity 
 
Buffers and solutions: 
 
Tris-Borate-EDTA (TBE):Buffer 
90 mM Tris-base 
90 mM Boric acid 
2mM EDTA 
 
1.2% Agarose Gel: 
1.2 g Agarose 
90 ml DEPC-H2O 
10 ml 1X Formaldehyde RNA 
Buffer 
 
10X Formaldehyde (FA) RNA Buffer  
200 mM MOPS  
50 mM NaOAc 
0.5 M pH 7.0 EDTA 
 
 
1X Formaldehyde (FA) RNA 
Buffer  
100 ml 10X FA RNA Buffer  
20 ml Formalydehide 37% 
880 ml DEPC-H2O 
RNA loading buffer 
0.25% Bromophenol blue 
4 mM EDTA 
0.9 M formaldehyde 37% 
20% Glycerol 
30 % Formamide 
4X FA gel buffer 
 
Total concentrations of RNA were quantified using a 1:100 dilution in RNase free 
water in a quartz cuvette using an Eppendorf spectrophotometer. Absorbance at 260 
nm indicates the RNA yield, which should be higher than 0.1 units. A ratio between 
A260/A280 indicates protein or phenol contamination and should not be lower than 
1.8. This value was used as an index of RNA purity. 
The integrity of RNA was tested using a denaturing agarose gel electrophoresis. 5 µg 
of RNA was mixed with RNA loading buffer, denatured at 65°C for 5 minutes and the 
mixture was cooled immediately for 2 minutes on ice. 1.2 % agarose in water was 
prepared by heating in a microwave oven for 5 minutes, avoiding boiling. After 
cooling down, 25 µl of EtBr (0.5 mg/ml) was pipetted to the gel mixture. 
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After loading the samples, the electrophoretic running was set at 75 V for 30 minutes. 
Finally the gel was photographed under UV light. Fig.11 shows an example of RNA 
integrity within different samples. 
 
 
                                                                                                             28s rRNA 
                                                                                                             18s rRNA 
 
                    
          Fig. 11.  1.2 % RNA agarose gel. Examples of normal small intestine tissue RNA integrity. 
 
2.7.2 RNA reverse transcription 
 
Buffers and solutions: 
DEPC-H2O 
Random Hexamer primer (Roche Diagnostics, Mannheim) 
5 x Reaction-Buffer (Promega, Madison, WI, USA) 
dNTP mix (10 mM each) (Eppendorf, Hamburg, Germany) 
RNAse Inhbitor (Eppendorf, Hamburg, Germany) 
M-MLV reverse transcriptase (Promega, Madison, WI, USA)
 
RT Reaction mix (per sample): 
4 µl 5x Reaction-Buffer 
1 µl dNTPs 
0.5 µl Rnase Inhibitor 
1 µl M-MLV reverse transcriptase 
  
No RT reaction mix (per sample) 
4 µl 5x Reaction-Buffer 
1 µl dNTPs 
0.5 µl Rnase Inhibitor 
1 µl DEPC
 
For each sample 1 µg of RNA was reverse-transcribed. 1 µl of Random hexamer 
primers 1 µM were added and incubated at 70°C for 2 minutes. Afterwards, the 
samples were cooled down on ice. 6.5 µl of reaction mix was pipetted to each sample 
and incubated at 42°C for 1 hour to start the reverse transcription. The reaction 
mixture was stopped by heating at 95° C step for 5 minutes. The samples were then 
diluted with 20 µl of DEPC-H2O. 
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2.7.3 Real Time PCR  
 
Buffers and solutions: 
10X Immobuffer (Bioline. London, UK) 
5 u/µl IMMOLASE Taq. Polymerase (Bioline, London, UK) 
50 mM MgCl2 (Bioline. London, UK) 
Eva-green (Biocat, Heidelberg) 
Aqua-braun sterile water (Braun-Melsungen AG, Melsungen) 
1mM Fluorescein (Bio-Rad, Munich) 
50 mM dNTPS (Eppendorf, Hamburg) 
100 µM Primers (Operon Gmbh, Cologne) 
100 µM Primers (Biomers Gmbh, Ulm) 
 
 
Eva-green(in aqua-braun water diluted) 
10 X Immobuffer 
1.6 mM dNTPs  
5 mM  MgCl2 
10 X Eva-green 
20 µM Fluoresceine 
 
PCR mix (25 µl per sample): 
12.375 µl Eva-green mix 
0.125 µl Immolase Taq. pol. 
8.5 µl Aqua Braun water 
1µl Forward primer 
1 µl Reverse primer  
2 µl cDNA  
 
A set of interesting genes was selected, especially those related to inflammation, 
proliferation and angiogenesis.  
Each primer pair was tested in a standard curve to determine efficiency of 
amplification. The Real Time PCR program was also adjusted for each gene. See 
Tab. 7 for a general scheme of the programs. 
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      Tab. 7. General Real Time PCR program 
 
 
 
 
 
 
 
 
 
 
       
 
The standard curve dilution series were adjusted for every single gene. A list of used 
primers is shown in the Tab.8. 
1 step        95 °C (6 min)          hot start Taq.pol activation 
2 step        95°C (30 s)           Denaturation 
3 step        55-60°C (30 s to 60 s)         Annealing      n   Cycles 
4 step        72 °C (30 to 60 s)                Extension 
5 step        72°C (5 min)                        Final extension 
6 step        57 °C (1 min)           Gap step 
7 step        gradient 55°-94°C (10 s)      Melting curve        80 Cycles 
8 step         hold 4 °C               
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Quantification of PCR products is based on the determination of Ct values. The Ct 
value is defined as the point at which the fluorescence of the amplified sample 
crosses the threshold is called the Ct. 
Eva-green is a dye that binds the minor groove of double stranded DNA. When Eva-
green dye binds to double stranded DNA, the intensity of the fluorescent emission 
increases. As more double stranded amplicons are produced, Eva-green dye signal 
will increase. Every sample was pipetted in triplicates and the final Ct value was 
calculated as a mean. 
2.7.4 Relative expression calculations 
 
The methods used to calculate the efficiency and gene expression quantification were 
done using the Pfaffl method (Pfaffl, 2001). In order to get precise and reproducible 
results, the reactions should have efficiency as close to 100% as possible. At this 
efficiency the template doubles after each cycle during exponential amplification. 
The slope of the standard curve can be used to establish the exponential amplification 
and efficiency of the PCR reaction by the subsequent equation: 
 
 
 
 
The ratio (gene fold induction) is established using the following formula:  
 
 
 
 
 
Fig. 12.  Mathematical method to calculate PCR efficiency and ratio. Adapted from Pfaffl et al. 2001 
 
 
 
 
 
PCR Efficiency = 10 [–1/slope] 
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2.8 Protein expression experiments  
Reagents for antigen retrival: 
 
Citrate Buffer (pH=6.0)                    Tris-EDTA Buffer (pH=9.0)                                             
10 mM Sodium citrate                    10 mM Tris-base  
 0.05 % Tween-20                      1 mM EDTA    
Adjusted with 1 N HCl                    0.05 % Tween 
 
Other reagents: 
Diaminobenzidine (DAB) Substrate  
1.5 mM DAB, in Tris-HCl Buffer 
pH=7.6 
0.03 % H2O2  
 
10x PBS Buffer pH=7.2: 
77mM Na2HPO4 
27 mM NaH2PO4 
9% NaCl 
Vector M.O.M. Immunodetection Kit PK-2200 (Vector lnc., Burlingame, CA,USA) 
Hematoxyline (Applichem GmbH, Darmstadt) 
DAPI (Molecular probes, Carlsbad, USA) 
SuperFrost® microscope slides (Menzel Gmbh, Braunschweig) 
Eukitt (Kindler, Freiburg) 
 
2.8.1 Formalin-Fixed Paraffin Embedded Preparation (collaboration with 
the Dept. of Pathology, Heidelberg University) 
 
Embedding in paraffin (Paraffin ParaplastR Plus) and cutting of liver, spleen, small 
intestinal and colon tissue was performed the in Dept. of Pathology of Heidelberg 
University (Ms. Karin Rebholz). Samples were fixed overnight in 4% formalin, 
dehydrated in increasing ethanol solutions (70%-80%-90%-100% 2 h each), 
incubated 3 times during 2 h in 100% anhydrous ethanol, and incubated in Xylene 3 
times at 1 h. Tissues were embedded in paraffin blocks for 1 h at 60°C. Blocks were 
cut by serial sections of 3 µm thickness using a microtome (Leica RM2235), placed 
on microscope slides SuperFrost ® and allowed to dry overnight at 37°C. Slides were 
kept at 4 °C until use. 
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The deparaffinization and Hematoxylin-Eosin (H&E) staining processes was 
performed as described in Tab.9. 
       
     Tab. 9. Deparaniffinization and H&E staining steps 
 
 
 
 
 
 
 
 
 
 
    
. 
2.8.2 Immunohistochemistry (IHC) protocol  
(Performed by Ms. Renate Steinle) 
 
A general IHC protocol is described below. Antibodies, incubations and all 
characteristics are summarized in the Tab. 10.  
Firstly, activation of tissue antigens is needed. The antigen retrieval buffer breaks the 
protein cross-links formed by formalin fixation and thereby uncovers hidden antigenic 
sites. Slides were heated up to 95°C without boiling in a microwave oven. Slides 
were cooled down for 30 min at 40°C in PBS/TBS, shortly washed in distilled water 
and 5 min in PBS/TBS at RT. Endogenous peroxidases were blocked for 15 min with 
3% H2O2-PBS and then washed in PBS/TBS 3 times for 5 min. Tissue sections were 
blocked according to each primary antibody. Between incubations or blocking steps 
slides were washed 2 times 5 min in PBS/TBS. Then, the respective primary 
antibody was added (See Tab.10 for blocking and primary/secondary antibody 
conditions). After washing 3 times for 5 minutes in PBS and slides were incubated 
with a biotintylated secondary antibody. The protein staining was performed using the 
ABC reagent (Vectastain®ABC Elite®, Vector MOM Kit), were the avidin binds with 
high affinity to secondary antibody coupled to biotintylated horseradish peroxidase.  
Hematoxylin-Eosin staining 
Hematoxylin 5 min 
Destilled water 5 min 
1 % Eosin 1 min 
Destilled water 5 s 
70% Ethanol   5 s 
96% Ethanol 5 s 
100 % Ethanol 2 x 2 min 
Xylol 2 x 2 min 
Eukitt 
     Deparaffinization 
     Xylol 3 x 5 min 
    100 % Ethanol   2 min 
    100 % Ethanol   2 min 
     80 % Ethanol    1.5 min 
     70 % Ethanol    1 min 
     50 % Ethanol    1 min 
     Destilled water   30 s 
     PBS/TBS   5 min 
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After washing for 5 min in PBS, ABC reagent was added for 30 min. The peroxidase 
is then developed by the DAB substrate incubated for 5 min to produce brownish 
colorimetric end products. Secondary antibody cross reactivity was checked using a 
negative control without first antibody. Meyers´ hemalaum staining was performed for 
5 s and washed with flowing tap water during 3 min. Sections were dehydrated 
through changes in ethanol solutions with increasing concentrations (50%- 70%- 
100%, 5 min each), incubated for 20 min in xylol, and mounted in cover-slides using 
Eukitt® solution. Slides were examined using an AxioSkop 2 MOT microscope. 
 
2.8.3 BCAC Immunostaining (collaboration with Prof. Mori and Dr. Yamada, 
Gifu University Japan) 
 
All colon sections were flat in paraffin embedded using a small metal tamper. 
Immunohistochemistry was performed on 4-μm-thick paraffin-embedded sections 
from all 3 segments of the colon. Deparaffinization and rehydration was done as 
described before. Citrate buffer was used for the antigen retrieval. 
Immunodetection of β-catenin was carried out using a Vector® M.O.M. ™ which 
detects mouse antigens in mouse tissue reducing the background. This was 
performed using the M.O.M blocking reagent for 60 min at RT. Slides were washed in 
PBS 2 times for 5 minutes. β-catenin primary antibody 1:750 (in PBS) was added and 
incubated overnight in a humid chamber. The following day slides were washed 3 
times for 5 min in PBS. 
For DAB staining, endogenous horseradish peroxidase activity was blocked by 
treatment with 3% H2O2 (in methanol) solution. The protein staining was carried out 
with a secondary biotynilated anti-mouse diluted 1:300 in PBS and incubated 30 min 
at RT. Slides were washed in PBS 3 times for 5 minutes and incubated with the ABC 
reagent. Staining was performed with a DAB solution for 4-5 min was used as 
substrate for the peroxidase enzyme. Hemamlaun and dehydration was performed 
as described in section 2.8.2. Immunoreactivities were regarded as positive if the 
apparent stainings were detected in cytoplasm and/or nuclei for determining BCAC. 
For fluorescent immunohistochemistry, after the primary antibody incubation slides 
were washed in PBS 3 times for 5 minutes. Anti-mouse Rhodamine-labeled (TRITC) 
secondary antibodies (Dako, Japan) were incubated for 30 min in the dark at RT and 
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washed 3 times for 5 minutes. A counterstained was performed with 1:1000 DAPI (in 
PBS) and incubated for 5 min at RT. Slides were washed 3 times for 5 minutes 
again. 
All slides were examined using the AxioSkop 2 MOT microscope whereas 
fluorescent staining was visualized using an F-View II firewire fluorescence camera. 
 
2.9 Reverse phase protein arrays (RPPA) (collaboration with Dr. 
Ulrike Korf and Heiko Mannsperger, Dept. Genome Analyses, DKFZ) 
 
Reagents: 
T-Per (Pierce, Rockford, IL, USA) 
NP-40 (Sigma, Steinheim) 
BCA kit (Pierce, Rockford, IL, USA) 
Whatman buffer (Whatman, London, UK) 
Fast green FCF (Sigma, Steinheim) 
IRDye™700DX-labeled secondary antibody (LI-COR, Lincoln, USA) 
Odyssey blocking buffer (LI-COR, Lincoln, USA) 
0.02% NP40 in PBS 
 
FCF staining buffer (in Millipore H2O): 
0.005 % Fast Green FCF in 10% acetic acid 
30% EtOH 
 
2.9.1 Protein adenoma lysates and determination of protein content 
 
Tumors were weighed and taken up in 12 volumes (v/w) of T-PER buffer in 
Eppendorf tubes. Lysis was made with a Qiagen dismembrator using steel balls, 30 
Hz for 4 min. Protein lysates were centrifuged at 13.000 rpm for 12 min at 4 °C. 
Supernatants were pipetted into fresh tube and ultracentrifuged for 30 minutes at 
30.000 rpm at 4°C. 
Supernatants were collected and the protein concentration was determined with the 
BCA method (see section 2.6.2). A BSA standard was used as a reference. 
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 For determination, 10 µl of tumor lysate and 190 µl BCA reagent was pipetted per 
well. Plates were incubated for 60 minutes at 37°C and then measured at 562 nm.  
 
2.9.2 Selection of monospecific antibodies 
 
Reagents: 
Polyacrylamide (Roth, Karlsruhe)  
Bromophenol blue (Serva, Heidelberg) 
Ammonium persulfate (APS) (Sigma, Steinheim) 
Sodium dodecyl sulphate (SDS) (Merck, Darmstadt) 
β-Mercaptoethanol (β-ME) (Sigma, Steinheim) 
 
Stacking gel 
8%-10% (v/v) Polyacrylamide 
25% (v/v) Tris-HCl 0.5 M, pH 8.8 
1% (v/v) SDS 10% 
1% (v/v) APS 10% 
0.1% TEMED 
 
SDS-loading buffer 
10% (w/v) SDS 
0.3 M Tris-HCl, pH 6.8 
50% (v/v) Glycerol 
0.5% (w/v) Bromphenol blue 
5% (v/v) β-ME 
 
Running  gel 
10%-15% (v/v) Polyacrylamide 
25% (v/v) Tris-HCl 0.5 M, pH 6.8 
1% (v/v) SDS 10% 
1% (v/v) APS 10% 
0.1% TEMED 
 
 
Runing Buffer 5x,pH 8.3 
120 mM Tris-base 
1.25 M Glycine 
5% (w/v) SDS 
 
Blotting buffer10x, pH 8.5 
250 mM Tris-base 
2 M Glycine 
 
Blotting buffer 1x (in destilled H2O) 
10% blotting buffer 
20% methanol 
 
TBS-T 10X pH=8.0 
0.2 M Tris 
1.36 M NaCl 
 
TBS 1X pH=8.0 
10% TBS-T 10x 
0.1% Tween-20 
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A reliable and precise detection of reverse protein arrays is dependent on the 
specificity and selectivity of the first antibody. All antibodies used (Tab. 11) have 
been previously tested in Western blot in order to determine their monospecificity.  
Proteins (25 µg) were mixed with 1x SDS-loading buffer, heated for 5 min at 95 °C 
before loading and separated by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE). An upper 8-10% polyacrylamide stacking gel concentrates the samples in 
the gel. The lower resolving gel had a 10-15% polyacrilamyde concentration, 
depending on the size of the proteins of interest. The electrophoresis was run at 100 
V in 1x protein running buffer. 
Proteins were transferred from the polyacrylamide gel onto a PVDF membrane using 
a protein mini-gel wet transfer System. PVFD membranes were soaked shortly in 
methanol and washed with PBS. The sandwich was prepared with a sponge pad, two 
sheets of Whatman filter, the PVDF membrane, the polyacrylamide gel, two sheets of 
Whatman filter paper and a sponge pad. This sandwich was placed in the anode part 
of the cassette, the cassette was filled with 1x blotting buffer and the proteins were 
transferred at 4°C at 100 V for 1.30 h. 
After the transfer, the membrane was washed in PBS buffer and incubated for 1 h in 
Odyssey® blocking buffer. Primary antibody was added to Odyssey blocking buffer at 
the appropriate concentration (range 1:500 to 1:5000) and incubated for 60 min at RT 
on a platform shaker. The membrane was subsequently washed in PBS-T 4 times for 
5 min and then exposed to the IRDye™700DX-labeled secondary antibody (1:8000) 
diluted in Odyssey blocking buffer for 1 h at RT. After that, the membrane was 
washed in PBS-T 4 times for 5 min and a last 5 min PBS wash was performed to 
remove residual Tween-20. 
Signals were detected using the Odyssey NIR scanner and protein intensities were 
calculated with the Odyssey 2.0 software following manufacturer´s instructions. 
Examples of western blots are given in the next figure, showing examples of a 
western blot and an RPPA for c-Myc (Fig. 12b). 
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    Tab. 11 List of used antibodies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             SC: Santa Cruz; CST: Cell Signalling technologies; RnD: RnD Systems; ABC: Abcam;  
               BD: Beckton Dickinson. a Dilution for WB only (1:300 for arrays) 
 
 
 
 
 
 
 
 
 
 
 
          Fig. 12b. Examples of c-Myc (64 kDa.) using the Odyssey system and Min mice adenoma  
           lysates; kDa: Kilodalton; WB: Western blot; RPPA: Reverse phase protein array.  
Antibody Company Catalogue nr 1st Ab Dilutiona 
pERK1/2 RnD AF1018 1:2000 
ERK SC sc-94 1:5000 
pMek SC M7683 1:2000 
Mek BD 610122 1:5000 
pp38 CST 9215 1:2000 
p38 SC sc-728 1:5000 
pAKT CST 4056 and 4058 1:2000 
Akt SC sc-1619 1:5000 
pSTAT3 CST 9131 1:2000 
Stat3 SC sc-482 1:2000 
Stat5 SC sc-853 1:2000 
cyclinD1 CST 2922 1:500 
β-catenin CST 9562 1:500 
c-myc SC sc-788 1:1000 
NfKB SC sc-109 1:1000 
PCNA SC sc-7907 1:1000 
iNOS SC sc-650 1:500 
PKC alpha ABC ab32376 1:1000 
 
80 
 
 
53 
42 
 
35 
27 
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kDa            WB c-Myc            c-Myc RPPA  
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2.9.3 Protein spotting onto nitrocellulose slides 
 
Protein lysates were adjusted to 2µg/µl and diluted 1:1 with Whatmann array buffer 
and a volume of 25 µl of each sample was pippetted in a 394 well plate. 
Clear supernatants were spotted with a Piezo spotter on nitrocellulose membranes. 
All samples were spotted in quadruplicate and three drops (333 pl per drop, 2 ng/ 
spot) were delivered per spot. The spotting needle was washed with PBS two times 
after each spotting. Of each slide, two sub-arrays were printed resulting in eight spots 
per sample and slide. In addition, a BSA calibration curve between 1 µg/µl and 100 
pg/µl and Whatman array buffer as negative control were also spotted. All the system 
was working at 4 °C. Spotted slides were kept dark at -20°C until analysis.  
2.9.4 Infrared-based protein array quantification 
 
Tumor protein arrays and analysis have been described by Loebke et al. (Loebke et 
al., 2007). 
Slides were blocked at 4°C overnight with a 1:3 mixture of Odyssey blocking 
buffer/PBS. Incubations with primary antibody were performed for 2 h at RT in 
Odyssey blocking buffer with a 1:300 dilution for all antibodies. After washing in PBS 
containing 0.02% NP40 (w/w) 4 times for 12 minutes, a 1:10.000 dilution of the 
IRDye™700DX-labeled secondary antibody in PBS containing 0.02% NP40 was 
applied for 30 min at RT. The slides were rinsed and dried at room temperature, 
scanned with the Odyssey NIR scanner, and signal intensities were detected with the 
Odyssey 2.0 software following manufacturer´s instructions. 
Fast green FCF was used to normalize signals to protein content. FCF binds to 
connective proteins. The slides were rinsed for 2 min with PBS containing 0.02% 
NP40 and incubated with FCF staining buffer protected from light for 1 h at RT. Then, 
the slides were properly washed in Millipore water and destained for 2 h with 30% 
ethanol (in acetic acid). A final washed was performed with Millipore water for 1 
minute. Samples were scanned at 700 nm. 
The average intensity of each single spot was determined (pixels/cm2). The mean 
intensity of the control spots was determined and subtracted from the mean intensity 
of the sample spots to correct for background and/or noise due to unspecific antibody 
Materials and methods 
 
 
 
87
binding. Intensity values were calculated using Genpix software and statistics were 
calculated using Sigma Plot 10.0. 
          
2.10 Statistical analysis 
Differences in food consumption, liquid uptake and body weight were determined 
using a multiple linear regression analysis for the Y-axis and the slope (ADAM 
statistics program, DKFZ), collaboration with Dr. W. Rittgen (Department of 
Biostatistics, DKFZ). 
Tumor values, clinical parameters, gene and protein expression experiments were 
evaluated by one-way ANOVA variance analysis. ANOVA on ranks was performed 
with non-normal data distribution. Both were calculated with SIGMA-STAT 2.0.   
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3. RESULTS 
 
In extension if our previous studies, the aim of the presented project was to 
reinvestigate the colon cancer-preventive potential of apple juice and apple juice 
extracts under more defined conditions. 
3.1 Inhibition of intestinal tumorigenesis in Min mice 
3.1.1 Characterisation of apple juices and extracts for intervention  
 
We have demonstrated previously that polyphenolic extracts from apple juice are 
biologically active in terms of radical scavenging, influence drug metabolism and 
posses anti-inflammatory and anti-hormonal potential in vitro (Zessner et al., 2008). 
In order to demonstrate whether CAJ and PAE are in vivo chemopreventive we have 
performed a first Min mouse experiment. In this previous animal experiment, a CAJ 
(AS04) and a mix of two PAEs were used. This PAE mix consisted of a 1:1 
combination of AE03B and PAE04 to include a wide range of polyphenolic 
compounds. CAJ04 and 0.2% PAE significantly reduced tumor multiplicity in the SI by 
38% and 40%, respectively (Gerhäuser 2007, Forum Deutsche Krebsgesellschaft).  
Although the results obtained were interesting, the possible mechanisms remained 
unclear. Therefore, as presented here, a second Min mouse experiment was planned. 
As intervention groups, the following treatments were used: water as a control, 
placebo juice, CAJ, 0.2 % B-PAE and a combination of CAJ plus 0.2 % B-PAE. The 
placebo juice (apple juice without polyphenols) was included to determine whether the 
polyphenols are the main chemopreventive compounds in apple juice. In addition, one 
CAJ and a mix of two different B-PAE (B polyphenolic apple extract) were used. B-
PAEs (B-polyphenolic apple extract) are lyophilized apple extracts obtained from apple 
pomace after an enzymatic digestion. Apple pomace is known as a rich source of 
procyanidins and digestion facilitates the extract of compounds bound to the cell 
membrane. We decided to use this procyanidin rich extract due to the strong in vitro 
chemopreventive activities reported by Zessner et al. (Zessner et al., 2008). The 
combination of CAJ and 0.2% B-PAE was intended to act as a "functional food" and 
hence to investigate whether such combination increases the chemopreventive 
potential.  
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Quantification of high molecular weight (HMW) and low molecular weight (LMW) 
components of B-PAE03 and B-PAE06 showed a difference in terms of oligomeric and 
polymeric procyanidins. PAE04 and B-PAE03 contained more procyanidins than B-
PAE06 (PAE04: 48%, B-PAE03:46% and B-PAE06:35%). 
PAE04, B-PAE03 and B-PAE06 as representative of Bittenfelder CAJ were tested in a 
set of in vitro bioassays to define in vitro bioactivity (Tab. 12). 
 
Tab. 12. Summary of potential cancer chemopreventive activities of PAEs.  
 
a IC50 : half maximal inhibitory concentration. Concentration that reduces the effect by 50% 
b ORAC Units are corresponding to fluoresceine protection against radicals in comparison with 1μM 
Trolox. The test was done at 1μg/ml. 
cCD: Concentration required to double the specific activity of quinone reductase.  
 
Briefly, both B-PAE03 and B-PAE06 were especially active in modulation of drug 
metabolism as well as anti-inflammatory and anti-hormonal potential in vitro. Three 
assays were used to test antioxidant capacity and radical scavenging potential. In the 
DPPH and the superoxide anion scavenging assay, both B-PAE06 and PAE04 
demonstrated strong radical scavenging compared to B-PAE03. Due to quercetin and 
its conjugates B-extracts possessed higher potential in inhibiting Cyp1A activity. In 
general, oligomeric and polymeric procyanidins resulted in strong aromatase inhibition 
in all extracts. All three extracts showed high anti-inflammatory activity with similar 
percentages of inhibition in the Cox-1 assay. This is attributed mostly to epicatechin. 
PAE04 and B-PAE03 content was different in terms of procyanidin concentration and 
therefore radical scavenging activity (DPPH and X/XO assays) was better compared 
to the B-PAE06. Differences might be explained by comparatively high percentages of 
carbohydrates in the B-extracts (PAE04: 7.5%, B-PAE03: 22.0% and B-PAE06: 
40.1%) and consequently reduced polyphenols content (PAE04: 48%, B-PAE03:46% 
and B-PAE06:35%). 
Sample DPPH X/XO ORACROO Cyp1A 
QR 
Induction Aromatase Cox-1 
 
IC50 
[µg/ml]a 
IC50 
 [µg/ml]a [units]
b IC50 [µg/ml]a CD [µg/ml]c IC50 [µg/ml]a 
% Inhibition 
(100 µg/ml)
PAE04 8.7 17.1 2.4 11.5 1.3 5.9 62 
B-PAE03 18.6 18.2 1.8 2.4 1.8 5.4 69 
B-PAE06 12.1 26.5 1.8 5.4 1.6 4.3 70 
Results 
 
 
 
90
Overall, these results are mainly similar to the prior in vitro experiments and agree with 
the data provided by Zessner et al.  
As described in Section 2.3 (Material and methods) in the present study, we planned 
to compare the effects of B-PAE, CAJ, CAJ+ B-PAE vs. water and polyphenol free 
placebo juice in terms of tumor development, various clinical parameters, potential 
biomarkers for chemoprevention and liver enzyme activities. Five groups of 18 male 
Min mice each (separated in 3 sub-experiments) received the intervention drinks 
instead of drinking water for a period of 10 weeks. 
3.1.2 Drink and Food consumption and weight development 
 
3.1.2.1 Liquid and food consumption 
 
During the intervention period, liquid and food consumption was documented daily to 
calculate the polyphenol dose per day for each treatment and to monitor if treatments 
interfere with the energetic balance, respectively. Both parameters were calculated as 
a mean ± standard error of mean (SEM) per treatment. Statistical analysis was 
performed using multiple linear regression analysis for the Y-axis and the slope. 
All animals drank similar quantities with an average daily liquid consumption of 2.9 ml 
(Water: 3.0 ± 0.3 ml/day, B-PAE: 3.0 ± 0.3 ml/day, placebo: 2.8 ± 0.8 ml/day, CAJ: 2.9 
± 0.8 ml/day and CAJ + B-PAE: 2.9 ± 0.6 ml/day). CAJ- and CAJ + B-PAE- treated 
animals consumed slightly less liquid than the other groups. 
A small difference was observed for food uptake. On average, the animals of the water 
and B-PAE groups consumed about 3 g chow per day (Water: 3.14 ± 0.33 mg/day and 
B-PAE: 2.96 ± 0.32 mg/day). Food consumption of the placebo (2.6 ± 0.3 mg/day), 
CAJ (2.7 ± 0.3 mg/day) and CAJ + B-PAE (2.7 ± 0.2 mg/day) was reduced by 10%. 
Overall, at the end of the intervention period, no significant differences between 
treatments were observed. Nevertheless, water and B-PAE groups drank more and 
consumed more chow than the groups receiving CAJ, placebo juice or CAJ + B-PAE. 
This is probably due to the additional calories provided by the carbohydrate content of 
the juice-based liquids (Fig. 13 A and B). 
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 Fig. 13. Daily average intake of liquid (A,B) and food (C,D) during 10 weeks intervention.   
 Multiple linear regression analysis for Y-axis and the slope. Mean (n=15). The first days of adjustment   
 to the intervention liquids were excluded from the analyses. 
 
3.1.2.2 Body weight 
 
Body weights (BW) were measured per animal twice a week and BW ± SEM was 
calculated per treatment average. In the Min mouse model, as a result of the intestinal 
adenoma development and subsequent intestinal haemorrhages the BW can 
decrease during intervention. Then, a higher weight may indicate better health 
condition and could suggest that treatments are well tolerated.   
Initially, animals of the water and B-PAE groups started the intervention with similar 
BW (average ± SEM; Water: 23 ± 0.2 g and B-PAE: 23 ± 0.3 g). Both treatments 
resulted roughly in similar body weight changes during the first 40 days of intervention 
(Water: 24.4 ± 0.3 g and B-PAE 24.3 ± 0.4 g). In contrast, from day 40 of intervention 
the water group started to increase the BW more slowly, and a loss of weight during 
the last 14 days was observed (Fig. 14 A). On the other hand, the BW of the B-PAE 
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group increased until the end of the intervention (Water: 24.6 ± 0.4 g and B-PAE: 25.6 
± 0.4 g). In the last week of intervention, the animals of the water group weighed 
significantly less than those of the B-PAE (Fig. 14 A).  
Placebo, CAJ and CAJ + B-PAE groups started the intervention with similar BW 
(average ± SEM; Placebo: 22.6 ± 0.3 g, CAJ: 22.8 ± 0.3 g and CAJ + B-PAE: 22.2 ± 
0.2 g). Due to the high liquid of consumption and reduced chow intake, they initially 
lost about 3% during the first 5 days. Then, the liquid and food consumption 
normalized. Up to day 30 of intervention all animals gained weight over time similar 
daily increases (average ± SEM day 30: Placebo: 22.9 ± 0.3 g, CAJ: 23 ± 0.3 g and 
CAJ + B-PAE: 23 ± 0.2 g). Between day 30 and 70, the average BW of the placebo 
group was slightly lower than that of CAJ and CAJ + B-PAE groups. However, ANOVA 
statistical analysis showed no significant difference in weekly BW gain among the 
Placebo, CAJ and CAJ + B-PAE treatments throughout the study. After intervention for 
10 weeks, the CAJ group had higher BW in comparison to water, placebo juice and 
CAJ + B-PAE groups (Placebo: 24.4 ± 0.50 g, CAJ: 25 ± 0.4 g and CAJ + B-PAE: 25.2 
± 0.4 g). These differences were not statistically significant (One-way ANOVA with 
Tukey multiple comparison) (Fig.14 B).  
 
 
 
     
  
     
     
  
   
              
 
Fig. 14. Average body weights (BW).  (A) Water and B-PAE, (a) p=0.058 and (b) p=0.038 Student´s t-
test comparison and  (B) Placebo, CAJ and CAJ + B-PAE, One-way ANOVA with Tukey  multiple 
comparison test. Mean SEM (n=15). 
3.1.2.3 Daily polyphenol consumption 
 
The mean intake of polyphenols was calculated for each treatment based on the daily 
mean drink uptake and the total polyphenolic content of CAJ and B-PAE. Values were 
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normalized by dividing with the average of BW per treatment. Due to difficulties in 
analyzing oligomeric and polymeric procyanidins, only LMW polyphenols were 
estimated for CAJ. 
Both CAJ and B-PAE 0.2% were given a similar dose (B-PAE: 70.8 mg/kg BW and 
CAJ: 55.1 mg/kg BW), whereas in the CAJ + B-PAE group animals received nearly 
twice the quantity of polyphenols (119.3 mg/kg bw) (Tab. 13). 
 
Tab.13. Polyphenol dose during intervention. Data were calculated without procyanidins (PCs)  
for CAJ. 
 
   
 
 
 
 
 
 
3.1.3 Multiplicity, distribution and size 
 
Min mice developed multiple intestinal neoplasias in their intestinal tracts within 
several weeks after birth in a range from 22 to 84 adenomas. As expected, tumors 
were mostly located in the SI and few were found in the colon. For adenoma scoring, 
the SI was divided in 3 parts: Int-1 (Proximal SI), Int-2 (Middle SI) and Int-3 (Distal SI). 
Adenoma multiplicity was determined to investigate whether treatments influence the 
development from normal tissue to adenomas. Moreover, the size was important to 
characterize if treatments affect adenoma progression.  
 
Adenoma numbers in SI 
 
In the SI, in the water group 52.1 ± 3.8 adenomas were counted (mean ± SEM). In 
contrast, 0.2% B-PAE and CAJ interventions resulted in 34.3 ± 2.4 and 39.6 ± 3.0 
adenomas, respectively. Overall, B-PAE and CAJ significantly reduced (p<0.05 by 
ANOVA) total adenoma number by 24% and 34%, respectively. In the placebo juice 
  Treatment                 Avg. daily dose      Polyphenol content     Mean daily liquid         Mean B.W. 
                                        [mg/kg bw]                    [mg/l]   intake [ml]            [g]            
  
 
B-PAE (0.2 % in water)        70.8                562   3.1               24.2 
CAJ                                  55.1 + PCs a            452   2.9         23.8 
CAJ + B-PAE (0.2%)        119.3 + PCs             1014   2.8         23.8 
 
 
aPC: Procyanidins 
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and CAJ+B-PAE groups, 48.7 ± 3.4 and 43.3 ± 2.8 adenomas were scored, 
correspondingly. This resulted in a non-significant 6% and 17% reduction (Tab.14). 
 
Adenoma numbers in the colon 
 
In the colon, only a few adenomas were found (Water: 1.9 ± 0.3; B-PAE: 1.2 ± 0.3; 
Placebo: 1.4 ± 0.3; CAJ: 1.6 ± 0.3; CAJ + B-PAE: 1.1 ± 0.2). There was no significant 
difference. Due to the small numbers in colonic adenomas, calculation of % inhibition 
does not provide meaningfully data (Tab.14). 
 
 Tab. 14. Adenoma number, localization and percentage of inhibition in SI and colon 
 
a Mean SEM 
b percentage of inhibition in comparison to the water control 
* p<0.05 One-way ANOVA with Tukey´s multiple comparisons test (in red numbers) 
 
 
Total adenoma numbers in GI tract 
 
Box-plots can be useful to display differences between populations. This graphic 
representation summarizes the following statistical measures: median and the 
percentiles. The percentiles measure the spread or dispersion around the median of a 
data set and they are represented as upper and lower whiskers. The upper whisker is 
the 25th percentile and the lower the 75th percentiles. The box itself contains the 
middle 50% of the data. 
Small Intestine (SI) Total SI    Colon  Treatment n 
Int-1 Int-2 Int-3   
 
1 Water 17 7.1 0.6a 18.2 1.9 26.8 2.2 52.1 3.8 1.9 0.33 
 
2 0.2 % B-PAE 17 
4.6 0.5 
35%* b 
11.1 0.9 
39%* 
18.7 1.5
30%* 
34.3 2.4 
34%* 
 1.2 0.31 
30% 
 
3 Placebo 16 
6.5 0.8 
9% 
16.5 1.5 
11% 
25.8 2.5
4% 
48.7 3.4 
6% 
1.4 0.31 
25% 
 
4 CAJ 18 
5.3 0.5 
25% 
13.1 1.1 
27% 
21.1 2.1
21% 
39.6 3.0 
24%* 
1.6 0.36 
16% 
 
5 
CAJ  + 
0.2 % B-PAE 18 
6.2 0.5 
13% 
15.2 1.1 
16% 
22.4 2.0
16% 
43.3 2.8 
17% 
1.1 0.25 
40% 
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Overall, in the GI tract, the water group developed 53.9 ± 3.6 adenomas. In contrast, 
0.2% B-PAE and CAJ interventions resulted in 35.6 ± 2.4 and 41.2 ± 3.0 adenomas, 
respectively. Treatments with CAJ and B-PAE 0.2% significantly suppressed tumor 
incidence compared with water control by 22% and 33% (p<0.05 by ANOVA). 
Correspondingly, CAJ + B-PAE intervention inhibited tumor load by 17% and placebo 
juice treatment resulted in an insignificant 7% reduction in adenoma numbers (Fig.15). 
 
 
 
 
 
 
 
 
 
 
 
 
           Fig. 15.  Box plot of total adenoma distribution in all GI tract. * p<0.05 One-way   
            ANOVA with Tukey´s multiple comparisons test. Treatments: (1) Water; (2) B-PAE 0.2%;    
            (3) Placebo; (4) CAJ and (5) CAJ + B-PAE 0.2 %. 
            Box: interquartile range, line: median, whiskers: 25th and 75th percentile and dots: outliers 
 
 
Adenoma distribution in the SI 
 
With respect to the distribution of the adenomas in the SI, approximately one half was 
found in Int-3 (Fig. 16). In each segment, adenoma values were reduced by B-PAE 
treatment in comparison with the water control (Int-1: control 7.1 0.6, B-PAE 4.6 ± 
0.5; Int-2: control 18.2 1.9, B-PAE 11.1 ± 0.9 and Int-3: control 26.8 2.2, B-PAE: 
18.71.5). This resulted in a significant adenoma reduction in all SI segments of 35%, 
39% and 30%, respectively (p<0.05 by ANOVA). The highest inhibition was observed 
in Int-2 (Tab.14 and Fig.16).   
CAJ-treatment reduced adenoma counts in all SI segments as well (Tab. 14) 
representing a 25%, 27% and 21% inhibition of adenoma numbers, correspondingly. 
Although each part was reduced in a non-significant manner, a significant (p<0.05 by 
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ANOVA) 24% tumor inhibition was observed in total SI. Again the highest inhibition 
was observed in Int-2 (Fig. 16). Placebo and CAJ + B-PAE led to non-significant 
reductions. 
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Fig. 16. Adenoma multiplicity and localization in SI and Colon. * p<0.05 One-way ANOVA 
with Tukey´s multiple comparisons test. Mean ± SEM. Int-1: Proximal SI; Int-2: Middle SI; Int-3: 
Distal SI. 
 
 Influence on adenoma size 
    
In order to discriminate between tumor size, adenomas were classified as small (<1 
mm), medium (1-3 mm) and large (>3 mm). According to this distribution most 
adenomas were of medium size (Water: 80%, B-PAE: 63%, Placebo: 61%, CAJ: 68% 
and CAJ + B-PAE: 73%). CAJ and B-PAE intervention significantly reduced medium 
size adenomas (1-3 mm) by 39% (p<0.05) and 49%, respectively (p<0.05) (water: 43 
± 5.0; CAJ: 28 ± 3.5; B-PAE: 22 ± 3.0). Placebo and CAJ + B-PAE treatments also 
decreased medium size adenomas by 32% and 25% (Placebo: 29.5 ± 3.3; CAJ + B-
PAE: 32 ± 3.2), but this decrease was not statistically significant (Fig.17). 
Interestingly, intervention with placebo juice significantly increased (p<0.05 by 
ANOVA) the total number of small adenomas (<1 mm) by 49% (water: 9.7 ± 1.5; 
placebo: 17.8 ± 2.0), whereas CAJ and B-PAE slightly increased small size adenomas 
by 14% and 21%, correspondingly. Nevertheless, this increase was not statistically 
significant (Fig. 17). 
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In animals receiving B-PAE and CAJ, we detected less medium and large size 
adenomas in all SI. Moreover, small (< 1mm) adenoma numbers were augmented in 
distal parts of SI in comparison to the control group. In CAJ + B-PAE treated animals 
we observed more large adenomas in proximal SI, compared with the control (control 
1.0 1.2 and CAJ + B-PAE 1.9 ± 1.0). 
 
 
 
 
 
 
 
 
 
 
      Fig. 17.  Adenoma size in SI and colon. Mean ± SEM. (a) *p<0.05 One way ANOVA with Dunn´s   
      multiple comparisons test, (b) p<0.05 One-way ANOVA with Tukey´s multiple comparisons test.  
      <1: Small size adenomas; 1-3: Middle size adenomas; >3: large size adenomas. 
 
3.1.4 Study of colon microadenomas  
 
Only few adenomas were found in the colon. Therefore, an evaluation of the effect of 
the intervention was difficult. To solve this problem, we investigated the possible 
effects of CAJ and B-PAE treatments on colonic microlesions. As mentioned in the 
introduction (chapter 1.3.4), colonic microadenomas are found in high frequency and 
regarded as preneoplastic lesions in the Min mouse colon. So far, no chemopreventive 
substance has been shown to reduce such preneoplastic lesions in the Min mouse 
model. A microadenoma compresses surrounding crypts and shows positive reactivity 
for β-catenin in the cytoplasm (Hata et al., 2006). An example of colon microlesions is 
shown in the Fig. 18.  
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        A                  B     
 
 
 
 
 
 
 
 
 
Fig. 18. Min mouse colon microlesions (β-Catenin accumulated crypts). White arrows indicate 
microlesions and yellow arrows show normal appearing crypts. A) β-catenin immunohistochemistry   
with fluorescence detection and B) -Catenin with colorimetric immunostaning. 
 
In the colon, normal crypts have a membrane β-catenin staining and no signs of 
dysplasia (yellow arrow Fig. 18). On the other hand, BCACs show a nuclear 
hyperchromatic staining of β-catenin and a higher grade of dysplasia. This represents 
an activation of the Wnt pathway which is involved in carcinogenesis progression 
stages.  
Immunohistochemistry experiments confirm that such colonic lesions also overexpress 
for other Wnt signalling targets such as Cyclin D1 and iNos. Moreover, colonic lesions 
were positive for the Ki67 proliferation marker (Fig. 19). 
   A       B         C    
  
 
 
 
 
 
Fig. 19. Min mouse colon microlesions. DAB immunhistochemistry detection of A) Ki67 as 
proliferation marker; B) iNos; C) Cyclin D1. 
 
The highest number of microlesions was observed in colon preparations of the water 
group (average ± SEM; Water: 71.5 ± 12.1 microlesions/cm2). In animals of the B-PAE 
and placebo treatment groups, 46.1 ± 10.3 and 32.3 ± 7.7 microlesions/cm2 were 
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counted, respectively. Both intervention groups demonstrated the strongest inhibition 
in numbers of colonic microlesions (Placebo: 55 % and B-PAE: 35% reduction); 
however, there were no significant differences between treatments (Fig. 20). 
Almost similar microadenoma numbers/cm2 were detected in colon preparations of 
CAJ and CAJ + B-PAE treatments (CAJ: 62.1 ± 12.1 microlesions/cm2 and CAJ + B-
PAE: 55.7 ± 6.3 microlesions/cm2). Both treatments did not significantly inhibit 
microlesion numbers compared to the water group (CAJ: 22% and CAJ + B-PAE: 
13.3%). 
  
 
 
 
 
 
 
 
 
 
 
 
Fig. 20. Min  mice colon microlesions in the different treatment groups. Total microlesions. Mean ± 
SEM. Treatments: (1) Water; (2) B-PAE 0.2%; (3) Placebo ;(4) CAJ and (5) CAJ + B-PAE 0.2%. 
 
Microlesion distribution  
 
Each colon was divided in 3 segments (proximal, middle and distal). In water treated 
animals, comparable numbers of microlesions were identified in all segments (Prox: 
23.5 ± 4.9; Middle: 20.7 ± 3.0 and Distal: 27.4 ± 9.8 microlesions/cm2). 
In the proximal part of the colon, we counted 23.5 ± 4.9 microlesions/cm2. Intervention 
with placebo juice and CAJ strongly reduced numbers of preneoplastic lesions to 6.7 ± 
2.0 and 7.4 ± 2.0, respectively. B-PAE and CAJ + PAE also reduce microlesions 
multiplicity to 11.0 ± 2.1 and 17.2 ± 3.0, correspondingly. Overall, statistically 
significant reductions (p<0.05 by ANOVA) were found by Placebo (71%) and CAJ 
(68%) treatments. Although not statistically significant, reductions were also found in 
the CAJ + B-PAE (53%) and B-PAE (27%)- treated groups (Fig. 21 A). 
In the middle part, 20.7 ± 3.0 microlesions/cm2 were found in colon samples of the 
water-treated controls. Only intervention with placebo juice reduced the number to 
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11.6 ± 1.2 microlesions/ cm2. However, this reduction (43.8%) was not statistically 
significant. In all other intervention groups, similar levels of microlesions/cm2 compared 
with the water group were counted (B-PAE: 18.5 ± 5.7, CAJ 20.7 ± 6.2, CAJ + B-PAE: 
17.5 ± 2.5). This resulted in non statistically significant reductions (Fig. 21 B). 
In the distal part of the colon, 27.4 ± 9.8 microlesions/cm2 were identified in water-
treated animals. Only in the placebo group with 13.5 ± 3.6 microlesions/cm2 and in the 
B-PAE group with 13.7 ± 3.0 microlesions/cm2, the numbers of lesions were reduced. 
In contrast, CAJ treatment increased preneoplastic lesions to 32.7 ± 4.8 (20% in 
comparison with the water group). Treatments with CAJ + B-PAE resulted in 27.2 ± 5.3 
microlesions/cm2. This represents a reduction by about 50% for placebo and B-PAE 
treatments (data were not statistically significant). On the other hand, for the CAJ + B-
PAE treatment no inhibition was found (Fig. 21 C).   
 
       A                          B                   C 
 
 
 
 
 
 
 
 
 
 
Fig. 21.  Min mice colon microlesions in different segments. Mean ± SEM. A) Proximal part of the 
colon; B) Middle part; C) Distal. *p>0.05 One-way ANOVA with Tukey´s multiple comparisons test (in 
comparison to water control). Treatments: (1) Water; (2) B-PAE 0.2%; (3) Placebo; (4) CAJ; (5) CAJ + 
B-PAE 0.2%. 
3.2 Pathologic analyses 
3.2.1 Spleen weights  
 
It has been well documented that Min mice display enlarged spleen and decreased 
hematocrit values. This is attributed to adenoma progression and the subsequent 
intestinal bleeding. Therefore, Min mice present anemia, and extramedullary 
hematopoeisis takes place in the spleen, increasing its weight. Fig. 22 summarizes 
average spleen weights and hematocrit values.  
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In all Min mice we observed enlarged spleen weights in comparison to wild-type (Wt) 
mice (mean ± SEM; Wt: 2.81 ± 0.2 mg/g BW). The most increased spleen weights 
were observed for the water-, CAJ + B-PAE- and placebo treatment groups (water 
14.7 ± 1.0 mg/g BW, Placebo: 14.0 ± 2.3 mg/g BW and CAJ + B-PAE: 17.5 ± 1.2 mg/g 
BW). Compared to Wt, this is a 5-, 5- and 6-fold induction, respectively. However, B-
PAE and CAJ treatment groups showed less increased spleen weights (B-PAE: 9.8 ± 
1.0 mg/g BW and CAJ: 13.0 ± 1.1 mg/g BW). This corresponds to an approximately 3- 
and 4-fold induction compared to Wt spleens. Taking water treatments as a reference, 
a significant reduction (p<0.05 by ANOVA) was observed for the B-PAE treatment 
group. In addition, CAJ reduced the spleen weight in a non-significant manner (Fig. 22 
A).  
3.2.2 Hematocrit values 
Hematocrit values in Wt animals were approximately 40 ± 0.4%. Animals of the water-, 
CAJ + B-PAE- and placebo group showed the lowest average hematocrit values 
(Water: 27.64 ± 1.3%, Placebo: 25.8 ± 1.1% and CAJ + B-PAE: 25.4 ± 0.8%). B-PAE 
and CAJ treatments increased the hematocrit value (B-PAE: 30.8 ± 1.4% and CAJ: 
28.8 ± 1.2%) in comparison with the water control group. Like for the spleen weights, 
there was a statistically significance (p<0.05) comparing hematocrit values of the B-
PAE treated group with water treated control. Furthermore, CAJ treatment also 
increased the hematocrit but this result was not statistically significant (Fig. 22 B). 
    
 
 
 
 
 
 
 
 
 
 
Fig. 22. Changes in A) Spleen Weight and B) Hematocrit values *p<0.05 One-way ANOVA with 
Bonferroni´s multiple comparisons test (in comparison with water control). Treatments: (1) Water; (2) B-
PAE 0.2%; (3) Placebo; (4) CAJ; (5) CAJ + B-PAE 0.2% and Wt (Wild type, taken from previous Min 
mouse experiment performed by Dr. Lydia Pan). 
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3.2.3 Histopathological analysis 
(collaboration with Prof. Karbe, Wülfrath) 
 
Animals were randomly selected for the following histological examinations: 
  
Liver:     Spleen 
Necrobiotic foci    Extramedullary hematopoiesis 
Extramedullary hematopoiesis 
Lobular pattern 
Cytoplasmatic vesicles 
Glycogen content 
Nuclear morphology 
 
Liver  
 
Liver slices were stained with H&E to determine differences at the histo-morphological 
level (necrobiotic foci, extramedullary hematopoieisis and lobular pattern) and at the 
cytoplasmatic level (cytoplasmatic vesicles, glycogen and nuclear morphology). 
Cytoplasmatic vesicles are a marker for liver stress and toxicity. No signs of toxicity 
were observed in this study for all treatments. Since the animals were kept in 
metabolic cages for 12 h before termination of the experiment and were therefore food 
deprived, all animals displayed reduced glycogen liver reserves.  To determine 
associated stress through mutagenic substances, the nuclear morphology was 
observed. In H&E liver staining, these nuclei are recognized for its increased volume 
with strong hematoxylin staining. This is mainly a result of polyploidy. All Min mice 
showed normal nuclear morphology and no differences between treatments were 
identified (Tab. 15). 
Another pathological examination to investigate the effects after substance exposure 
is the formation of an increased lobular structure in the liver. Generally, this is 
associated with liver hypertrophy which can be identified in an increase of Kupffer 
cells. Unexpectedly, some water control animals had symptoms of liver hypertrophy. 
However, all animals from the B-PAE treated group contained signs of hypertrophy but 
no adverse effects through metabolic exposure were reported (Tab 15). 
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Necrobiotic foci are another morphological structure to examine putative liver stress 
through compound exposure but no differences were observed for all treatments. All 
animals presented high extramedullary hematopoiesis which is associated to GI 
bleeding (Tab. 15).  
 
     Tab. 15. Histopathologic liver examination.  
 
 
 
 
 
 
 
    Different animal numbers were used for pathological analysis.  
                E.H. (extramedullary hematopoiesis: erythroid, myeloid and megakaryocytes foci) 
 
Spleen 
 
In the spleen, almost all animals revealed strong extramedullary hematopoiesis (EH). 
The increase in mean spleen mass is consistent with EH, possibly secondary to 
intestinal bleeding. The EH grade was determined detecting hematopoietic foci in the 
spleen, which are clumps of erythroid and myeloid precursors together with 
megakaryocytes. 
For this parameter, 12 animals per group were examined. For the evaluation, each 
spleen was rated in a range of 0 (low grade of EH) to 5 (high grade of EH) and then an 
average was calculated. B-PAE treatment resulted in a reduced grade of 
extramedullary hematopoiesis. One placebo group also showed a reduced grade 
(Tab.16). So far, the difference between both placebo groups can not been explained. 
Groups Necrobiotic foci E.H grade Lobular pattern  
Water 4/4 3/4 3/4 
0.2 % B-PAE 3/6 4/6 6/6 
Placebo 5/8 5/8 3/4 
CAJ 4/4 4/4 2/4 
CAJ + B-PAE 5/9 6/9 4/9 
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    Tab. 16. Histopathologic spleen examination. 
 
 
 
 
 
 
     
 
 
 
 
    Grades: From 0 (low grade) to 5 (high grade) 
     EH (extramedullary hematopoeisis) 
3.3 Urine analyses 
3.3.1 Urine volume 
 
Urine was collected to determine the bioavailability of apple polyphenols. This analysis 
is very useful to characterize which polyphenols may act locally in the SI or if they are 
absorbed and further conjugated in the liver. Local or systemic effects can be 
responsible to inhibit adenoma development in SI. 
After finishing the intervention, a set of Min mice from each experimental group were 
housed in rodent metabolism cages to collect urine for different determinations. During 
this time, animals had only access to intervention drinks, but not food. It is worth 
pointing out that animals were fasted overnight for 12 h before collecting urine 
samples. Therefore, data were analyzed independently for groups with fasted (Water 
vs. B-PAE) and non-fasted animals (Placebo vs. CAJ and CAJ + B-PAE). The 
difference is because non-fasted animals received sugars as a source of energy from 
their drinks, whereas fasted animals did not received such carbohydrates. 
As observed in Fig. 23, urine volumes were affected by treatments (mean ± SEM; 
Water: 0.97± 0.08 ml, B-PAE: 0.79 ± 0.09 ml, Placebo: 4.8 ± 0.31 ml, CAJ: 4.4 ± 0.21 
ml and CAJ + B-PAE: 3.9 ± 0.06 ml). Urine volumes of the placebo, CAJ and CAJ + B-
Groups n E.H. grade 
6 4.5 / 5 
Water 
6 4.1 / 5 
6 3.2 / 5 
0.2 % B-PAE 
6 3.5 / 5 
6 4.6 / 5 
Placebo 
5 3.5 / 5 
6 4.8 / 5 
CAJ 
6 4.2 / 5 
6 4.5 / 5 
CAJ + B-PAE 
6 4.6 / 5 
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PAE groups were increased up to 4-fold (P<0.001 by ANOVA) in comparison with the 
water and B-PAE groups (Fig. 23). Since the liquid uptake was not monitored during 
the period in the metabolic cages, it is not clear whether the increased urine volume is 
due to increased consumption of these carbohydrate- containing drinks (to prevent 
being hungry). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 23. Urine volume.  Urine was collected over night. 3 mice were allocated per cage (Mean ± SEM) 
*** p<0.001 One-way ANOVA with Bonferroni´s multiple comparisons test (in comparison to water 
control). Treatments: (1) Water ;(2) B-PAE 0.2%; (3) Placebo; (4) CAJ and (5) CAJ + B-PAE 0.2%. 
 
3.3.2 Minerals 
 
Mineral and carbohydrate analyses were performed to better understand differences in 
urine volume. Dietary potassium intake can lead to hyperkalemia, which increases 
urine excretion as a physiological response to remove excess of potassium ions. The 
renin-angiotensin system in the kidney is involved in this process and may increase 
urine volumes (Kacsoh et al., 2000). 
It has been reported that AJ contains up to 1.1 g/L of potassium (Jarman et al., 2001). 
Potassium and calcium ions were determined using atomic absorption spectrometry. 
All data were calculated as mean ± SEM and normalized to mg creatinine per 
treatment.  
In the urine of placebo- treated mice, 0.87  0.18 mg Ca2+/mg creatinine was detected. 
In urine of CAJ- and CAJ + B-PAE- treated animals concentrations were increased up 
to 1.17  0.15 Ca2+/mg creatinine and 1.33  0.42 mg Ca2+/mg creatinine. However, 
values showed a high SEM. 
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Potassium analysis resulted in similar urinary values for all three intervention groups, 
11.9  0.9 K+/mg creatinine for the placebo group, 11.3  0.5 K+/mg creatinine for the 
CAJ treated animals and 11.9  1.1 K+/mg creatinine for the mice receiving CAJ + 
PAE. Overall, there were no statistically significant differences between treatments in 
both Ca2+ and K+ determination (Tab.17). Water and B-PAE treatment groups were not 
determined because of limited urine availability. 
 
                   Tab. 17. Ca2+ and K+ determination in urine 
 
 
 
 
 
 
 
 
 
           a Mean ± SEM. Data normalized to creatinine (creat).  
 
 
3.3.3 Carbohydrates 
 
 
As already mentioned, glucose and fructose are the most common sugars in CAJ and 
placebo drink. Drinks contain approximately 20 g/L glucose and 70 g/L fructose. As in 
diabetes, higher amounts of sugars can induce polyuria. We performed a urinary 
carbohydrate analysis for groups receiving a juice- based intervention.  
In the group treated with placebo juice, we measured 2.7  2.0 mg glucose/mg 
creatinine in the urine. Intervention with CAJ + B-PAE and CAJ reduced the glucose 
concentrations in the urine to 0.61  0.06 mg glucose/ mg creatinine and to 2.1  1.4 
mg glucose/ mg creatinine, respectively.  
Normalized fructose levels in urine were higher than glucose concentrations. In 
placebo treated animals, 11.5  6.1 mg fructose/mg creatinine were observed. With 
mice treated with CAJ and CAJ + B-PAE, concentrations of 8.7  4.4 and 4.4  1.7 mg 
fructose/mg creatinine were measured, respectively. 
All differences were not statistically significant and values showed a high standard 
error (Tab. 18). Again, urine of water and B-PAE treated animals was not analyzed 
due to limited availability. 
Treatment                      Urine 
Measure Ca
2+ 
(mg/mg creat)
K+ 
 (mg/mg creat) n 
Placebo    0.87  0.18 a 11.9  0.9 6 
CAJ  1.17  0.15 11.3  0.5 4 
CAJ+B-PAE   1.33  0.42 12.1  1.1 6 
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          Tab.18. Glucose and fructose determination in urine 
 
 
 
 
 
 
 
 
 
         a Mean ± SEM. Data normalized to creatinine (creat) 
 
 
3.3.4 Analysis of phenolic compounds and metabolites  
(collaboration with Jn.Prof. Elke Richling and Ms. Hannah Bergmann) 
 
Quantification of apple juice polyphenols and metabolites by HPLC separation coupled 
with UV detection (HPLC/UV) was very useful to study the bioavailability of the 
phenolic apple compounds. If polyphenols are found in urine, that implies absorption in 
the liver, possibly effects in plasma, and systemic distribution. The HPLC/UV 
technique enabled the identification of 8 polyphenols and their metabolites in urine 
from Min mice (epicatechin, quinic acid, 4-hydroxy-phenylacetic acid, ferulic acid, 3,4-
di-hydroxy-phenylacetic acid, caffeic acid and isoferulic acid). Data were given in 
mean ± SEM and in µg polyphenol/mg creatinine (Fig. 24). 
Treatment Urine 
Assay Glucose (mg/mg creat.)
Fructose 
(mg/mg creat.) n 
Placebo   2.7  2.1 a 11.5  6.1 5 
CAJ 2.1  1.4 8.7   4.4 3 
CAJ+B-PAE 0.6  0.06 4.4  1.7 5 
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  Fig. 24. Concentration of polyphenols and metabolites in urine of Min mice. Mean ± SEM.  
  Data normalized to creatinine. Treatments: (1) Water; (2) B-PAE; 0.2%; (3) Placebo; (4) CAJ and  
  (5) CAJ + B-PAE 0.2%. * p<0.05 One-way ANOVA with Tukey´s multiple comparisons test.  
  (Each group n=4). 
 
All 8 compounds were detected in urine collected from all groups, although at different 
concentrations. Only in urine of mice treated with CAJ + B-PAE we identified an 
statistically significant increase (p< 0.05 by ANOVA) in 7 polyphenols and metabolites 
compared with rest of groups (in µg polyphenols/mg creatinine; epicatechin: 2690.1  
1035.9, quinic acid: 1358.2  489.9, 4-hydroxy-phenylacetic acid: 747.0  181.6, 
ferulic acid: 458.54  89.6, 3,4 di-hydroxy-phenylacetic acid: 350.1  64.6, caffeic acid: 
240.5  55.6 and isoferulic acid: 230.8  50.1). In the urine of CAJ-treated animals, 
urinary excretion of 5 metabolites could be detected in considerable amounts 
compared to water control (in µg polyphenols/mg creatinine; epicatechin: 530.9  44.5, 
4-hydroxy-phenylacetic acid: 128.0  19.2, ferulic acid: 71.1  34.2 nd 3,4 di-hydroxy-
phenylacetic acid: 126.2  30.4. All other polyphenols were detected at lower 
concentration (Fig. 24). 
In urine of water-, placebo juice- and B-PAE- treated animals, low amounts of all 
compounds and metabolites, respectively, were found. Only epicatechin was detected 
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in appreciable amounts (in µg polyphenol/mg creatinine; Water: 146.2  50.1, placebo: 
190.0  26.1 and B-PAE: 63.3  30.4). Small amounts of quinic acid (in µg 
polyphenol/mg creatinine: 52.8  7.6) and 4-hydroxy-phenylacetic acid (in µg 
polyphenol/mg creatinine: 114.0  65.3) were found in urine from B-PAE animals. 
Since all 8 metabolites were detected of very low amounts in urine of water and 
placebo treated mice, these results indicate that some polyphenols and metabolites 
may be derived from food uptake (Fig. 24). 
Overall, intervention with CAJ + B-PAE resulted in higher urinary excretion of all 
analysed metabolites in comparison with all other treatments. In urine from the CAJ 
group, these compounds were also detected but approximately at 5 fold lower 
concentrations compared to CAJ + B-PAE. Therefore, these results imply that in the 
CAJ + B-PAE group a part of the high molecular weight polyphenols such as 
procyanidins are absorbed and metabolized in the liver. In contrast, when the animals 
received CAJ or B-PAE, the majority of polyphenols may remain in the GI tract. 
 
3.3.5 Urine inflammatory markers  
3.3.5.1 Nitric oxide (NO) 
 
 
Measurement of NO in biological fluids has attracted attention in the field of 
inflammation biomarkers. Upregulation of iNOS, and the consequent overproduction of 
NO, has been implicated as a promoter of several diseases including cancer (Itzkowitz 
and Yio, 2004; Wink et al., 1998). Detection of NO in urine is associated with 
inflammation and its increase is detected in colon cancer patients (Groschel et al., 
1992). We were interested to study whether the anti-inflammatory in vitro potential of 
apple juice is also detected in vivo. After detecting polyphenols in urine of CAJ and 
CAJ+B-PAE we investigated the possible effect on NO production. Moreover in Min 
mice, administration of iNOS inhibitors or iNOS gene knock out results in suppression 
of intestinal polyposis in all GI tract (Ahn and Ohshima, 2001). 
Total NO detection (NO2- + NO3-) revealed similar urinary levels in all treatment groups 
(µmol total NO / mg creatinine; Water: 2.20  0.1, B-PAE: 2.03  0.18 Placebo: 2.09  
0.30, CAJ: 1.90  0.11 and CAJ + B-PAE: 2.38  0.32). Treatments did not 
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significantly affect urinary nitrite excretion and fasting effects were not observed (Tab. 
19). 
3.3.5.2 Protein content 
 
Proteinuria is associated with nephrotoxicity and common in diabetes and 
inflammation. In addition, it has been suggested as a paraneoplastic phenomenon in 
CRC (Roumen and Wijnen, 1998). Protein was detectable in the urine of all animals 
independent of the intervention. Normalized levels in the water control group were in 
the range of 4.0 ± 0.3 µg protein/ mg creatinine. Unexpectedly, intervention with B-
PAE significantly increased urinary protein levels by 35% to 6.2 ± 0.7 µg protein/ mg 
creatinine. Intervention with placebo juice, CAJ and CAJ + B-PAE did not influence 
protein levels in the urine, indicating that polyphenol consumption as such may not 
directly be responsible for the observed effects in the B-PAE group (Tab. 19). Rather, 
the combination of fasting and polyphenol consumption may lead to higher urinary 
protein excretion.  
            
                Tab. 19. Effect of treatments on urine parameters 
 
 
 
 
 
 
 
 
 
  
         a Mean ± SEM. Data normalized to creatinine (creat) 
         * p=0.01 Student´s t-test comparison versus water control. 
 
 
 
 
 
 
  
 Assay 
Treatment NO2
- / NO3- 
(nmol /mg creat.) n 
Protein 
(µg /mg creat.) n 
Water  2.20  0.11a 14 4.0  0.30 12 
0.2 % B-PAE 2.03  0.18 17 6.2  0.68* 14 
Placebo 2.09  0.30 17 4.8  0.51 16 
CAJ 1.90  0.11 15 3.8  0.48 15 
CAJ+B-PAE 2.38  0.32 17 3.7  0.44 17 
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3.4 Plasma analyses 
    
3.4.1 ORAC 
 
The HPLC experiments revealed that some metabolites derived from CAJ and B-PAE 
were detectable in urine. It was of interest to study whether these phenolic compounds 
exert systemic anti-oxidant effects in the plasma. Therefore, an ORAC assay with 
plasma from Min mice was performed. Data were normalized to protein content. 
As summarized in Tab. 20, all treatments resulted in similar plasma ORAC values in 
the range of 11-12 ORAC units/µg protein. No statistically significant differences were 
observed (Tab. 20). Determination of protein concentration in plasma resulted in a 
range of 35.8-37.0 mg/ml for water, placebo, CAJ and CAJ + B-PAE treatments 
groups. B-PAE treatment increased in a non-significant manner the plasma protein 
levels to 42 mg/ml (Tab 20). According to Green et. al,  C57BL/6J male mice contain 
about 52.0 ± 1.0 mg/ml of protein in serum (Green et. al,  1966).         
                 
 
          Tab. 20 Effect of treatments on protein concentration and antioxidant capacity (ORAC) 
          in plasma 
 
       
 
 
 
 
 
 
 
 
                 aMean ± SEM. ORAC data normalized to protein (µg) 
3.4.2 PGE2 
 
We next tested the hypothesis whether components of CAJ or B-PAE may inhibit COX 
activity as another indication of anti-inflammatory activity (Wu, 2005). PGE2 are 
synthesized by the microsomal prostaglandin synthase E (mPGE-synthase). The rate-
                             Determination  
Treatment protein (mg/ml) ORAC (units/µg) n 
Water  37.0  2.4 a 11.8  0.5 17 
0.2 % B-PAE 42.0  1.3 11.0  0.9 13 
Placebo 36.5  1.4  11.9  0.9  16 
CAJ 35.8  1.6 11.3  0.5 18 
CAJ+B-PAE 37.0  1.0 12.1  1.1 17 
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limiting enzymes in PGE2 synthesis are Cox-1 and Cox-2 enzymes. For that reason, 
detection of PGE2 in plasma is a good biomarker to detect influences on Cox activity. 
Data were given in pg PGE2/ µg protein. PGE2 was quantified using an ELISA-based 
method. PGE2 levels were normalized to protein levels. As summarized in Tab. 21, 
PGE2 plasma levels were in the range of 119-137 pg/µg. Overall, no statistically 
significant difference was measurable (Tab. 21).  
                             
   Tab. 21 Effect of treatments on PGE2  levels in plasma  
 
 
 
 
 
 
                                     a Mean ± SEM. Data normalized to protein (µg) 
3.5 Influence on liver enzymatic activities 
 
Certain dietary ingredients may modulate biotransformation of carcinogens. 
Biotransformation is the process whereby a substance is changed from one chemical 
to another (transformed) by a chemical reaction within the body (Rushmore and Kong, 
2002). The liver is the first organ for biotransformation. 
Enzymatic activities were determined to analyze whether the in vitro chemopreventive 
potential of CAJ and B-PAE may be relevant in an in vivo system. We focused our 
experiments on Phase I enzymes (Cyp1A1 and Cyp2B1), Phase II enzymes (GST, QR 
and TrxR) and glutathione (GSH) levels. These parameters were analyzed in liver 
microsomes (Phase I enzymes) and cytosolic preparations (Phase II enzymes and 
GSH). Data were normalized to the respective protein content. 
 
 
 Assay 
Treatment PGE2 (pg/µg prot) n 
Water  118.9   16.2a 18 
0.2 % B-PAE 119.0   16.6 16 
Placebo 136.9   16.9 16 
CAJ 148.7   19.5 15 
CAJ+B-PAE  121.4   21.8 16 
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3.5.1 Liver weights 
 
As already described, all animals were housed in metabolic cages with free access to 
drinks. In this section, fasted vs. non-fasted animals were compared independently. 
The first observation associated with fasting was a statistically significant reduction of 
liver weight, which is indicative of glycogen degradation (fasted (water and B-PAE) 
0.042 ± 0.005 g/g BW vs. not-fasted (placebo juice, CAJ and CAJ + B-PAE) 0.052 ± 
0.005 g/g BW). Liver weights were approximately 20% reduce. This reduction was 
strongly associated with a decrease in protein concentration (fasted: 5.87 ± 0.09 and 
not fasted: 7.02 ± 0.01 mg/ml) (Fig. 25). 
                     
           
 
 
 
 
 
 
 
 
 
    Fig. 25. Effects of fasting on A) liver weights (g liver/ g BW) and B) protein content. (mg/ml)   
    ***p<0.001 and *p<0.05 Student´s t-test comparison.Box: Interquartil range; line: median; whiskers:  
   25th and 75th quartile; dots: outliners. Fasted group: water, B-PAE; Not-fasted group: Placebo, CAJ  
   and CAJ + B-PAE.  
                 
3.5.2 Phase I enzymes 
 
Metabolic activation is performed by cytochrome P450 (Cyp) proteins (phase I 
enzymes). This family of proteins acts as monoxigenases. Apple polyphenols such as 
quercetin have been described in vitro as extremely potent inhibitors of Cyp1A activity 
(Zessner et al., 2008). Therefore, it was of interest to measure the effect of our 
interventions on hepatic Phase I enzyme activities. As shown in Fig. 26, fasting had a 
striking effect on Cyp1A activity. In the fasted group, the mean microsomal activity 
(18.4 ± 7 nmol/min/mg) was about 50% lower than in the not-fasted groups (40.5 ± 
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14.5 nmol/min/mg; p<0.001 Student´s t-test). Within the two groups, we did not detect 
statistically significant differences (Tab. 22). In contrast to Cyp1A activity, Cyp2B1 was 
not influenced by fasting. Also, no statistically significant changes were measurable 
within the fasted and not-fasted groups, respectively (Tab. 22). 
       
 
 
 
 
 
 
 
 
   
   Fig. 26. Fasting effects on hepatic Cyp1A1 activity. ). ***p<0.001 Student´s t-test comparison. 
 
 
                     Tab. 22.  Effects of treatments on liver microsomal enzyme activities  
 
 
 
 
 
 
 
 
 
  
  
        a Mean ± SEM. Data normalized to protein (mg)           
 
 
 
 
 
 
 
 
 
 
 
 
 
 Liver microsomal activity 
Treatment EROD (Cyp1A1) nmol/ min /mg 
PROD (Cyp2B1) 
nmol/ min /mg n 
Water 17.73.4a           8.21.3 4 
0.2 % B-PAE 21.33.1          10.5 1.3 4 
Placebo 40.76.4 8.9 0.8 6 
CAJ 41.25.2 7.60.7 6 
CAJ+B-PAE 45.8 9.1 7.7 0.9 4 
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3.5.3 Phase II enzymes 
 
Cytosolic liver fractions were used to determine the activity of GST, QR and TrxR 
enzymes (summary in Tab. 23). 
 
Tab. 23.  Effects of treatments on liver cytosolic enzyme activities 
 
a GST: Glutathione-S- transferase; QR: NAD(P)H: Quinone oxidoreductase; TrxR: Thioredoxin 
reductase  
b Mean ± SEM. Data normalized to protein (mg) 
*p=0.02 Student’s t-test comparison (in comparison to placebo). 
 
3.5.3.1 Glutathione-S-transferases (GST) activity 
 
GSTs catalyze the addition of aliphatic, aromatic, or heterocyclic free radicals as well 
as epoxides and arene oxides to GSH (Hayes and McLellan, 1999). B-PAE treatment 
increased hepatic GST activity using chlorodinitrobenzene as a substrate from 1740.3 
305.3 nmol/min/mg (water control) to 2448.1 553.6 nmol/min/mg (Tab. 23). Even 
though this is a 29% increase, differences were not statistically significant. Intervention 
with the placebo juice resulted in GST cytosolic activities of 1837.4 248.0 
nmol/min/mg. Treatment with CAJ and CAJ + B-PAE further increased GST activities 
up to 1990.0 306.4 and 2235.3  221.4 nmol/min/mg, respectively. A trend for 
induction can be observed but this increase was not statistically significant. CAJ + B-
PAE induced GST activity by 20% compared to placebo juice (Tab. 23). GST activities 
were not affected by fasting. 
 
 Liver cytosolic activities 
Treatment GST
 a 
nmol/ min /mg  
QR 
nmol/ min /mg 
TrxR 
nmol/ min /mg n 
Water 1740.3 305.3b 33.6 3.3 10.01.6 4 
0.2 % B-PAE 2448.1 553.6 25.82.0 12.7  3.2 4 
Placebo 1837.4 248.0 40.14.7 18.11.3 6 
CAJ 1990.0 306.4 43.44.4 20.91.9 6 
CAJ+B-PAE 2235.3  221.4 49.93.4  25.31.5* 4 
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3.5.3.2 NADPH: quinone reductase activity (QR) 
 
QR are flavoproteins catalyzing a two-electron reduction with preference for short-
chain acceptor quinones. For the water control group, we measured an activity of 
33.6 3.3 nmol/min/mg based on the menadione-mediated reduction of MTT. QR 
activity was reduced to 25.82.0 nmol/min/mg by B-PAE intervention. This indicates 
a 24% reduction but data were not statistically significant. In the placebo group, we 
detected a QR activity of 40.14.7 nmol/min/mg. CAJ and CAJ+B-PAE intervention 
increased QR activities up to 43.44.4 and 49.93.4, correspondingly. Like with the 
GST activities, CAJ + B-PAE induced 20% the QR activity in a non-significant manner 
(Tab. 23). Similar to Cyp1A microsomal activity, fasting significantly reduced QR 
activity by about 30% from 47.7 ± 10.4 nmol/min/mg in the not fasted groups to 31.1 ± 
7.0 nmol/min/mg in the fasted groups (Fig. 27). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 27. The impact of fasting on liver QR and TrxR activities. A) QR enzyme activity; B) TrxR 
enzyme activity. Data normalized to mg of protein ***p<0.001 and *p<0.05 Student’s t-test comparison. 
Fasted groups: water, B-PAE; not-fasted groups: placebo juice, CAJ, CAJ + B-PAE. 
 
3.5.3.3 Thioredoxin Reductase (TrxR) 
 
TrxR are an oxidoreductase enzyme family and catalyse the NADPH-dependent 
reduction of the redox protein thioredoxin. They play a role in several cellular 
processes such as oxidative stress, cell growth, apoptosis, ascorbate recycling and 
are involved in several human diseases (Mustacich and Powis, 2000). TrxR activity in 
the liver was not affected by B-PAE treatment (12.7 ± 3.2 nmol/min/mg) compared to 
the water control (10.0 ± 1.6 nmol/min/mg). Placebo juice- treated animals showed a 
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liver TrxR activity of 18.11.3 nmol/min/mg, and CAJ intervention resulted in 
20.91.9 nmol/min/mg TrxR activity. Compared to placebo, CAJ + B-PAE treatment 
(25.31.5 nmol/min/mg) statistically significantly induced TrxR activity by 39% 
(p<0.05 Student t-test) (Tab. 23). Overall, the three not-fasted groups had an about 
50% higher hepatic TrxR activity (average 21.0 ± 4.5 nmol/min/mg) than fasted groups 
(average 11.5 ± 4.6 nmol/min/mg) (Fig. 27). 
 
3.5.3.4 Hepatic glutathione (GSH) levels  
 
 
Glutathione (γ-L-Glutamyl-L-cysteinylglycine) plays an important role in redox 
regulation. GSH can be oxidized to GSSG which protects cells from oxidative stress 
due to free radicals (Hayes and McLellan, 1999). GSH levels are reported as mean ± 
SEM and normalized to protein concentration. We determined total GSH levels with 
dithionitrobenzene (DTNB) as a measure of indirect antioxidant effects of apple 
components. As observed with several enzyme activities, fasting significantly reduced 
hepatic GSH levels by about 35% from 149.4 24.1 nmol GSH/mg prot in the not-
fasted groups to 97.2 15.5 nmol GSH/mg prot in the fasted group (p<0.001 
Student´s t-test, Fig. 28). 
 
 
 
 
 
 
 
 
 
 
         Fig 28. Effects of fasting on hepatic GSH levels. Data normalized to mg of protein  
         ***p<0.001 Student’s t-test comparison. 
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                      Tab. 24. Effects of treatments on liver GSH levels 
 
 
 
 
 
    a Mean ± SE. Data normalized to protein (mg) 
 
Within the fasted and not-fasted groups, treatments did not affect glutathione levels 
(Tab. 24). 
 
3.6 Mechanisms in normal mucosa 
 
As previously described, we had performed a first Min mouse experiment investigating 
the effects of CAJ04 and a 1:1 mix of an A- and B- 
PAE on adenoma development in Min mice (Gerhäuser, Forum DKG 2008). From this 
experiment, 1 cm each of normal tissue derived from the three SI segments (Int-1, Int-
2 and Int-3; proximal, middle, distal) and the colons were collected for gene 
expression analyses. Also, swiss rolls were prepared from all segments. 
Briefly, in this previous experiment, the total number of adenoma in the water control 
was higher than in the present experiment (total number of adenomas in the SI; 1. 
experiment: 64.7 7.2, 2. experiment: 52.1 3.8, compare Tab. 14). Importantly, 
CAJ04 and PAE significantly reduced tumor multiplicity in the SI by 38% and 40%, 
respectively. Highest adenoma reduction was observed in the middle (CAJ04: 39% 
and PAE: 41%) and the distal part of the SI (CAJ04: 52% and PAE: 34%, Tab. 25). 
 
 
 
 
 
 
 
            
Treatment GSH nmol GSH / mg n 
Water 99.8 5.4a 4 
0.2 % B-PAE 94.610.9 4 
Placebo 155.8 9.5 6 
CAJ 138.511.0 6 
CAJ+B-PAE 159.312.7 4 
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     Tab. 25. First Min mouse experiment: Treatment effects in GI and adenoma localisation. 
Small Intestine (SI) Total SI Colon 
Treatment 
n Int-1 Int-2 Int-3   
Water 12 7.6 ±  1.3 22.8  ± 2.6 34.3 ± 4.6 64.7 ± 7.2 1.3 ±  0.3 
AS04 12 6.3 ± 1.4 13.9 ± 1.6 39 %* 
20.2 ± 2.6 
52 %* 40.3 ± 5.0 1.8 ± 0.4 
PAE 0.2% 12 5.4 ±  2.1 11.0 ±  4.3* 41 % 
22.5 ± 1.5 
34 % 38.9 ± 2.9 0.9 ±  0.2 
 
      GI was divided in 4 parts Int-1, Int-2 and Int-3 and colon. Adenoma multiplicity in the SI and colon   
      parts. (*) p<0.05 (Kruskal-Wallis One way ANOVA on Ranks). Mean ± SEM. 
 
After demonstrating that PAE and CAJ prevent adenoma development in the Min 
mouse model, we were interested in identifing which genes are involved in the 
progression from normal mucosa to adenoma. Therefore, we measured gene 
expression by quantitative RT-PCR. Genes related to proliferation (Cyclin D1 and c-
Myc), inflammation (Cox-2), and angiogenesis (VEGF and MMP7) were investigated in 
these normal tissue samples (not containing adenoma). 
3.6.1 Determinations at the transcriptional level 
 
RNA was extracted from normal mucosa. Gene expression was quantified by the 
Sybr-Green method, based on the computation of Ct values (Bio-Rad, iCycler).  
GAPDH, β-actin and Cyclophilin E were used as housekeeping genes in order to 
obtain more reliable results. Ct (Cycle threshold) values for the housekeeping genes 
varied from 23 to 28. In quantitative RT-PCR, Ct values represent the cycle when the 
PCR increases exponentially the synthesis of the amplicon and the detected 
fluorescence increases over the detection threshold. Consequently, higher Ct values 
mean less mRNA expression and lower values imply a higher expression.  
Cyclin D1 mRNA was detectable in all GI tract (Ct values from 26 to 30). However, 
mRNA of c-Myc, VEGF and MMP7 were expressed at very low levels (Ct > 32, relative 
expression data not shown). Because this implies a higher error in the ratio 
calculations, c-Myc, VEGF and MMP7 were not further investigated.  
Cyclin D1 mRNA expression was analyzed in mucosal samples of all SI and Colon. In 
Int-1 segments, CAJ04 and PAE treatments resulted in an increase of expression 
(average ratio ± SEM; Water: 1.00 ± 0.05, CAJ: 1.44 ± 0.06 and A-PAE: 1.76 ± 0.22). 
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In Int-2 parts, expression in samples of water and CAJ04 treated animals was similar, 
but PAE intervention reduced Cyclin D1 gene expression by 30% (Water: 1.00 ± 0.13, 
CAJ: 1.23 ± 0.18 and PAE: 0.68 ± 0.0.09). In Int-3 parts, the normalized ratio was 
close to 1 for water- and CAJ- treated animals whereas PAE treatment reduced Cyclin 
D1 mRNA expression by 25% (Water: 1.00 ± 0.20, CAJ: 0.98 ± 0.10 and PAE: 0.74 ± 
0.08). This trend was also observed in the colon (Water: 1.00 ± 0.19, CAJ: 0.91 ± 0.13 
and PAE: 0.68 ± 0.07). Overall, Cyclin D1 was slightly reduced in the distal regions of 
the GI albeit non-significantly (Fig. 29). However, results did not correlate with the 
tumor yield in the SI. 
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Fig. 29.  Cyclin D1 mRNA expression (qPCR) in SI segments and colon. Values were normalized 
using GAPDH, β-actin and Cyclophilin E as housekeeping genes. Mean ± SEM (n=6).  
 
Analysis of Cox-2 mRNA by quantitative RT-PCR resulted in high Ct values (>32). 
These values were shown in all SI segments indicating low expression. In the colon, 
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lower Ct values were observed (from 28 to 30). Both intervention using CAJ04 and 
PAE reduced in a non- significant manner Cox-2 relative mRNA expression by 30%-
43% (Water: 1.00 ± 0.12, CAJ: 0.57 ± 0.10 and PAE: 0.69 ± 0.13) (Fig. 30).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 30. Cox-2 gene expression (qPCR) in colon. Ratios were normalized using GAPDH, β-actin and 
Cyclophilin E housekeeping genes. Mean ± SEM (n= 6). 
 
3.6.2 Determination at the protein level 
 
In order to investigate Cox-2 and Cyclin D1 protein expression, immunohistochemical 
(IHC) experiments were performed in normal mucosa. In comparison to qRT-PCR, this 
technique is less sensitive but allows to asses the expression profile of the specific 
proteins and to evaluate tissue localisation. 
As shown in Fig. 31A, Cox-2 protein was detected in the lamina propria and the 
stroma, whereas it was absent in the epithelia (crypts and villi). There was no 
difference in Int-3 that could be related to the treatment with CAJ03 and PAE. Cyclin 
D1 expression was limited to nuclei in the crypts (Fig. 31 B). Expression was not 
influenced by the treatment. In Int-2 segments no changes Cyclin D1 and Cox-2 
expression were observed (data not shown).  
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   A 
  
 
 
 
 
 
  
      B 
 
 
 
 
 
 
       
              WATER         CAJ                A-PAE 0.2% 
 
Fig. 31. IHC detection of Cox-2 and Cyclin D1 in SI segment Int-3 (normal tissue). (A) Cox-2 non- 
epithelial staining: Lamina propria (black arrows) and stroma (yellow arrows). (B) Cyclin D1: nuclear 
staining in the crypts (black arrows). C: Crypt; Lp: Lamina propria; St: Stroma and V: Villi. Original 
magnification 200x. 
 
 
Since all these experiments with normal mucosa samples were not very informative, 
we thought of a technology which would enable us to quantitatively compare protein 
expression and/or post-translational modifications in larger sample sets in a high-
throughput manner. In cooperation with Dr. Ulrike Korf and Heiko Mannsperger 
(DKFZ), we were able to apply the method of RPPA (reverse phase protein array) to 
our tumor samples of these second Min mouse experiments.  
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3.7 Proteomic analysis in tumor tissue  
3.7.1 Principle of reverse phase protein arrays 
 
RPPA (Reverse phase protein array) technology is a new useful tool for monitoring 
protein abundance and turnover of posttranslational modifications on a large scale, 
and is ideal for hypothesis-based post-translational analyses in cell signalling (Spurrier 
et al., 2008). 
With RPPA, protein lysates are spotted on a nitrocellulose membrane and the protein 
of interest is detected by incubation with a specific primary antibody. The captured 
primary antibody is then subsequently visualized by a secondary antibody which is 
coupled with a near-infrared dye. The final read-out is performed using an infrared 
scanning system (Fig. 32). 
 
 
 
 
 
 
 
      Fig. 32 Schematic illustration of  RPPA (Loebke et al., 2007). 
 
This technique allows protein quantification with high reproducibility and an error rate 
of <5% (Loebke et al., 2007). In comparison, a total standard deviation of 20–35% is 
commonly reported for quantitative Western blotting (Koller and Watzig, 2005). On the 
other hand, immunohistochemistry can provide valuable information regarding 
abundance of cellular protein antigens in tissue. However, immunohistochemistry has 
been reported to be subjective, nonquantitative and subject to processing variability 
(e.g., formalin fixation artefacts) (Mighell et al., 1998). 
Proteomic studies based on RPPA were performed to identify which proteins are 
involved in adenoma development and to elucidate mechanisms involved in the 
reduction of adenoma development by apple juice intervention. A set of protein arrays 
were prepared using ultracentrifuged lysates of adenomas derived from Int-2 and Int-
3. Only these parts are shown since here we observed the strongest inhibition in 
adenoma multiplicity in comparison to the water control. To avoid bias because of 
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fasting effects, treatments were independently analyzed (Fasted: Water vs. B-PAE 
and not- fasted: Placebo vs. CAJ and CAJ + B-PAE). 
 
3.7.2 Protein expression of Proliferating Cell Nuclear Antigen (PCNA) 
 
PCNA is an auxiliary protein of DNA polymerase that is specifically expressed in cells 
during the S phase of the cell cycle and it is used as a marker for cellular proliferation 
(Kelman, 1997).  
As indicated in Fig. 33, intervention with B-PAE on the one hand, and CAJ and CAJ + 
B-PAE on the other hand did not significantly decrease cell proliferation, based on 
PCNA protein expression. B-PAE treatment reduced expression by 20% compared to 
the water control in Int-3, whereas similar PCNA levels were observed in Int-2 (Fig. 
33). CAJ and CAJ + B-PAE non-significantly increased PCNA expression in 
adenomas of Int-2 by 31 and 32%, respectively, in comparison to the placebo group. 
In contrast in Int-3 samples, we observed a reduction of PCNA expression by about 
25% (Fig. 33). 
   
 
 
 
 
 
 
 
 
 
 
Fig. 33. PCNA expression in adenoma tissue. Signals were expressed in Relative Fluorescence 
Units (RFU). Int-1 was not calculated due to low protein concentration of the prepared lysates. 
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3.7.3 Wnt signalling pathway 
 
3.7.3.1 β-catenin  
β-catenin is a key component of the Wnt signalling pathway. As already mentioned in 
chapter 1.3.1, inappropriate activation of the Wnt signalling pathway is considered to 
be an initiating event in the transformation of intestinal epithelial cells (Dihlmann and 
von Knebel Doeberitz, 2005). 
Using the RPPA technology strong expression levels of β-catenin were found in the 
adenoma samples. In Int-2 adenoma samples, neither B-PAE nor CAJ nor CAJ + B-
PAE treatment resulted in significant changes in β-catenin expression. In Int-3 
samples, B-PAE had also no influence on β-catenin levels (Fig. 34). However, 
intervention with CAJ and CAJ + B-PAE non-significantly reduced β-catenin 
expression by 49% and 57% in comparison with the placebo juice group (p=0.07 and 
p=0.13 ANOVA Bonferroni test).  
 
 
 
 
 
 
 
 
 
Fig. 34. β-Catenin protein expression in adenoma tissue. Signals were expressed in Relative 
Fluorescence Units (RFU). Mean ± SEM. (a) p= 0.07 and (b) p= 0.13 One-way ANOVA with 
Bonferroni´s multiple comparisons test (comparison with placebo juice group). 
 
3.7.3.2 Cyclin D1 
 
Cyclin D1 is a target of Wnt signalling. It was therefore of interest to analyze whether 
the effects on β-catenin expression could be translated to effects on Cyclin D1 
expression. In comparison with the water control, B-PAE treatment did not significantly 
reduce Cyclin D1 expression in adenoma samples of Int -2 and Int-3 (Fig. 35). 
However in Int-2 adenomas, a trend of a reduction was observed by B-PAE 
intervention (Fig. 35). In all three non-fasted groups (Placebo, CAJ and CAJ + B-PAE), 
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Cyclin D1 expression was reduced by approximately 50% in comparison with the 
water control in a non-significant manner (p= 0.16, Student t-test). This effect was not 
seen in samples of Int-3. In Int-3 adenomas, water and placebo control Cyclin D1 
levels were in a similar range. Interestingly, in comparison with the placebo juice 
group, intervention with CAJ or CAJ + B-PAE significantly reduced Cyclin D1 
expression by 70% and 83%, respectively (p<0.05 by ANOVA). This reduction might 
be a consequence of reduced β-catenin levels as described in chapter 3.7.3.1. 
 
 
 
 
 
 
 
 
Fig. 35. Protein expression and expression of Cyclin D1 in adenoma tissue. Signals were 
expressed in Relative Fluorescence Units (RFU). Mean ± SEM. *p<0.05 One-way ANOVA with 
Bonferroni´s multiple comparisons test (comparison to placebo). 
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3.7.4 Mitogen activated protein kinase (MAPK) pathway 
 
 
The MAPK pathway mediates signal transduction from cell membrane receptors to 
downstream transcription factors, leading to cellular responses such as cell 
proliferation, growth, apoptosis, motility and survival (Dhillon et al., 2007) (Fig. 36).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 36. General scheme of the MAPK and p38 signalling pathway.  ATF, activating transcription 
factor; Cdc42, cyclin-dependent kinase 42; EGFR, Epidermal growth factor receptor; ERK1/2, 
Extracellular-regulated kinase 1/2; Grb-Sos, GTPase son of sevenless; HSP1, heat shock protein-1; IL-
1, Interleukin-1; MEK, Mitogen-regulated kinase; Raf, rapidly growing fibrosarcoma or rat fibrosarcoma; 
Ras, rous avian sarcoma homologue; TAK, TGF-β activated kinase; TCF/LEF, T-cell factor/Lymphoid 
enhancer-binding factor 1; TAB, TAK binding protein; TGF-β, Transforming growth factor-beta; TNF, 
Tumor necrosis factor; TRAD/DAX, Tumor necrosis factor receptor-1/Dosage-Sensitive Sex Reversal; 
VGFR-2, Vascular growth factor receptor-2. Adapted from KEGGS database.  
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3.7.4.1 MEK and ERK 
 
MEK and ERK proteins are crucial proteins in the EGFR signaling pathway. When 
MEK or ERK are phosphorylated, the pathway is active and activates genes related to 
proliferation, angiogenesis and inflammation (Fig. 36). In the Min mouse model, 
phosphorylated ERK is increased in adenomas (Khor et al., 2008). Based on this 
information, we were interested whether apple juice intervention may reduce MAPK 
signaling and therefore reduce adenoma growth. Phosphorylation of MEK and ERK as 
a downstream target was analysed by RPPA, using antibodies specific for the 
phosphorylated forms of MEK and ERK. Specificity was tested by Western blotting 
(data not shown). For comparison, antibodies for the un-phosphorylated forms of MEK 
and ERK were utilized. 
In fasted groups, administration of B-PAE reduced MEK1/2 phosphorylation in 
adenomas of Int-2 and Int-3 with borderline significance (Int-2: 25%, p=0.10 and Int-3: 
29%, p=0.09) compared to the water control (Fig. 37 A). This reduction was specific 
for the phosphorylated form of MEK, as total MEK levels were not changed by the 
intervention with B-PAE (Fig. 37 B). In contrast, in the non-fasted groups, neither 
phosphorylation nor expression of the non-phosphorylated form of MEK was 
influenced by intervention with CAJ and CAJ + B-PAE (Fig. 37 A+B). 
In adenomas of the placebo juice-treated animals, MEK phosphorylation was about 
50% higher than in adenomas of the water control group. But both reductions were not 
statistically significant. These data may imply that fasting and fasting-associated stress 
activates the MAPK signaling pathway. However, B-PAE treatment prevented this 
activation (Fig. 37 A) 
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Fig. 37. Phosphorylation and protein expression of MEK and ERK in adenoma tissue. Signals 
were expressed in Relative Fluorescence Units (RFU). (A) Detection of p-MEK, (B) unphosphorylated 
MEK, (C) p-ERK and (D) unphosphorylated ERK. Mean ± SEM; (a): p = 0.1; (b) p = 0.09; (c) p = 0.10; 
(d) p = 0.053 and *p= 0.038 Student´s t-test comparison (in comparison with water control). 
 
To confirm the role of the MAPK signaling pathway, we further analysed ERK 
phosphorylation and expression as a downstream protein. In adenomas of the B-PAE- 
treated group, p-ERK levels were (borderline) significantly reduced in comparison to 
water control (Int-2: 42%, p=0.10 and Int-3: 40%, p=0.053, Student´s t-test) (Fig. 37 
C). Highest expression was detected in samples of the water control group. Again, 
these effects were specific for a reduction of phosphorylation, since expression of the 
unphosphorylated form was not changed by intervention (Fig. 38 D). Similar ERK 
phosphorylation levels were found in adenomas of the CAJ- and CAJ + B-PAE- 
treated animals compared to the placebo control (Fig. 37 C). Also, total ERK levels 
were not affected (Fig. 37 D). In comparison to the placebo group, ERK 
phosphorylation was about 2-fold increase in adenomas of the water control group in 
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both Int-2 and Int-3 (Int-2: p=0.16 and Int-3: 0.038; Student´s t-test). Like with the MEK 
results, these data may indicate that fasting and fasting-associated stress activates 
the MAPK signaling pathway. Again, this activation was prevented by B-PAE 
intervention. 
 
3.7.4.2 iNOS 
 
iNOS is induced in inflamed tissues and generates nitric oxide (NO) that can promote 
mutagenic changes like DNA oxidization and protein nitrosylation (Hussain and Harris, 
2007). iNOS is a downstream target of the MAPK pathway (Surh, 2003). 
As shown in Fig. 38, protein levels of iNOS were higher in adenomas of water treated 
mice in comparison to B-PAE treatment. B-PAE treatment decreased iNOS protein 
expression in Int-2 and Int-3 tumors (Int-2: 54%, p=0.035 and Int-3: 28%, p=0.14, 
Student´s t-test). CAJ and CAJ + B-PAE treatments did not significantly reduce iNOS 
levels compared to the placebo juice group. 
 
 
 
 
 
 
 
 
 
Fig. 38. Protein expression of iNOS in adenoma tissue. Signals were expressed in Relative 
Fluorescence Units (RFU). Mean ± SEM. (a) p = 0.035 t-test and *p = 0.018 Student´s t-test 
comparison (in comparison with water control). 
 
As a downstream effect of activation of the MEK/ERK signaling pathway, expression 
of iNOS was significantly upregulated in adenomas of the water in comparison with the 
placebo juice group especially in Int-2. Again, this result may be due to fasting-induced 
stress (p= 0.018 Student´s t-test). Intervention with B-PAE normalized elevated iNOS 
expression detected in the water control group to levels similar to those in the CAJ and 
CAJ + B-PAE group (Int-2). A similar trend was observed in Int-3 adenomas (Fig. 38). 
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Cox-2 is another protein with an important role in inflammation and promotion of tumor 
growth (Buchanan and DuBois, 2006; Wang and Dubois, 2006). However, due to 
difficulties in finding a suitable specific antibody, the RPPA technology could not be 
used to analyse Cox-2 expression. 
 
3.7.4.3 p38  
 
The p38 signalling pathway is activated in response to a wide range of cellular stress 
stimuli and cytokines (Olson and Hallahan, 2004). 
In contrast to the ERK pathway, when p38 protein levels were measured, neither 
expression nor phosphorylation was affected. Similar low intensities in all groups were 
found for p-p38 (Fig. 39 A and B). 
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Fig. 39. p38 phosphorylation and protein expression and in adenoma tissue. Signals were 
expressed in Relative Fluorescence Units (RFU). Mean ± SEM. 
 
3.7.5 Summary of all proteomic results investigated by RPPA  
 
In addition to proteins of the Wnt- and MAPK signalling pathways mentioned above, 
we analysed the expression and/or phosphorylation of AKT, STAT3, STAT5, c-Myc 
and PKC. None of these proteins were significantly regulated by B-PAE treatment in 
comparison to the water control (Tab. 26), or by CAJ or CAJ + B-PAE in comparison 
with the placebo juice control (Tab. 27). 
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4. DISCUSSION 
 
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in 
western societies. The progression of the disease from benign adenoma through 
early carcinoma to malignant metastatic cancer requires years or even decades. Due 
to a long asymptomatic period preceding detection, the disease is mostly threatening. 
The chance of long-term survival for colon, rectal, or other cancers improves 
significantly upon early detection. Although early detection is a key contemplation in 
the fight against cancer, ideally, researchers and clinicians would like to prevent 
cancer from developing. 
In recent years, it has been suggested that diet contains many compounds that can 
inhibit CRC, at least in animal models (Corpet and Pierre, 2003; Corpet and Tache, 
2002). This is also supported by epidemiological studies in humans (Donaldson, 
2004). It has been estimated that improvement of diet and exercise could reduce the 
number of new cancer cases by 30–40% (WCF/AICR, 2007). 
A WHO/FAO report recommends as a population-wide intake goal the consumption 
of a minimum of 400g of fruit and vegetables per day for the prevention of chronic 
diseases such as cancer (WCF/AICR, 2003). Different countries have initiated health 
programs such as the 5–a–day program, which recommends eating 5 or more 
portions of a variety of fruit and vegetables. One of the servings can be a 100% fruit 
juice. However, the role of juices in cancer prevention has not been completely 
investigated. 
Dietary components aim to promote health and prevent diseases such as CRC are 
rapidly increasing in popularity. To show convincingly that these compounds really 
are chemopreventive, their efficacy in animal models should be first demonstrated, 
and their mechanism of action in cancer prevention should be understood.  
The main objective of this thesis was to investigate which mechanisms are involved 
in the prevention of adenoma formation by AJ and PAE the Min mouse model. 
Therefore, the work has focused on the initiation and the promotion stage of 
carcinogenesis. Proteomic and transcriptional profiles of adenomas and normal 
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tissue were investigated after intervention using different techniques in order to 
identify proteins/genes and pathways involved in the inhibition of adenoma formation. 
Before termination of the experiment, animals were kept in metabolic cages for 12 h 
to collect urine and feces for subsequent analyses. During this time period, animals 
had access to their respective intervention drinks. As a consequence, two groups 
(water control and B-PAE) were kept under fasting conditions, whereas the remaining 
three groups consumed calories in the form of carbohydrates provided by placebo 
juice and CAJ, respectively. Since fasting effects apparently influenced several end 
points addressed in this study, the potential impact of its effects will be discussed. 
 
4.1 Inhibition of intestinal tumorigenesis   
4.1.1 Effect of apple polyphenols on adenoma development 
 
In our previous first animal experiment both CAJ04 and PAE treatments reduced 
adenoma development in the small intestine (SI). These findings have been 
confirmed by the present animal experiment using CAJ06 and B-PAE interventions. 
In the SI, CAJ06 resulted in a lower inhibitory effect on adenoma numbers than 
CAJ04 (CAJ04: 40% and CAJ06: 24%). Similar inhibition percentages were caused 
by B-PAE and PAE (PAE: 39% and B-PAE: 34%) (Tab. 14 and Tab. 25).  
 
Adenoma number 
The highest inhibition of the adenoma numbers was observed by B-PAE treatments. 
As already explained, B-PAE is obtained from an apple pomace enzymatic digestion, 
and consequently the content of oligomeric and polymeric procyandins is increased. 
Since intervention with B-PAE resulted in the highest percentage of adenoma 
inhibition (34%), this may indicate the role of procyanidins as active chemopreventive 
compounds in vivo (Tab. 14 and Fig. 15).  
Our previous animal experiment and the present animal study confirm that 
procyanidin–rich PAE are chemopreventive in the Min mouse model.  So far, the in 
vivo effect of PAE has only been demonstrated in the AOM model. Although both are 
models for CRC prevention, it is important to point out that the AOM model is a 
chemically induced colon cancer model. Nevertheless, 0.01% of an apple 
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procyanidin fraction resulted in a 50% reduction of hyperproliferative crypts and ACF. 
This represents a satisfactory effect at low procyanidin concentration (Gosse et al., 
2005). However, Barth et al. have suggested that the chemopreventive potential of 
CAJ in the AOM-model might be a synergistic effect of the procyanidins and cloud 
particle fractions (Barth et al., 2007). But as already mentioned, the effect of dietary 
fiber in the Min mouse model seems to have a lower effect on adenoma reduction 
(Corpet and Pierre, 2003). In the present study, we may therefore speculate that 
polyphenols are the main chemopreventive compounds.  
Although CAJ- and B-PAE-treated animals received nearly a similar polyphenol dose, 
CAJ potential was weaker than B-PAE intervention. A difference may be determined 
by analyzing the mean degree of polymerisation (DPm) of procyanidins. Generally, 
CAJ or commercial AJ contain a DPm of 4-6. But this value increases to 8 in B-
PAE03 due to the enzymatic extraction. An increased DPm might result in a more 
efficient chemopreventive potential. Unexpectedly, the CAJ04 used for the first Min 
mouse experiment showed a DPm of 13. Hence, the differences in DPm between 
CAJ04 and CAJ06 might be the reason of the weaker potential in adenoma inhibition 
of the CAJ06 used for the present work.   
Isolated OPC have been identified in our earlier investigations as important active 
compounds of apples (Zessner et al., 2008). Other in vitro experiments have 
demonstrated the chemopreventive potential of oligomeric procyanidins in colorectal, 
prostate, breast and oesophageal cancer cell lines (Nandakumar et al., 2008). 
Although we did not examine dysplastic crypts in the SI, we can assume that initiated 
crypts will develop adenomas over time. Therefore, the tumor multiplicity indicates 
whether treatments took effect at the initial stage of the adenoma-carcinoma 
sequence. As already described, two events are involved in the initiation of the 
adenoma-carcinoma sequence, Apc mutations and the subsequent TCF/LEF targets, 
and epigenetic modifications. For the first possibility, Kern et al. described that 
TCF/LEF reporter gene assay showed no inhibition after AP treatment. The authors 
conclude that PAE does not mediate growth-stimulating effects in HT29 via the Wnt 
signaling pathway (Kern et al., 2005). Detailed transduction mechanisms will be 
discussed in section 4.6. 
In contrast, PAE incubation has recently been reported to cause demethylation in the 
DNA repair gene hMLH1 in the RKO CRC cell line. In addition, strong inhibition of the 
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methyltransferases DMNT-1 and DMNT-3b was observed. Both results were related 
to the diminished cell viability of RKO cells (Fini et al., 2007). Taking in consideration 
both investigations, epigenetic events may play a crucial role during initiation stages 
in the Min mice.   
Another evidence for the efficacy of polyphenols at initial stages is the effect of 
placebo intervention. Interestingly, placebo juice treatment decreased adenoma 
numbers in the SI by 7%. This result indicates that polyphenols are the main active 
compounds in CAJ and B-PAE treatments (Tab. 14 and Fig. 15).  
CAJ + B-PAE treatments did not result in a synergistic effect of CAJ and B-PAE 
intervention. A dose of 120 mg/kg resulted in a less inhibitory potential but in a higher 
bioavailability. HPLC analysis identified higher amounts of catechins and polyphenol 
metabolites in CAJ + B-PAE-treated animals. In contrast, no polyphenol metabolites 
were identified in the urine of B-PAE–treated animals (Tab. 13 and Fig. 24). This 
finding may implicate that a reduced local effect is happening in the SI for CAJ + B-
PAE intervention, which in turn reduces the effect of adenoma inhibition. Other 
reported intervention experiments using polyphenolic compounds in the Min mouse 
model have caused less inhibitory effects. As an example, interventions with 2% rutin 
or 2% quercetin, suppressed about 15% of adenomas in the SI. Similar results were 
observed with 20% freeze-dried cherries. Both authors argued in each discussion 
that such an effect may be dependent on the bioavailability of the polyphenols, and 
therefore less local effects may occur (Kang et al., 2003; Mahmoud et al., 2000). 
Overall, a kind of dose-response effect was observed when comparing all treatments. 
Water and placebo juice interventions resulted in almost similar number of adenomas 
in the SI. The most effective adenoma inhibition was observed for CAJ and B-PAE 
treatment groups. In the CAJ + B-PAE intervention group, higher amounts of 
polyphenols did not cause an increase in adenoma inhibition as compared to B-PAE 
and CAJ treatments (Tab. 14). However, these effects were dependent on the 
bioavailability. 
In a Min mouse experiment, EGCG in drinking water in the range of 0.02% to 0.32% 
inhibited small intestinal tumorigenesis from 37% to 47%. The authors discussed that 
a saturation trend of the adenoma inhibition was observed as the concentration of 
EGCG increases in a dose-dependent manner (Ju et al., 2005). Other previous 
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experiments demonstrated similar results with green tea extracts (Suganuma et al., 
2001). 
 
Adenoma size 
Both B-PAE and CAJ intervention groups confirmed the results of our previous 
animal experiment. As in the first animal experiment, treatments with CAJ and B-PAE 
reduced middle–sized (1–3 mm) adenomas and increased the small ones (<1 mm). 
This value represents the adenoma progression during the intervention. Our results 
revealed that CAJ and B-PAE polyphenolic components block the adenoma size 
(Fig. 17). Procyanidins might be responsible for reducing adenoma size, and thus 
anti-proliferative effects should be associated. The possible anti-proliferative 
mechanisms will be discussed in section 4.6.  
However, the present study shows that placebo juice treatments statistically 
significantly increased small–size adenomas by 50% in comparison to the water 
control group. Taken together, these findings indicated that placebo juice intervention 
might have an effect in the reduction of adenomas Placebo juice contains a high 
concentration of carbohydrates and lower amounts of pectin (Tab. 4 and Fig. 17). 
It has been reported that higher–sucrose diets in the Min mouse model enhanced 
tumor development and epithelial cell proliferation in the SI. IGF-I and insulin serum 
levels were increased, suggesting a relevant mechanism involved in the adenoma 
development (Wang et al., 2009). IGF-I and insulin effects are strongly linked to 
inhibition of apoptosis and cell cycle activations in intestinal epithelia (Giovannucci, 
2007). 
Pectin might be a second candidate to explain this increase this effect in the SI by 
placebo treatment. But in one Min mouse experiment, resistant carbohydrates from 
bran wheat doubled the occurrences of adenomas of the proximal SI. Moreover, 
when the source of carbohydrates was obtained from apple pomace, a 2-fold 
increase was observed in the whole SI. The authors suggested the possible role of 
fermentation products as tumor enhancers (Mandir et al., 2008). In contrast, as 
already described in the introduction, other positive effects have been described with 
dietary fiber such as white or rye bran. The possible preventive effects are also 
discussed in the next subchapter (see 4.1.2)    
Discussion 
 
 
 
 
139
4.1.2 Effects of apple polyphenolic compounds in the colon 
 
Based on the multistep carcinogenesis in the colon, it is suggested that there are at 
least two distinct stages for colon tumorigenesis in Min mice: macroscopic tumors 
and microadenomas. Therefore, additional events are accordingly required for 
evolution from microadenomas to macroscopic tumors (Yamada et al., 2005). 
Moreover, a higher microflora biotransformation occurs in the colon, thus increasing 
the pro-oxidant environment (Sanders et al., 2004). 
In the colon, similar adenoma numbers were detected in all treatment groups. All 
animals developed a range from 0 to 3 adenomas, and therefore we decided to 
investigate microlesions, which are considered to be putative premalignant lesions 
and are found in high frequency. 
Placebo juice intervention significantly reduced proximal colon microlesion numbers 
compared to water control by 71% (Fig. 21 A). In addition, placebo treatments 
resulted in non-significant microlesion reduction in middle and distal colon (Fig. 21 B 
and C). The putative effects of the placebo juice require an explanation. Inhibitory 
effects of placebo seem to remain in the whole colon. Again two possibilities may be 
considered, carbohydrates or pectin.  
Since carbohydrates, such as glucose or saccharose, have been described to 
increase colonic proliferation in Min mice, these compounds might have no relation to 
the inhibitory potential of placebo juice (Mandir et al., 2008). 
On the other hand, as already described, CAJ contains 4 times more pectin than 
placebo and is linked to cloud particles. Pectin is able to pass through the SI more or 
less intactly and subsequently colonic microflora can degrade the pectin and liberate 
short-chain fatty acids (SCFA) that may have an influence on the mucosa (Harris and 
Ferguson, 1993). Placebo juice has no cloud particles but analytics have identified 
free pectin, which might be efficiently degraded by colonic microflora.  
But the effects of pectin and SCFA on CRC remain controversial. Pre-clinical models 
have been used to test its protective potential. In one reported Min mouse 
experiment, 10% pectin–enriched diets did not inhibit intestinal tumorigenesis but 
rather increased the numbers of adenomas slightly (Jacobasch et al., 2008). 
However, in the AOM model, 10 % pectin in the diet increased the SCFA content 4-
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fold in cecum. In addition, ACF were significantly suppressed by intervention (Rao et 
al., 1998).  The role of SCFA is still controversial because no consistent results have 
been obtained neither in animal models and nor in human intervention studies. 
Differences may be attributed to the colonic microflora, composition of basal diets 
and duration of intervention (Pool-Zobel, 2005).  
It was difficult to identify the possible effect of placebo intervention. Therefore, an 
analytical identification in feces would be very valuable to identify SCFA in the colon. 
Until now, there is no evidence that chemopreventive agents reduce microlesions in 
Min mouse colon. But in the AOM-induced rat model, and after carcinogen injection, 
the rats develop microlesions in the colon. In this model, the dietary agents myricitrin 
and sesaminol glucosides significantly reduced microlesions in the colon (Asano et 
al., 2007; Sheng et al., 2007). 
 
4.2 Pathologic analyses 
 
In B-PAE–treated animals, a smaller spleen weight and a higher hematocrit 
percentage were observed in comparison to water controls. Both results indicated 
reduced intestinal haemorrhages, which are associated with the lower total adenoma 
number and size reduction in comparison to water control. These observations are in 
line with the low grade of extramedullary hematopoieses (E.H.) in the spleen of the 
B-PAE intervention. B-PAE polyphenolic compounds prevented paraneoplastic 
effects of adenoma development (Fig. 22 and Tab.16). 
In our first animal study, a positive correlation (r = 0.91) between spleen weight and 
tumor load and a negative correlation between hematocrit values and tumor load (r= 
– 0.82) were calculated. In the present study, this correlation could not be confirmed. 
This might be explained as an effect of fasting. 
Combination of CAJ and B-PAE slightly increased spleen weights in comparison to 
the placebo intervention. This may be related to the E.H. grade, which was slightly 
increased in the histopathological analysis of the spleen. Moreover, CAJ + B-PAE 
intervention showed a hematocrit percentage similar to that of the placebo controls 
(Fig. 22 and Tab. 16). It has been suggested that regular consumption of 
polyphenols reduces the absorption of non–haem iron due to the chelating 
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characteristics of the polyphenols (Mennen et al., 2005). In vitro studies with the Ca-
Co2 cell line have demonstrated that iron absorption was reduced in the baso-lateral 
layer after a grape seed extract incubation (Kim et al., 2008). 
Since no signs of toxicity were observed in CAJ + B-PAE–treated animals, the higher 
polyphenol doses in the CAJ + B-PAE treatment may reduce iron absorption. 
Subsequently, the hematocrit percentage is diminished, and to compensate the 
reduced absorption, the spleen starts processes of extramedullary hematopoiesis. 
So far, little is known about the toxicology of apple polyphenols. However, when 
Applephenon® (an extract from unripe apples) was given to rats in a dose of 2000 
mg/kg, neither acute nor subchronic toxicity was detected (Shoji et al., 2004). Our 
administered dose was 10 times lower for the CAJ + B-PAE treatments than in the 
experiment with Applephenon®, for that reason we can assume that the given dose 
was not toxic for the animals. In addition, histo-pathological analysis did not show 
toxicity in the liver. 
 
4.3 Urine analyses 
4.3.1 Bioavailability of CAJ and CAJ + B-PAE 
 
As shown in Fig. 24, CAJ treatments slightly increased epicatechin concentrations in 
urine. This increase indicated that a small proportion of the catechin pool passed 
through the epithelial intestinal barrier and was metabolized in the liver. In contrast, 
HPLC analysis has revealed that CAJ + B-PAE components were highly absorbed 
and metabolized in the liver. The consequence of a high polyphenol intake has been 
described by Silberg et al. In rats, high flavonoid doses resulted in the saturation of 
the intestinal secretion of conjugates, which might improve the bioavailability 
(Silberberg et al., 2006). 
The major degradation products of procyanidins are epicatechin, 4-OH-phenylacetic 
acid and 3,4-diOH-phenylacetic acid. OPC and polymeric procyanidins are mostly 
degraded to catechin monomers by depolymerisation. Such monomers might be 
oxidized to 4-OH-phenylacetic acid and 3,4-diOH-phenylacetic by the gut microflora 
(Couteau et al., 2001). 
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The rest of the detected metabolites, i.e. quinic acid, p-coumaric acid, ferulic acid and 
caffeic acid, were also identified in the urine of CAJ + B-PAE-treated animals. Ferulic 
and isoferulic acids might be degraded by the colonic microflora from epicatechin and 
further metabolised in the liver to m-coumaric acid and caffeic acid (Gonthier et al., 
2003). Quinic acids are mostly degraded from chlorogenic acid due to the esterase 
activity of the gut microflora. But there also reports of p-coumaric, ferulic and caffeic 
acid detected in urine as a degradation compound of chlorogenic acid (Gonthier et 
al., 2006). 
A good way to determine the absorption and metabolism of colon chemopreventive 
substances is the analysis of ilestomy fluids. Our network collaborators (WG 
Richling) have developed this method which consists of ileostomy patients drinking 
CAJ and the subsequent collection of ileostomy fluids in bags at various points in 
time. Polyphenols and metabolites are determined by HPLC (Kahle et al., 2005). 
In the first ileostomy  experiment, after ingestion of 1 L of CAJ, a range of 0 to 33% of 
the initial quantity was recovered in the ileostomy bags with maximum excretion at 2 
h (Kahle et al., 2005). Interestingly, identified polyphenols in ileostomy fluids still 
displayed antioxidant activity after SI passage (Gerhauser et al., 2008). Further 
studies with ileostomy patients showed that the majority of procyanidins (90%) were 
detected in the ileostomy bags, demonstrating that substantial amounts of these 
compounds in fact reach the colon under physiologic circumstances. But other 
metabolic products of polyphenols, such as phenol carbonic acids metabolites, were 
also detected (Kahle et al., 2007). 
The present study confirms for the first time in a pre-clinical model that apple 
polyphenols such as catechins and metabolites are in part absorbed by the SI and 
the colon. 
4.3.2 Protein content in plasma and urine. 
 
Unexpectedly, B-PAE intervention significantly increased the protein concentration in 
urine compared to water control animals by 35%. Likewise, serum protein content in 
B-PAE-treated animals was 20% higher in comparison to water control (Tab. 19 and 
20). Both findings may be associated with the higher hematocrit value in comparison 
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to the rest of the treatments (Fig. 22). Higher hematocrit implies a lower serum 
volume and therefore an increase in serum protein concentration (Cirillo et al., 1992). 
A possible increase of high blood pressure might be due to the paraneoplastic effect 
of less adenoma numbers instead of being a direct consequence of B-PAE 
intervention. Polyphenols and metabolites were not detected in the urine of B-PAE-
treated animals due to the very low bioavailability. This implies insignificant plasma 
availability and consequently no systemic effects (Tab. 14 and Fig 24). 
Also in urine, protein content was increased by B-PAE treatments. Generally, protein 
in urine is a sign of inflammation and possible renal failure. Although in our previous 
work no protein concentration was determined in urine of PAE-treated animals, histo-
pathological kidney analysis did not reveal any signs of renal failure associated with a 
higher hematocrit. The hypothesis that B-PAE intervention might result in adverse 
effects in the kidney absorption tubules as a result of an increase of protein content 
in urine was not contemplated because several reports indicated that polyphenolic 
compounds reduce proteinuria and associated effects. It has been described that in 
rats with renal failure induced by arginine, green tea diminished toxicity by reducing 
total NO in urine (Yokozawa et al., 2003). Also, red wine polyphenols reduced high 
blood pressure and proteinuria in an induced hypertension mouse model (Jimenez et 
al., 2007). 
Physiologically, in the B-PAE intervention, the protein content in urine might increase 
as a result of the augmented protein content in serum. Higher protein content in 
serum might increase kidney reabsorption, and therefore higher protein content in 
urine was detected. It is important to mention that the rest of the interventions groups 
showed a decrease of serum protein content in comparison to normal Wt values as a 
result of intestinal bleeding. In contrast, B-PAE intervention restores protein 
concentration in serum due to lower intestinal haemorrhages (Fig. 22 and Tab. 20). 
Overall, our findings revealed that as a result of strong paraneoplastic effects in the 
Min mouse, determination of protein in urine should only be interpreted cautiously as 
an inflammation marker. 
Another remarkable finding is the reduction of glucose and fructose in urine of CAJ + 
B-PAE-treated animals. The increase of carbohydrates in placebo juice treatments 
suggested that polyphenols caused a decrease of glycosuria (Tab. 18). A frequent 
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model used for obesity or noninsulin-dependent mellitus diabetes is the Zucker rat. In 
this rat strain, lyophilized apples suppressed glycosuria and proteinuria. The authors 
suggested that these beneficial consequences might be caused by an improvement 
of lipid plasma levels and the limitation of oxidative damage in the kidneys (Aprikian 
et al., 2002). Other reported in vivo experiments have shown that tea catechins 
inhibit the carbohydrate digestive enzymes α-amylase, intestinal sucrase, and α-
glucosidase in the intestines of rats. This suggests that glucose production may be 
decreased in the gut, in turn lowering glucose and insulin concentrations (Kobayashi 
et al., 2000). 
   
4.4 Enzymatic activities 
4.4.1 Effects of fasting in liver weight 
 
In the GI tract and the liver, phase I and phase II enzymes are especially important 
for defense against environmental carcinogens due to constant exposure of toxins 
through ingested food. Additionally, these enzymes are abundant in epithelial tissues 
and can be modulated by dietary compounds found in the GI tract (Yang et al., 
2001). 
After finishing the intervention, the first observation was a significant reduction in liver 
weight of fasted animals. On the one hand, the histo-pathological analysis revealed a 
glycogen reduction in all animals. But on the other, we have observed a decrease of 
protein liver content in fasted mice. Therefore, protein degradation occurred during 
the first 12 h of food deprivation (Fig. 25A and B).  
During starving, the growth hormone (GH) rises causing an insuline decline, and 
glucose homeostasis is maintained. Moreover, glucagon avoids hypoglycemia by 
inducing glucogenesis and glycogenolysis and initiating hepatic glucose release 
(Klover and Mooney, 2004). All these biochemical changes are strongly regulated by 
the PGC-1α protein, which is increased during fasting (Yoon et al., 2001).  
In a reported in vivo experiment, mice were fasted for 12, 24 and 72 h and microarray 
gene expression was used to determine differences after fasting.  During the first 12 
h of fasting, carbohydrate, amino-acid and lipid metabolic pathways were 
upregulated. Moreover, gene expression analysis revealed a strong induction of the 
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phosphoenolpyruvate carboxykinase-1 (pepck1), malate-aspartate shuttle and a 
consequent upregulation of the TCA cycle. after 12 h the authors also detected an 
induction of unfolded-protein response and of the metallothionein-1 which are related 
signs of oxidative stress (Sokolovic et al., 2008).  
On the other hand, Sokolovic et al. have pointed out that after 12 h of fasting, many 
proteins related to amino–acid metabolism are strongly activated. Similarly, 
according to a review of Finn et al, during short term fasting, proteolysis is activated 
to supply amino acids as a source of energy. In hepatocytes, during fasting, protein 
degradation is regulated by the low levels of insulin and the increased levels of 
glucagon, IGF-I and glucocorticoids. Finn et al. have pointed out that in this process 
of protein catabolism, chaperons may facilitate the degradation of cytosolic proteins 
(Finn and Dice, 2006).  
4.4.2 Phase I enzymes 
 
CYP1A1 and CYP2B1 play critical roles in the metabolic activation of carcinogenic 
compounds leading to toxicity and CRC (Oyama et al., 2004). It has been 
demonstrated that diets rich in meat increase CRC risk. The consumption of meat 
cooked at high temperatures forms PAH and heterocyclic aromatic amines that 
increase CYP1A activity (Sugimura, 2002). Similarly, the consumption of red meat 
induces CYP2B activity through N-nitrosamines (Bingham et al., 2002). 
In the present work, CYP1A1 hepatic enzymatic activity was dramatically reduced 
after fasting, whereas no difference was observed for CYP2B1 (Fig. 26). These 
findings agree with previous published studies. Decreases in CYP1A activities during 
starvation have been reported in rats (Dixon et al., 1960; Ma et al., 1989). However, 
totally different enzymatic activity results were reported in rats that were fasted for 12 
h. In this experiment, CYP1A1 remained unchanged but CYP2B1 was significantly 
induced after fasting (Brown et al., 1995). It is important to point out that our results 
differ from caloric restriction (CR) experiments. CR experiments in fasted rats 
showed an increase of  both CYP1A1 and CY2B1 activities (Chou et al., 1993).  
The main reason of CYP1A1 reduction might be associated with liver protein 
degradation after fasting. But the influence of oxidative stress might help to reduce its 
activity. Sokolovic et al. have shown that 12 h fasting was able to cause initial stages 
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of oxidative stress in the liver. In rabbits, liver-induced inflammation revealed that 
CYP1A1 was strongly downregulated in the absence of change of protein expression 
(El-Kadi et al., 2000). 
4.4.3 Phase II enzymes 
 
Both QR and TrxR phase II enzymes were significantly reduced after fasting. In 
addition food deprivation had a striking effect on reducing GSH levels (Fig. 27 and 
28). 
The reduction of TrxR enzymatic activity might be related to Txnip. This protein is a 
negative regulator of TrxR and induces its degradation. Txnip is known to maintain 
glucose homeostasis during fasting by preventing excess glucose uptake or 
metabolism. Hepatic overexpression of Tnxip causes elevated serum glucose levels 
and decreased ketone bodies (Chutkow et al., 2008).  
Other reported experiments have shown GSH depletion in the rat liver after 18 h of 
fasting. In addition, GST liver activity remained unchanged. Moreover, refeeding of 
mice restored GSH liver levels (Leeuwenburgh and Ji, 1996; Szkudelski et al., 2004).  
These findings are in line with our results. 
So far, no direct relation between QR and fasting has been demonstrated. However, 
Van den Bosch et al. investigated the effects in 24 h-fasted rats in Phase II intestinal 
enzymes. Gene expression experiments using cDNA array technology validated with 
qRT-PCR showed no difference in Phase II intestinal enzymes, whereas GST and 
GSH were strongly reduced. A possible justification would be that during starving 
dietary electrophiles are not present and consequently the detoxification system may 
be downregulated (van den Bosch et al., 2007). 
It is remarkable that all CYP1A1, QR, TrxR and GSH were significantly decreased 
after fasting. On the one hand, it is possible that the detoxification system is 
downregulated since there is no need to detoxify. But on the other, fasting may 
reduce total protein content in the liver. 
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Effects of CAJ and B-PAE in phase II enzymes 
 
Treatments with CAJ and CAJ + B-PAE induced GST and QR in the liver in a non-
significant manner. Interestingly, CAJ + B-PAE intervention resulted in a statistically 
significant increase of Trx enzyme activity. These results were strongly associated 
with the bioavailability because HPLC analysis revealed that CAJ + B-PAE 
components are highly absorbed and metabolized in the liver. As result of this 
absorption, the activity of the investigated phase II enzymes was induced (Fig. 24 
and Tab. 23).  
Other reported experiments have demonstrated similar effects. Hepatic QR and GST 
enzymatic activities were upregulated in rats treated with apple, grape and black 
currant juices. In contrast, neither a carbohydrate drink nor an orange juice resulted 
in the induction of the hepatic phase II enzymes (Breinholt et al., 2003). Together 
with our experiment,s this indicates that the polyphenols are the main compounds 
involved in phase II enzyme induction. 
Although in different tissues, similar results were observed by our collaborators from 
Jena (Pool-Zobel and Wölfl). They reported an increase of GST and UDP genes in 
LT97 cells with PAE incubations (Veeriah et al., 2008). However, in the DMH-initiated 
rat model, CAJ treatments showed no difference in GST levels in normal colon 
mucosa (Barth et al., 2005). 
The possible mechanism of induction might be via Nrf2 and the transcription of 
antioxidant responsive elements (ARE). The AREs are regulatory sequences found 
on promoters of several phase II detoxification genes that are inducible by 
xenobiotics and antioxidants (Dinkova-Kostova et al., 2002).  
The Nrf2 activation is mediated by the repressor protein Keap1, which acts by 
directly interacting with Nrf2, thus preventing its nuclear accumulation. The activation 
occurs whenever this interaction and repression is disrupted, allowing Nrf2 to 
translocate and accumulate in the nucleus. It has been also demonstrated that Nrf2 
activation is mediated by mechanisms that lead to its stabilization or the upregulation 
of Nrf2 gene expression at the transcriptional level, such as MAPK or PI3K activation 
(Na and Surh, 2008).  
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In our experiments, due to the relatively high absorption, the putative candidate for 
this effect in the CAJ and CAJ + B-PAE treatments is epicatechin. Other in vivo 
bioavailability experiments have demonstrated that epicatechin is relatively well 
absorbed in the SI and its metabolites are found in plasma after 2 h administration 
(Feng, 2006). 
In vivo experiments with green tea showed similar findings (Embola et al., 2002; 
Khan et al., 1992; Maliakal et al., 2001). EGCG and other catechins might be 
absorbed in the liver and be responsible for detoxification–gene activation. Green tea 
polyphenols activate MAPK and PI3 signalling pathways, leading to activation of Nrf2 
and ARE with subsequent induction of phase II enzymes. But it has been discussed 
that green tea polyphenols may interact with cysteine residues present in Keap1, 
thereby inducing Nrf2 dissociation and nuclear activation of the ARE (Na and Surh, 
2008). 
Other in vivo experiments have demonstrated that polymeric black tea polyphenols 
induce phase II enzymes via Nrf2 in mouse liver and lungs through PKC and PI3- 
pathways (Patel and Maru, 2008). This suggests that different black and green tea 
polyphenols induce Nrf2 activation by different pathways. 
Furthermore, polyphenol degradation products such as ferulic and coumaric acids 
are able to induce phase II enzymes (Yeh and Yen, 2006). In the CAJ + B-PAE 
treatment group, such compounds might help to induce phase II enzymes in a 
synergistic way. Nevertheless, lower amounts of such compounds were detected in 
urine of the CAJ intervention group. These low concentrations might not be sufficient 
to induce detoxification enzymes. Other apple compounds such as chlorogenic acid 
and quercetin have been described to be involved in Nrf2 activation as well (Eggler et 
al., 2008; Feng et al., 2005). 
4.5 Mechanisms in normal mucosa  
We have already mentioned the importance of Apc mutations as one of the initial 
events in the progression of carcinogenesis. In the Min mouse model, after the third 
week and due to the loss of Apc heterozygocity, any area of intestinal mucosa might 
presumably develop polyps. However, most of the adenomas start to be detectable 
at 6–8 weeks of age. Whenever normal mucosa of Min mice was compared with Wt 
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mice, longer villi were found in the ileum at 12 weeks. Moreover, immunologic 
changes such as increases of CD8+ cells, Ig A and PGE2 at 5 weeks of age are 
increased in normal mucosa (Kettunen et al., 2003). 
Therefore it was of interest to determine whether TCF/LEF target genes were 
involved in early stages of adenoma development. For this purpose, the normal 
mucosa of Min mice of the first animal experiment was investigated. 
In the distal parts of the SI and the colon, Cyclin D1 was non-significantly reduced by 
PAE treatments. Nevertheless, there was no direct relation with adenoma inhibition 
since CAJ intervention showed the strongest tumor inhibition and yet no association 
with Cyclin D1 was observed (Tab. 25 and Fig. 29). These results might indicate that 
Cyclin D1 is not important for the early stages but may be involved as a secondary 
event. In fact, Cyclin D1 is not essential for the development of intestinal 
tumorigenesis because ApcMin/+ cyclin D1-/- mice still develop adenomas, albeit at a 
lower frequency (Hulit et al., 2004). On the other hand, it has been observed that 
Cyclin D1 is upregulated in middle and large size adenomas. Therefore, Cyclin D1 
expression may be involved as a secondary event and an important factor in 
adenoma establishment and growth. The same authors have suggested that Cyclin 
D1 is not a direct target of Wnt signalling pathway. This was demonstrated using 
promoter reporter constructs to measure increases of cyclin D1 expression (Sansom 
et al., 2005). 
In the Min mouse, other TCF/LEF target genes such as c-myc play an important role 
at initiation stages. C-Myc was initially identified as an oncogene but has also been 
associated with homeostatic mucosa maintenance. Conditional intestinal c-myc 
deletion resulted in a crypt loss within weeks (Muncan et al., 2006). Interestingly, 
simultaneous deletion of c-myc and Apc in the intestinal epithelia rescued 
phenotypes of perturbed differentiation, migration, proliferation and apoptosis, which 
occur on deletion of Apc (Sansom et al., 2007).  
In the colon, qPCR experiments allowed detecting a 50% reduction in Cox-2 gene 
expression after CAJ and PAE treatments. However, both results were not 
statistically significant (Fig. 30).   
In one animal experiment, Chen et al. observed a Cox-2 gene reduction in the 
colonic mucosa in 23 weeks old Wt in comparison to Min mice (Chen et al., 2004). In 
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the present study, the possible overexpression of Cox-2 in normal mucosa may be 
reduced by CAJ and PAE treatments and therefore may decrease inflammation in 
the large bowel. Nevertheless, there was no relation with colon tumors. Due to the 
low number of adenomas in the colon, it would be valuable to analyze whether the 
treatments reduced the microlesions in the colon.  
Moreover, in the DMH-induced rat model treated with CAJ, Barth et al. did not find 
any associated Cox-2 reduction in the colonic mucosa (Barth et al., 2007). 
Wnt targets are required to keep the integrity and renewal of the mucosa. But low 
levels are needed to preserve the homeostasis. So far, in Min mice, the mechanism 
of regulation in the normal mucosa is not fully understood. The effects of CAJ and 
PAE in normal mucosa remain to be elucidated. 
 
4.6 Mechanistic investigations in adenomas 
Since the results from the previous animal experiment in normal mucosa were not 
clear, the aim of the present work was to elucidate the cellular mechanisms in 
adenomas.  
As already discussed, the liver was strongly affected by food deprivation. Therefore, 
the difference between fasted (B-PAE and water groups) and non-fasted (Placebo, 
CAJ and CAJ + B-PAE groups) mice adds another factor that we would like to 
explain. 
It has become clear that the intestinal epithelium is an important metabolic site and to 
a great extent responsible for the first-pass metabolism of nutrients and xenobiotics. 
Prolonged fasting has several effects that may modulate the physical forces acting 
on the gut mucosa. First, the intermittent switch to postprandial motility patterns is 
lost, along with changes in volume, density, and composition of the luminal contents. 
Second, the mucosa itself becomes atrophic, with shortened villi in the small bowel 
mucosa (Inoue et al., 1993; Martins et al., 2001). It has been suggested that this 
change in the mucosa may happen via ROS action (Brownlee et al., 2007). 
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4.6.1 Fasting effects and Cyclin D1 expression 
 
Cyclin D1 is a Wnt target gene activated through nuclear β-catenin in CRC cell lines 
(Tetsu and McCormick, 1999). In addition, its expression is increased in Min mice 
adenomas. As already mentioned, crossing Min mice with cyclin D1–/– mice reduced 
the intestinal tumor number in the SI and the colon (Hulit et al., 2004). Cyclin D1 
forms a protein complex and functions as a regulatory subunit of CDK4 or CDK6, 
(Cyclin-dependent kinases) the activity of which is required for cell cycle G1/S 
transition (Alao, 2007). In Int-2, fasting-associated effects increased Cyclin D1 
expression in a non-significant manner by approximately a half (Fig. 35). 
Interestingly, in vivo experiments in normal mucosa of fasted mice performed by 
Sokolovic revealed that different cell cycle and apoptosis genes were strongly 
downregulated in normal mucosa. The authors described a robust decrease in Cyclin 
D1 expression after 12 h fasting. Consequently, CDCK4, Cyclin E and Rb proteins 
were also downregulated. This indicated an overall slow-down of the cell turnover. 
The authors argued that this decreased turnover might be associated with a 
proportional contraction of all components in the SI (Sokolovic et al., 2007).  
Totally different results were observed in the present thesis. Our findings imply that 
after 12 h food deprivation, adenomas trend to activate cell cycle and to increase cell 
turnover. 
 
Effects of treatments in Cyclin D1 
  
Food deprivation almost did not affect Cyclin D1 expression in Int-3. But CAJ and 
CAJ + B-PAE interventions reduced its expression by 3 and 4 times, respectively, 
thereby reducing fasting-associated effects. Although not statistically significant, a 
similar pattern was found for β-catenin in Int-3 segments (Fig. 35 and 34). 
A feasible elucidation of the protective mechanism is difficult due to the food 
deprivation. But a possible speculation might be that β-catenin reduction is 
associated with polyphenol bioavailability in both CAJ and CAJ + B-PAE 
interventions (Fig. 24). 
Our data also suggested that some low molecular compounds might penetrate inside 
the enterocytes and interact with proteins. These absorbed compounds might be 
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responsible for β-catenin reduction by CAJ and CAJ+B-PAE treatments. Moran et al. 
described in Min mice experiment in which 0.1% carnosol from rosemary significantly 
reduced adenomas by nearly 50%. A cytosolic effect was described in which 
treatments restored both E-cadherin and ß-catenin to the enterocyte membranes in a 
similar way as in Wt mice. Phenolic diterpenes such as carnosol are known for their 
high permeability, and therefore intracellular effects could easily take place (Moran et 
al., 2005).  
4.6.2 Fasting effects in MEK/ERK phosphorylation 
 
EGFR transduction is actively involved in controlling proliferation, survival and 
migration of epithelial cells. Physiologically, gastrointestinal mucosa is a rapidly self-
renewing tissue where enterocyte differentiation and migration are needed and 
controlled by EGFR activity (Stappenbeck and Gordon, 2000). Promotion and 
progression steps of CRC are stimulated by EGFR activity (Mendelsohn and 
Baselga, 2000). 
After 12 h of fasting, we observed a strong reduction in both MEK and ERK 
phosphorylation (Fig. 37). Both results implied that a decreased EGFR transduction 
signal affects transcription factors such as Elk-1, c-fos and CREB. The AP-1 
transcription factor is a heterodimer formed by c-jun and c-fos. This protein is actively 
involved in CRC development by regulating cell proliferation, differentiation, 
transformation and/or apoptosis. Moreover, c-fos is positively regulated by Elk-1 
transcription factors. Furthermore, Elk-1 induces TCF-LEF genes, whereas CREB 
acts as a repressor of β-catenin (Milde-Langosch, 2005). A detailed target promoter 
analysis may be important to elucidate possible pathway connection. A 
transcriptional regulator of Cyclin D1 is the AP-1 binding domain and consequently 
activated by ERK phosphorylation. Therefore, food deprivation may be responsible 
for Cyclin D1 increase via ERK phosphorylation (Fig. 35 and 37). 
Solokovic et al. have described that after 12 h of fasting, mainly amino-acid and 
carbohydrate metabolism-related genes are strongly affected. One of the most 
affected metabolic pathways is the glutamine synthesis. After 12 h of food 
deprivation, preservation of cytosolic glutamine levels is a principal metabolic change 
because enterocytes use glutamine as a primary source of energy (Sokolovic et al., 
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2007). Moreover, glutamine administration reduces gut mucosal atrophy. 
Interestingly, in vitro experiments with rat intestinal epithelial cells demonstrated an 
increase in ERK phosphorylation after 4 h of glutamine incubation. The authors 
further discussed that the connection between glutamine and ERK activation may be 
relevant as an early fasting adaptation stage to maintain the integrity of the intestinal 
mucosa (Larson et al., 2007). On the other hand, one of the known biological 
processes in the small intestine during fasting is the increase of oxidative stress 
(Jonas et al., 2000). Moreover, it has been reported that ERK signalling together with 
c-Jun N-terminal kinase (JNK) are activated in the intestine during oxidative stress 
(Zhou et al., 2005).  
Nevertheless, these findings have been reported in normal mucosa. In the present 
study, fasting increased proliferation in adenomas through p-ERK. As already 
explained, one reason might be a possible increase of glutamine as a source of 
energy and oxidative stress. 
 
Suppression of fasting effects by B-PAE intervention 
 
B-PAE treatment is shown to reduce half ERK and MEK phosphorylation in 
adenomas compared to water control in a non-significant manner and consequently 
the derived effects of 12 h fasting (Fig. 37). Significance may be affected due to a 
low animal number, and thus increasing the number of samples might result in a 
statistically significant difference. These results are in line with earlier investigations 
from Gossé et. al. In the AOM-induced rat model, a procyanidin–rich fraction (0.01% 
in drinking water) reduced ACF/colon by 50% and also decreased ERK 
phosphorylation. 
Although it is difficult to describe a possible molecular mechanism due to fasting, 
OPC and polymeric procyanidins reduce fasting–associated effects. B-PAE contains 
mostly polymeric and oligomeric procyanidins that can be responsible for this EGFR 
pathway inhibitory potential. In addition, flavonols in B-PAE identified by HPLC 
analysis can modulate signal transduction.  
Our speculations were supported by in vitro experiments. HT29 cells stimulated with 
EGF in the presence of low PAE concentrations (from 0.6 to 6 nM) significantly 
reduced ERK phosphorylation (Kern et al., 2005). The same group described that 
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PAE significantly inhibited EGFR signal transduction in the human colon cancer cell 
line HT29. Pure compounds such as dimeric procyanidins and quercetin glucosides 
were found to be the most active polyphenols (Fridrich et al., 2007b). Further 
investigations with trimeric and dimeric procyanidins isolated from grapes 
significantly reduced EGFR autophosphorylation in the human vulva carcinoma cell 
line A431(Fridrich et al., 2007a). 
Overall, B-PAE treatments reduced fasting-associated effects in adenomas by 
reducing ERK phosphorylation. 
4.6.3 iNOS upregulation and fasting 
 
Two key proteins during inflammation processes in adenoma development are Cox-2 
and iNos. Both are increased in adenomas and are putative targets for 
chemoprevention (Hull et al., 1999; Scott et al., 2001).  
Similar to ERK and MEK expression, during fasting, iNOS was inhibited in Int-2 and 
Int-3 approximately by a half and a third, respectively (Fig. 37 and 38). So far, no 
association between inflammation and fasting has been investigated in the SI, but it 
has recently been described that LPS-induced liver inflammation in rats is increased 
by fasting. Expression of Cox-2 and iNOS was enhanced by fasting, and feeding 
declined this upregulation (Adams et al., 2009).  
iNOS promoter contains a AP-1, NF-κB, CREB and C/EBP binding domains. All 
these transcription factors result in a complex regulation of the gene. But p-ERK is 
one of the upstream regulators of iNOS. The activation of iNOS via ERK transduction 
has been demonstrated in melanoma epithelial cell lines. Blocking EGFR signalling 
through MEK inhibitors, iNos expression was subsequently downregulated. The 
same effects were obtained knocking down B-raf by RNAi. Despite the connection 
between MAPK activation and iNOS expression, authors also discussed that other 
factors might be involved (Ellerhorst et al., 2006). Nevertheless, the MAPK cascade 
is an upstream activator of NF-kB (Seger and Krebs, 1995). In fact, evidence exists 
in several cell types for the involvement of NF-kB in mediating the regulation of iNOS 
by ERK (Kim et al., 2007; Pergola et al., 2006). 
Overall, this result indicated that fasting increased the inflammation process in 
adenomas. A general conclusion of fasting effects in adenomas is the increased 
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expression of Cyclin D1 and iNOS via p-ERK. As already mentioned in the last 
section, this might be related to the use of glutamine as an energy source and 
possible oxidative stress in epithelial tissues. 
 
Effects of B-PAE in iNOS expression 
 
Similar to p-ERK, we have observed that B-PAE intervention reduced iNOS 
expression compared to water control. The increment of iNOS expression during 
fasting is downregulated by B-PAE treatments. Similar to the comparison of fasted 
vs. non-fasted animals, both p-ERK and iNOS were reduced in a similar fashion, 
comparing B-PAE- and water-treated animals (Fig. 37 and 38). 
One of the aims of the present study was to investigate into the effects of CAJ and 
PAE treatments in inflammation. We decided to investigate NO and PGE2 synthesis 
as inflammation biomarkers. As already described, iNOS is expressed in Min mice 
adenomas and therefore NO production increases the oxidative status. Moreover, 
NO production activates Cox-2 expression.  
The mechanism that links PGE2 and adenoma development was described by Pai et 
al. PGE2 transactivates EGFR activating downstream proteins thus promoting CRC 
growth and gastrointestinal hypertrophy (Pai et al., 2002). On the other hand, PGE2 
can also induce the Wnt pathway through accumulation of β-catenin in the nucleus 
via Akt or Gα subunits (EP receptor) (Buchanan and DuBois, 2006). Therefore, it was 
of interest to determine whether CAJ and B-PAE treatments might reduce NO and 
PGE2 production in urine and serum, respectively. Both biomarkers resulted in similar 
values for all treatments (Tab. 19 and 21). 
The similar PGE2 levels in serum indicated a lower effectivity in Cox enzymes 
inhibition in vivo. Our previous in vitro results demonstrated that PAE inhibited Cox 
activity with an IC50 of 400 µg/ml, which is a high concentration. Epicatechin, 
phloretin, trimeric and tetrameric procyanidins were described as the main inhibitory 
compounds of PAE (Zessner et al., 2008). Other more efficient polyphenolic 
compounds such as tricin potently inhibited in vitro Cox enzymes with an IC50 value 
of 1 µM. Similarly to B-PAE, tricin inhibited adenoma number by 33%, but PGE2 
levels in plasma were reduced by 40% (Cai et al., 2005).  
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Since iNOS was one of the affected targets, NO determination was planned as a 
putative biomarker in urine. But NO detection depends on concentration, short half-
life, and high reactivity with other chemical compounds such as superoxide radicals, 
thiols, and haem proteins. This difficulty can be avoided by analyzing PGE2 and NO 
directly in adenomas after the snap-frozen collection, and more valuable information 
would be obtained.  
The increased inflammation due to the fasting effects is reduced by B-PAE 
intervention in adenomas. A general overview of all possible mechanisms and 
pathways is summarized in Fig. 40. 
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Fig. 40.  Putative mechanism for A) fasted animals and B) fasted animals receiving B-PAE treatment 
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4.7 From pre-clinical models to the human situation  
The role of fruit juices in cancer prevention is still an on-going question. Many studies 
have addressed fruit juices and modulation of oxidative status.  
In one study, our collaborators (WG Rechkemmer/Briviba) used two different 
polyphenolic-rich juices in human subjects. Antioxidant parameters such as plasma 
malondialdehyde and oxidative DNA damage in lymphocytes were reduced. One 
juice contained a mixture of apple, mango and orange juice and the other was rich in 
anthocyanin-providing aronia, blueberries, and boysenberries, while both juices 
contained similar polyphenol amounts (Bub et al., 2003). Likewise, another 
intervention with rich polyphenolic fruit juices caused comparable antioxidant effects. 
Moreover, GST and GSH levels were increased and the DNA-binding activity of NF-
κB was reduced (Hofmann et al., 2006; Spormann et al., 2008). Improved antioxidant 
capacity against hydroxyl radicals was detected in serum of volunteers who drank 
150 ml CAJ (Ko et al., 2005). Further comparable results were obtained in one 
human intervention study after 1 h CAJ ingestion in terms of serum DPPH 
(Chrzczanowicz et al., 2008). In contrast, our collaborators (WG Briviba) have 
reported that consumption of 1 Kg of apples did not affect plasma parameters like 
antioxidant capacity, endogenous DNA strand breaks and inhibition of H2O2-induced 
DNA damage in lymphocytes. But, DNA from lymphocytes was protected from iron 
damage and the oxidized pyrimidines were diminished (Briviba et al., 2007). 
In a recent human intervention study with patients with colorectal adenomas, fruit 
juice was associated with reduced adenoma risk. A RR of 0.74 (95% CI = 0.58-0.96) 
was described, similar to vegetables or fruits (Wu et al., 2009). In a further human 
intervention study with 10 % freeze-dried berries, when patients with CRC and/or 
polyps were taking 60 g of a berry extract, proliferation and angiogenesis biomarkers 
were significantly reduced. Moreover, apoptosis was enhanced (Stoner et al., 2008). 
Targeting inflammation in CRC has provided interesting results in FAP patients. 
Together with celecoxib, NSAIDs and sulindac have been also the focus of human 
studies. Unfortunately, both sulindac and aspirin usage have been related to bleeding 
events. In a randomized clinical trial with a flavonoid mix in patients with acute 
bleeding from internal haemorrhoids, treatments prevented bleeding and a reduced 
risk of relapse (Ho and Seow-Choen, 2000). Recently, it has been reported that a 
Discussion 
 
 
 
 
159
PAE in combination with aspirin reduced rat gastrointestinal injury in terms of 
decreased acute and chronic injury (D'Argenio et al., 2008). 
We have presented the chemopreventive potential of CAJ and B-PAE in Min mouse 
as a pre-clinical model. Both treatments have caused positive results in initiation and 
promotion stages of colon carcinogenesis. Moreover, fasting-associated effects were 
in some cases suppressed. This indicates that dietary compounds positively affected 
the development of CRC. B-PAE was described as a potent chemopreventive agent. 
This might be attributed to the procyanidin content, which has been widely 
investigated in cancer chemoprevention. On the other hand, CAJ is presented as a 
source of secondary plant compounds, which demonstrates that diet is one of the 
major factors affecting CRC. Other western-associated malignancies such as 
cardiovascular and neuronal diseases might also be prevented with rich polyphenolic 
diets. To date, one of the most popular rich polyphenolic drinks is green tea. 
Therefore, clinical trials with green tea have started some years ago. In the same 
way, we propose CAJ and PAE as chemopreventive agents, which should therefore 
be taken into consideration for clinical trials and human intervention studies.  
4.8 General conclusions 
To date, there is a huge interest in finding new compounds and molecules that could 
prevent the development of several malignant diseases. Our aim was to determine 
the in vivo signalling pathway involved in cancer prevention. 
 
1- One of the purposes of the present work was to determine mechanistic effects of 
CAJ and PAE in normal mucosa from our previous animal experiment. PAE 
intervention reduced Cyclin D1 expression in the distal SI and Cox-2 expression in 
the colon. Nevertheless, both reductions were statistically not significant, and no 
relation with the adenoma numbers was observed. Further investigations are 
necessary to study the effects of CAJ and PAE at the initiation stage of adenoma 
formation. 
2- In the present work, the possible effect of apple polyphenolic compounds in 
adenomas was studied in a second animal experiment. First, the results indicated 
that polyphenols are the active compounds since placebo treatment only inhibited 
adenoma development in animals by 7%. Second, apple polyphenols might act as 
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chemopreventive compounds in a dose-response manner because treatments with 
CAJ + B-PAE showed less adenoma inhibition compared to CAJ and B-PAE (B-PAE: 
34%, CAJ06: 24% and CAJ + B-PAE: 17%). Third, the highest inhibition was shown 
with B-PAE intervention. This indicated that procyandins are major active 
compounds. These findings confirmed previous in vitro experiments performed in our 
work group. All these results have a strong relation to the bioavailability of apple 
polyphenols. Further possible effects of placebo juice intervention in the small 
intestine and the colon remain unclear and require additional investigations.   
3- In B-PAE (procyanidin-rich) intervention, mechanistically investigations in 
adenomas might indicate that ERK signalling is one of the possible transductions 
pathways modulated by oligomeric and polymeric procyanidins. The poor 
bioavailability of B-PAE compounds and a consequently local effect in the small 
intestine could be the reason to block EGFR transduction signalling. 
CAJ inhibitory potential might be reduced due to the lower amount procyanidins. But 
other monomeric polyphenols may also be responsible for an intracellular effect. In 
the distal SI, potential targets are β-catenin and Cyclin D1. However, due to 
unexpected fasting conditions in both treatments, these assumptions remain 
speculative. 
4- Another of the aims of the present work was to determine the active potential of 
CAJ and B-PAE in terms of drug metabolism and anti-inflammatory capacity. CAJ- 
and CAJ + B-PAE-treated animals induced QR and GST in a non-significant manner. 
Moreover, CAJ + B-PAE intervention caused a statistically significant increase of 
TrxR enzymatic activity. These results are strongly related to the bioavailability. The 
induction of phase II enzymes agrees with our previous in vitro experiments and it is 
for the first time in mice reported. Inflammatory effects in urine and plasma could not 
be demonstrated. Interestingly, B-PAE treatment reduced iNOS expression in 
adenomas compared to water control.  
5- Reductions of GSH content as well as CYP1A1, QR and TrxR may be explained 
as a consequence of protein reduction in the liver, being in turn as a consequence of 
unexpected fasting effects. In adenomas, fasting effects increase proliferation (Cyclin 
D1) and inflammation (iNOS) via p-ERK. These findings were suppressed by B-PAE 
intervention. 
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Finally, these findings strongly suggest that CAJ and PAE contain promising 
chemopreventive compounds that should be further explored for prevention of CRC 
in human intervention studies and clinical trials.  
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